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RSV LOWER RESPIRATORY TRACT INFECTIONS
Lower respiratory tract infections (LRTIs) are among the most frequent indications 
for hospitalization and form worldwide the leading cause of death in children 
under 5 years of age.1 Respiratory syncytial virus (RSV) is the most important 
cause of respiratory tract infections in infants and young children worldwide 
and a major reason for hospitalization.2 Clinical manifestations of RSV infections 
range from mild upper respiratory tract symptoms such as cough, rhinorrhea 
and conjunctivitis to severe LRTI and in its most severe form life-threatening 
respiratory insufficiency requiring mechanical ventilation. Treatment for LRTI by 
RSV is largely supportive and a vaccine is not yet available, although several 
phase 2 and 3 studies are ongoing.3, 4 
The annual global incidence of LRTIs caused by RSV among children younger 
than 5 years, has been estimated at 34 million per year leading to at least 
3.4 million hospital admissions and up to 199.000 deaths, the majority in 
developing countries.2 Most children have been exposed to RSV by the age of 2 
years. Approximately 1 to 2% of all children infected by RSV (10% of those with 
lower respiratory tract involvement) are hospitalized and about 6-11% of these 
children require mechanical ventilation for a severe RSV LRTI.5, 6 Meijboom et al. 
recently estimated the burden of RSV disease in children below the age of 12 
months in the Netherlands, and reported almost 29.000 RSV related visits to the 
general practitioner, 1623 hospitalizations, and 5 deaths.7 Hence, RSV infection 
is the most frequent cause of non-elective pediatric intensive care unit (PICU) 
admission for mechanical ventilatory support in infants during the winter season 
resulting in annual capacity problems at the PICUs in the winter months.
DISEASE SEVERITY
Risk factors for severe RSV infection – including prematurity, chronic lung disease, 
congenital heart disease and immune deficiency – have been well described. 
However, more than half of the RSV-infected children requiring intensive care 
admission are otherwise healthy.5, 8 It is unclear why some children develop a 
more severe course of disease than others. 
Disease severity is the result of a dynamic interplay between direct viral damage 
and the immune response of the host. Upon infection, virus specific structural 
components are recognized by pattern recognition receptors of the host, 
triggering mechanisms to suppress viral replication and elimination of viral 
infected cells. At the same time, however, this immune response also results 
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in inflammation of the respiratory tract and determines the extent of disease 
severity.9 
It is not completely clear whether severe manifestations of lower respiratory tract 
disease are caused by directly induced viral damage or by the immune response 
of the host. In addition, there is little agreement whether disease severity is 
associated with a defective/immature or an excessive immune response. While 
some studies show the presence of a strong inflammatory response characterized 
by abundant inflammatory cytokines and activated granulocytes in the airways 
of infants and children with severe RSV disease 10-15, others report decreased 
concentrations of inflammatory cytokines and other markers of cell injury in the 
more severe phenotypes of RSV disease.16-18 
Assessment of Disease Severity
To date, physicians have few tools to predict disease severity and outcome in 
the individual patient. The decision to admit a young infant with bronchiolitis 
to the hospital is based on clinical parameters combined with an assessment 
of risk factors for severe disease. However, 35% of the children hospitalized 
with bronchiolitis do not require supportive interventions during hospitalization 
19 and 4.6-6.8% of the patients initially discharged from the outpatient clinic, 
require hospitalization later on during the course of infection.20, 21 
To improve patient management, laboratory tests identifying those patients who 
are at risk for a severe course of disease and who require supportive interventions 
and/or intensive care admission are needed. Alternatively, accurate selection 
of patients with milder manifestations of disease could prevent unnecessary 
hospitalizations and reduce health care costs. At this moment no clinical tools are 
available that allow differentiation between these patient groups. In our opinion, 
there is a need to develop biomarkers that may help clinicians to select those 
patients who can be safely discharged home or who require close monitoring 
and/or supportive interventions in their course of disease.
AIM OF THE THESIS
The aim of this thesis is to identify diagnostic biomarkers that have the potential 
to differentiate between mild and severe cases of RSV-caused bronchiolitis. Viral 
factors and host immune response patterns are evaluated in young children with 
viral bronchiolitis to select markers that may differentiate between mild and 
severe disease and may be used as future biomarkers for disease severity. 
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OUTLINE OF THE THESIS
Chapter 2 provides a general introduction to the field of biomarkers in pediatric 
infectious diseases. Recent advances in the application of genomics and 
proteomics to develop biomarkers for infectious diseases are described and 
current clinical applications and future perspectives are discussed. 
Viral factors and host immune responses contribute to disease severity and may 
be used as biomarkers. In chapter 3, we evaluate the role of viral factors such 
as infection by multiple viral pathogens or viral load in disease severity in young 
children with bronchiolitis. 
In the subsequent chapters specific host immune factors are analyzed for their 
ability to discriminate between mild and severe disease in young children with viral 
bronchiolitis. In chapter 4, we explore the role of the matrix metalloproteinases 
MMP-8 and MMP-9 as biological markers to assess disease severity in viral lower 
respiratory tract infections in children. We additionally investigated in chapter 
5 if disease severity in RSV-infected infants can be distinguished by the use of 
combinations of several immunological markers. 
In the last part of this thesis, proteomic and transcriptomic technologies are 
used to identify proteins and genes which may be potential targets for the 
development of future therapy or prevention of severe viral respiratory diseases. 
In chapter 6 we aimed to identify genes that can be used as novel biomarkers 
for disease severity using transcriptomic analyses of human leukocyte subsets 
obtained from children with LRTIs. In chapter 7, an in vitro study was performed 
to describe the effect of respiratory virus infection on protein expression levels in 
human airway epithelial cells by 2-D DIGE analyses. In chapter 8, an experimental 
murine infection model was used to study the molecular mechanism underlying 
vaccine induced RSV-specific enhanced disease by applying mass spectrometry 
assisted protein profiling.
Finally, in chapter 9 we discuss the results of our studies, a short update on 
the use of proteomics and transcriptomics in RSV research is provided and 
perspectives for further research are presented. 
Chapter 1
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INTRODUCTION
Infectious diseases are an important cause of death among children under the 
age of 5.1 Most of these deaths are caused by preventable or curable infections. 
Limited access to medical care, antibiotics, and vaccinations remains a major 
problem in developing countries. But infectious diseases also continue to be an 
important public health issue in developed countries. With the help of modern 
technologies, some infections have been effectively controlled; however, new 
diseases such as SARS and West Nile virus infections are constantly emerging. In 
addition, other diseases such as malaria, tuberculosis, and bacterial pneumonia 
are increasingly resistant to antimicrobial treatment.
The physician who manages pediatric patients with infectious diseases is 
confronted with several related challenges. First, one should establish a specific 
diagnosis, preferably early in the course of disease. Despite improvements in 
culture and non-culture diagnostics, in many cases, the causative microorganism 
remains unknown. Consequent delays in initiation of appropriate treatment can 
contribute to the emergence of antibiotic resistance. 
A second challenge is to identify those patients most likely to develop severe 
disease. To date, physicians have little information on prognosis and disease 
outcome in the individual patient. It would be extremely useful to be able 
to identify patients at risk for more severe disease (e.g., secondary bacterial 
infection during viral respiratory tract infection), as such prediction could inform 
management decisions. The third associated challenge is to select the most 
appropriate treatment strategy for an individual patient. While some patients 
require intensive support, others will recover without additional medication or 
supportive care. To date, few tools are available to monitor the course of disease 
after initiation of medical treatment.
Biomarkers have been used for years to help clinical decision-making. C-reactive 
protein (CRP) is probably the best known marker used to monitor infection. 
Although useful, it does not reliably distinguish viral from bacterial infections. 
More recently-developed markers such as procalcitonin seem promising, with 
detectable rises early in the course of infection and high negative predictive 
value as seen in children with fever of unknown origin. 2-4  However, this marker 
has also insufficient power to discriminate between viral and bacterial infections. 
Additionally, these conventional biomarkers for infectious diseases do not 
provide microorganism-specific prognostic information.
The completion of the Human Genome Project and the introduction of powerful 
DNA microarray chips and proteomic technologies in the mid-1990s have created 
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the opportunity to identify genes and proteins that may serve as biomarkers in 
infectious diseases. The identification of biomarkers may enable the development 
of exciting potential clinical applications in which genes and proteins that are 
differentially expressed in healthy and infected individuals can be investigated.5 
These approaches may provide detailed insight into the pathogenesis of disease, 
host pathogen interactions, and disease-specific expression patterns. In addition, 
diagnostic and prognostic biomarkers and markers that monitor disease or 
response to therapy may be developed using these technologies. 
This chapter describes recent advances in genomics and proteomics in the field of 
biomarkers for infectious diseases and summarizes current clinical applications 
and future perspectives.
MOLECULAR PROFILING: CURRENT TECHNIQUES
Genomics
Single nucleotide polymorphisms (SNPs), single base pair changes at specific 
spots in the genome, are the most common type of genetic variation. The 
human genome carries over 10 million nucleotides that vary in at least 1% of the 
population. Currently, approximately 6 million nucleotides have been validated 
and this number is still growing.6, 7 Although SNPs are the changes most frequently 
explored using high throughput technologies, other genetic variations are also 
common in the human genome and may influence the individual’s susceptibility 
to disease. These include variations in gene copy number, repeating sequence 
motifs, insertions, and deletions.8 
The completion of the human genome map in combination with the development 
of microarray-based comparative genomic hybridization and genome-wide SNP 
platforms have permitted the screening of the entire genome to identify genetic 
loci linked to certain diseases, susceptibility to disease or response to therapy.9 
These genome wide association studies allow identification of genetic risk 
factors for a wide variety of common and more complex diseases by measuring 
hundreds of thousands of genetic variants simultaneously. Using SNP platforms, 
MalariaGen, a genomic epidemiological network, and the Wellcome Trust Case-
Control Consortium (WTCCC) have performed a large scale study on disease 
susceptibility.10, 11 Both consortia have analyzed up to 500,000 SNPs in thousands 
of African individuals diagnosed with malaria or tuberculosis between 2006 
and 2008. In addition, the WTCCC will include approximately 2,000 cases and 
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3,000 controls for 8 other diseases, which makes it one of the biggest projects 
aimed at the identification of genetic variations that may predispose a patient 
to disease.12 These genome-wide analyses may contribute to the identification 
of individuals at risk and produce more effective prevention strategies and 
individual treatment strategies.
Transcriptomics
Where genomics provides information on genetic susceptibility to certain 
infectious diseases, transcriptomics provides information on the activity of genes 
at a certain moment under certain conditions. It is the study of the complete set 
of RNA transcripts produced by the genome. During all biological processes, 
part of the genome is specifically transcribed into messenger RNA (mRNA, 
transcriptome) and translated to proteins (proteome). The transcriptome can 
be analyzed using gene expression microarrays. These chips contain either the 
whole genome or a subset of specific genes. mRNA is extracted from experimental 
samples, reverse transcribed and labeled with fluorescent dyes. The extracted 
labeled cDNA is then hybridized with the microarray and the fluorescence of 
the array is determined using an array scanner. Following image analysis, the 
data are subjected to bioinformatics processes to identify statistically significant 
changes in gene expression between different samples. The technique can be 
used to characterize gene expression in both pathogen and host, providing 
detailed insight into host-pathogen interactions during infection.13 To study 
them on a molecular level, Kawada et al. generated gene-expression profiles in 
peripheral blood mononuclear cells (PBMCs) isolated from children with influenza 
virus infection.14  Many genes associated with the immune response such as 
interferon regulated genes appeared to be strongly upregulated during influenza 
infection. In addition, they compared gene expression profiles of influenza-
infected children with and without convulsions. They found that transcription 
levels of pro-inflammatory cytokine genes in patients with a febrile convulsion 
were not significantly different from those in patients without febrile convulsion. 
This kind of approach may help to clarify the pathogenesis of influenza and its 
neurological complications.14 
Proteomics
While gene expression profiles may not completely correlate with intracellular 
protein content, proteomics can provide insight into the structure and dynamics 
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of the end product, proteins. Proteomics is the study of the proteome, the 
complete set of proteins, their modifications, interactions, and localization. 
Proteomic technologies enable detailed analyses of protein expression and 
evaluation of post-translational modification and protein stability and turnover 
that cannot be assessed by genomic and transcriptomic profiling alone. For many 
years, two-dimensional gel electrophoresis has been the standard technology to 
isolate specific proteins and allow protein identification by subsequent mass 
spectrometry. During the past decade, mass spectrometry has improved and 
now enables the analysis of protein expression, structure, and function without 
the need for labor intensive and time consuming electrophoresis.15, 16 In addition, 
several mass spectrometry-based approaches have been developed that allow 
the relative or absolute quantification of proteins.
In an attempt to identify biomarkers and to develop screening tools with high 
sensitivity and specificity, proteomics technology has been applied to analyze 
biofluids such as serum, saliva, or urine. A commonly used technique is a surface 
enhanced laser desorption/ionization time-of-flight (SELDI-TOF), which is a 
proteomics technique that allows the identification of large numbers of proteins 
in a short period of time. This technique provides a specific mass spectral 
profile from each analyzed protein sample. By comparing profiles from affected 
individuals to those derived from healthy controls, a specific protein signature 
is obtained.17, 18 Agranoff and colleagues have used it to characterise distinct 
profiles for several microbial infections and to investigate serum responsiveness 
to M. tuberculosis identifying serum biomarkers from patients with advanced 
tuberculosis.19 SELDI-TOF has the potential to identify tuberculosis at an early 
stage, assisting early diagnosis and therapy, which is important for favorable 
outcome.19 
CLINICAL APPLICATIONS IN PEDIATRIC INFECTIOUS DISEASES
The recent advances in proteomic and genomic technologies have allowed 
the identification of genes and proteins that may serve as biomarkers for the 
diagnosis and monitoring of infectious diseases. Application of knowledge 
from these technologies into clinical practice is still at an early stage. In the 
following sections, we will first discuss current literature on the contribution of 
the aforementioned technologies for the determination of disease pathogenesis, 
for the susceptibility to infection, and for diagnostics. In the next section, we will 
discuss clinical applications of proteomic and transcriptomic technologies, and, 
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in the last section, we will focus on their future perspectives.
What Has Been Studied up to now?
With increasing use of genomic and proteomic technologies, more insight has 
been obtained into host-pathogen interactions and pathogenesis of infectious 
diseases. The response of the host to pathogens is reflected in changes in 
gene expression and can be measured by microarray based gene expression 
technologies. Likewise, transcriptional profiling studies have proven to be a 
powerful approach for analyzing and understanding host–pathogen interactions. 
Based upon the host response to various pathogens, Jenner et al. have identified 
common and more specific gene expression patterns.20 They collected and 
systematically compared transcriptional profiling datasets from 32 published 
microarray-based in vitro studies which collectively examined 77 different 
host-pathogen interactions. In response to this wide variety of pathogens, 
they identified a cluster of 511 genes that share a common response upon 
infection with a pathogen. According to the localization of the cell in which 
they function, these genes have been clustered into different functional groups 
in order to provide an overview of cellular physiology involved in the common 
host response. Moreover, analyzing different transcriptional profiling studies 
also revealed pathogen specific gene expression patterns. Several host genes of 
the aforementioned common host response were found to be downregulated in 
the presence of pathogens or specific pathogen proteins. These transcriptional 
profiling studies has provided insight into how microorganisms alter host 
gene expression patterns to subvert the immune responses. For example, 
transcriptional profiling has identified that viruses such as herpes simplex virus 
(HSV)-1, human cytomegalovirus, and human papillomavirus-31 are partially or 
completely able to inhibit the induction of Interferon stimulated genes, which 
have a central role in the defense against viruses.20 
Streptococcus pneumoniae and influenza virus are the most common causes of 
pneumonia. Consequently, they contribute to substantial morbidity and mortality 
worldwide. It has been known for years that influenza infection predisposes to 
secondary bacterial infection, mainly caused by S. pneumoniae and S. aureus. 
The catastrophic influenza A pandemic in 1918 in which approximately 40–50 
million persons were killed, may have involved synergy between influenza and 
pneumococcal infections. Gene expression profiling is a powerful tool to explore 
the molecular mechanism of synergy between pathogens. By host gene expression 
analyses of the lungs in mice, Rosseau et al. differentiated pneumococcal 
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infections from influenza. Rosseau et al. have also identified common gene 
expression patterns in infectious disease as well as unique pathogen-specific 
gene expression signatures that may help clarify the mechanisms behind the 
synergy between influenza virus and S. pneumoniae.21  In response to influenza 
infection, Tong et al. performed gene expression analyses of middle ear epithelial 
cells.22 They suggest that increased expression of inflammatory mediator genes 
such as Interferon gamma-induced protein (IP-)10 and C-X-C motif chemokine 
(CXCL-)11 could lead to a shift in S. pneumoniae adherence by activation of host 
epithelial and endothelial cells, providing a favorable environment in the middle 
ear cavity for a secondary bacterial infection with S. pneumoniae. 
The response upon exposure to pathogens varies widely between individuals. 
Some people are more susceptible to a certain infection than others. This 
differential susceptibility is partly caused by genetic variations between individuals 
that may predispose either to development of disease or to a more severe 
course. Although the large variation in clinical responses among individuals, 
also depends upon environmental and microbial factors. The classic example 
of host genetic susceptibility is the resistance of heterozygous hemoglobin S 
individuals to malaria infection (caused by Plasmodium falciparum).23 Other 
approaches used to elucidate genetic and environmental effects on infections 
include studies in identical and non-identical twins and comparisons of risk in 
adopted children and their biological and adoptive parents.24- 26 One such study 
suggested that adopted children with a biological parent who died early of an 
infectious disease had a higher risk of mortality from similar infections while 
the death of an adoptive parent due to infection had no influence on the risk of 
disease in the children.27
Recent advances in microarray technologies have enabled genome wide searches 
for genes influencing susceptibility to infectious diseases. Analysis of genetic 
susceptibility aims to link the genetic code (genotype) to the risk of a certain disease 
state (phenotype). Given the large number of human genes, many with unknown 
function, genome wide studies have the advantage that previously unconsidered 
genes can be identified and provide more sensitivity for the detection of subtle 
genetic effects and gene recruitment in affected individuals. However, many 
reported genetic associations have not been replicated in subsequent studies, 
and, for secure results, large numbers of affected and unaffected individuals are 
required. Furthermore, because of the complexity of data analysis, microarray 
technologies are time and labor intensive.28- 30 Nevertheless, several large scale 
population based studies have been performed and support the role of genome 
wide searches in the identification of genes influencing disease susceptibility.11, 
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31-33 For example, a genetic association study performed by O’Brien et al. has led 
to the identification of various genetic factors that affect HIV-1/AIDS.31 Genetic 
association analysis of several large cohorts of HIV infected individuals resulted 
in the identification of 14 AIDS restriction genes, which are human genes with 
polymorphic variants that influence the outcome of HIV-1 exposure or infection. 
This study illustrates the discovery of previously unknown genes involved in 
susceptibility to infection using SNP haplotype-based association studies in 
clinically well-described epidemiological cohorts. 
Another potential application of microarray technologies is diagnosis of infection 
both by direct and indirect identification of pathogens. For example, microarrays 
composed of DNA sequences of various pathogens allow the identification of 
many organisms in a single test. Wang et al. developed an array composed 
of all fully sequenced reference viral genomes that allows the detection of 
approximately 1000 viruses.34 Moreover, by sequencing hybridized material of 
unknown pathogens, this array permits identification of new viruses, and, in 
2003, it proved successful in the global effort to identify the novel corona virus 
associated with severe acute respiratory syndrome (SARS).34, 35 
In contrast to direct identification, infections can also be characterised indirectly 
through specific host responses. An advantage of such pathogen-specific 
molecular signatures in the host is that they may be present at various stages 
of infection, even when the pathogen is not detectable using standard or direct 
diagnostic tests. Ramilo et al. used gene expression analysis to diagnose different 
pathogen fingerprints in pediatric patients with respiratory infections caused by 
influenza A virus and Gram-negative (E.coli) or Gram-positive (Staphylococcus 
aureus and Streptococcus pneumoniae) bacteria.36 Classifier genes, which 
discriminate influenza A from bacterial infections (S. pneumoniae and S. aureus) 
and E. coli from S. aureus infections, were identified and validated. Another 
example of “–omic” technology use in diagnosing infection is the development of 
a protein based signature for diagnosing trypanosomiasis or sleeping sickness, 
which affects half a million people yearly in sub-Saharan Africa. Trypanosomiasis, 
if left untreated, is a debilitating disease with a lethal outcome; it was successfully 
controlled in the past, but, since the 1970s, has re-emerged as an epidemic 
of immense proportions causing huge, yet widely underestimated morbidity 
and mortality of up to 50,000 cases every year.37  Establishing the diagnosis 
remains complicated, as current diagnostic tests lack the sensitivity to detect 
low parasite loads in peripheral blood. Papadopoulos et al. analyzed serum 
samples from patients and controls using SELDI–TOF mass spectrometry and 
identified distinct serum proteomic signatures in both groups.38 After depleting 
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serum samples of antibody components, the authors identified two prominent 
protein peaks at 23/24 and 47 kDa in patients. These proteomic signatures may 
provide the basis for new diagnostic tests and alternative methods to monitor 
the host response to treatment. Moreover, additional characterization of these 
differentially expressed proteins may allow the development of simpler, cheaper 
antibody based tests.19,38
Current and Potential Clinical Applications of “–omic” Technologies
More than 50% of all children admitted to the hospital have fever or other 
nonspecific symptoms related to infection.39 Although not necessarily suffering 
from bacterial infection, a significant proportion of these children will receive 
antibiotics. Although clinical history, physical examination and conventional 
diagnostic investigations (e.g., x-rays, blood tests) may point to an extent 
towards cause, pathogen identification remains difficult or even impossible. 
During episodes of acute fever, clinicians prefer to rely on cultures taken from 
the site of infection. However, such cultures often cannot be obtained at the 
right time or from the relevant site (e.g., middle ear or lungs) and results are 
not available for at least 24 h after sampling so that pathogens often remain 
undetected. Furthermore, contamination and colonization, particularly in upper 
airway samples, can obscure results. Gene expression profiles may identify 
bacterial pathogens and discriminate between bacterial infections, infections 
caused by other pathogens, and non-infectious causes of fever (like auto-
inflammatory diseases). Using microarrays, organisms can be identified either 
directly or indirectly through their effects on host gene expression.
Tang et al. showed that gene expression profiling of neutrophils can distinguish 
sepsis from non-infectious inflammation (e.g. Systematic Inflammatory Response 
Syndrome, SIRS) in intensive care patients.40 They performed microarrays on a 
cohort of septic (N=71) and non-septic (N=23) patients and identified 50 classifier 
genes differentially expressed between the two groups, which are involved in 
inflammatory responses, immune regulation, and mitochondrial function. Broadly 
genes involved in the upregulation of immune responses were expressed less in 
patients with sepsis than in control patients, whereas genes involved in down 
regulation of immune responses were expressed more, suggesting that sepsis 
may have an inhibitory effect on immune regulation. Pathway analyses support 
the finding that immune regulation is inhibited during sepsis by showing that 
genes involved in the NF-B pathway were expressed less in patients with sepsis, 
whereas the inhibitory gene NFKBIA was expressed more. A prediction model 
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for disease severity was developed from these data and validated in a second 
more heterogeneous patient group.40 A major advantage of gene expression 
profiling is that it may enable the development of less expensive diagnostic tools 
such as quantitative real-time polymerase chain reaction (RT-PCR) detection and 
quantification of specific DNA sequences in septic patients instead of entire gene 
expression profiles. 
Children with auto-inflammatory diseases often present with non-specific 
systemic symptoms like rash and fever, which precede more specific symptoms 
like arthritis. Diagnosis of autoinflammatory diseases is often difficult due to the 
presentation with non-specific symptoms and the low incidence of these diseases. 
Patients are often empirically treated for more likely causes of symptoms, 
including infections. Such delay in diagnosis and initiation of appropriate 
treatment is suboptimal for the child and may also result in misuse of antibiotics, 
contributing to emergence of antibiotic resistance. To differentiate patients with 
auto-inflammatory diseases (e.g., systemic onset juvenile idiopathic arthritis) 
from patients with acute viral and bacterial infections, Allantez et al. analyzed 
leukocyte gene expression profiles of different blood leukocyte subpopulations 
that were obtained from these patients. Based on their results, a specific blood 
signature was developed that enabled differentiation between infection and 
other febrile inflammatory diseases.41 
Along with permitting characterization of infections when pathogens are not 
directly detectable, measurement of specific gene expression by the host can 
potentially permit distinction between colonization and infection with pathogenic 
microorganisms. For example, secondary bacterial infections in children with 
viral lower respiratory tract infections are often diagnosed based on cultures 
from upper airway samples. The question remains whether the detected 
organism is really the cause of infection or whether it is just a contaminant 
from the upper airway.42 The development of a diagnostic test based on gene 
expression patterns in the host may provide more specific information. In the 
future, the development of such diagnostic tools may help the clinician choosing 
an effective treatment strategy and reducing inappropriate antibiotic use.
A diagnostic delay in infectious diseases can lead to delayed initiation of therapy, 
severe complications, and long term consequences that may include death. 
Such a delay in diagnosis may be prevented by the development of diagnostic 
biomarkers. Encephalitis, for example, is a complex, severe, neurological 
syndrome associated with significant morbidity and mortality. It is characterized 
by inflammation of the brain parenchyma, and children often present with 
drowsiness, fever, headache, seizures, or focal neurological signs. A delay in 
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treatment may lead to irreversible brain damage. Diagnosis is often presumptive 
and based on clinical characteristics or increased serological antibody titers. 
Unfortunately, the causative pathogen is often hard to detect in the central 
nervous system itself. The final diagnosis is sometimes based on the detection of 
pathogens in cultures from other sites such as the respiratory tract.43 Indirectly 
diagnosing encephalitis based on respiratory samples is rather inaccurate and 
demonstrates the need for new and better diagnostic tools. New microarray and 
proteomics technologies may contribute to improved diagnosis and treatment. 
Microarrays have been developed to simultaneously identify different viral and 
bacterial pathogens in cerebrospinal fluid (CSF).44, 45 To our knowledge, gene 
expression studies for differentiating pathogens based on the host response 
have not yet been performed. The differentiation of pathogens based on the 
host response may provide better insight in pathogenesis and disease specific 
profiles in blood or cerebrospinal fluid; it may also prove useful in diagnosing 
encephalitis. The identification of biomarkers related to clinical profiles or 
recognition of subgroups in encephalitis may help predict outcome and provide 
insight into the efficacy of therapy. 
Another infection in which diagnostic difficulties often lead to a delay in appropriate 
therapy is infective endocarditis. The clinical diagnosis of infective endocarditis 
may be difficult, as fever can be the only symptom. Rapid diagnosis followed by 
appropriate treatment is of critical importance for survival. However, in 3–31% 
of patients, causative pathogens remain undetected. Fenollar et al. analyzed 
serum samples from 88 patients with a clinical suspicion of endocarditis. They 
identified 66 different protein peaks in patients with confirmed endocarditis as 
compared to those in whom the diagnosis was excluded.46 From these 66, they 
developed a diagnostic assay based on 7 protein peaks. Despite this limited 
number of differentially expressed proteins, the test was still able to classify the 
majority (88%) of patients correctly.
Future Perspectives for Biomarker Development
Proteomic and genomic technologies have been shown to contribute to improved 
insight into disease pathogenesis and may be useful in diagnosing infections and 
providing information about disease susceptibility. However, clinical application 
of these technologies has not yet been developed. Future research should focus 
on the validation of previously identified biomarkers as well as the development 
of new diagnostic assays.
The relationship between gene expression profiles and disease outcome is 
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another interesting field of research. Prognostic biomarkers could be important 
in infectious diseases, helping to predict disease outcome and to select patients 
that may benefit from treatment. At present, their clinical use is limited to the field 
of cancer research where several studies suggest that molecular classification of 
tumors, based on gene expression, may identify distinct prognostic subtypes. 
Alizedah et al. have detected two subtypes of diffuse B-cell lymphoma with 
different survival patterns.47 The Mamma print, a test developed by the Dutch 
Cancer Institute, identifies different breast cancer subtypes by analysis of 
expression profiles involving 70 genes indicative of poor prognosis.48, 49 These 
studies are based on hierarchical clustering of subgroups with similar gene 
expression profiles. Hierarchical clustering methods in gene expression proriling 
might prove useful in pediatric infectious diseases; although to date, few studies 
have been done. Chaussabel et al. have generated a potentially useful framework 
for the visualization and functional interpretation of microarray based disease 
specific transcriptional signatures.50 In addition, the identification of biomarkers 
for monitoring inflammatory disease activity (in SLE) may contribute to better 
evaluation of disease progression and thus prognosis.50
At our department, we are currently conducting a clinical study to identify 
classifier genes that can assess disease severity in children suffering from 
viral LRTIs (VIRGO study). Using microarray analyses of blood leukocytes and 
respiratory samples, we aim to identify biomarkers that distinguish children with 
a relatively mild course of disease from those who will deteriorate and require 
supplemental oxygen or mechanical ventilation. In the early phase of infection, 
this may help decide whether a child needs to be hospitalized. 
Another potential application is to guide treatment by allowing therapy to be 
tailored both to the specific pathogen, including its antimicrobial resistance 
properties and to host characteristics, including the immune response, which 
leads to more focused drug use and improved outcome. An early example of 
genotype guided, individualized treatment strategy is the adjustment of isoniazid 
dosing regimen in adults with tuberculosis. N-acetyltransferase type 2 (NAT2) 
plays an important role in isoniazid metabolism and genetic polymorphisms of 
this enzyme can alter the response to the drug. Determining the NAT2 genotype 
prior to isoniazid administration can predict individual pharmacokinetic 
variability and therapeutic response.51
Individualized treatment strategies will be extremely helpful in treating 
tuberculosis in children. At present, children with tuberculosis are treated 
with up to four tuberculostatic agents for two months followed by a two drug 
regimen during a 4 month continuation phase. To date, there is no laboratory 
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tool to monitor response to therapy. Moreover, difficulties in identification of M. 
tuberculosis from, for example, induced sputum or gastric lavage, contribute 
to diagnostic and therapeutic uncertainty.52 Consequently, non-specific clinical 
features such as symptom improvement, weight gain, and radiological features of 
chest disease are used as markers for therapeutic response.53 The identification 
of biomarkers for tuberculosis disease activity may provide more specific 
monitoring strategies leading to more focused prescribing, fewer adverse effects, 
and less multidrug resistance.
CONCLUSIONS
Diagnostic uncertainty in infectious disease may result in a delay in diagnosis 
and inappropriate use of antibiotics. The development of diagnostic biomarkers 
for infectious diseases may contribute to more rapid diagnosis, more reliable 
discrimination between infection and non-infectious diseases, more improved 
management, better course and outcomes, and less inappropriate use of 
antibiotics. Microarray and proteomic technologies are beginning to contribute 
to improved understanding of the pathogenesis of a wide variety of infectious 
diseases and have great prospects for the future. These technologies can be 
targeted both at direct pathogen detection and at characterization of the host 
response, which may also assist in diagnosis and disease monitoring as well 
as predicting the individual’s susceptibility to disease, response to medical 
therapy, and overall prognosis. Although promising, the clinical application of 
these technologies in infectious diseases is limited at present. Current research 
focuses on sophisticated highly specialized techniques, but future work will need 
to be directed at clinical validation studies to collect data on clinical applicability, 
accuracy and cost effectiveness. Translating biomarker research into clinically 
useful tests will be difficult and time and labor intensive. The ultimate goal is 
to develop clinically relevant, cheap, rapid diagnostic and prognostic biomarker 
tests which use biological samples that are easy to obtain from the patient and 
which generate reliable and easily interpreted results.
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ABSTRACT
Background
The clinical relevance of parallel detection of multiple viruses by real-time 
polymerase chain reaction (RT-PCR) remains unclear. This study evaluated the 
association between the detection of multiple viruses by RT-PCR and disease 
severity in children with bronchiolitis.
Methods
Children less than 2 years of age with clinical symptoms of bronchiolitis were 
prospectively included during three winter seasons. Patients were categorized in 
three groups based on disease severity; mild (no supportive treatment), moderate 
(supplemental oxygen and/or nasogastric feeding), and severe (mechanical 
ventilation). Multiplex RT-PCR of 15 respiratory viruses was performed on 
nasopharyngeal aspirates.
Results
In total, 142 samples were obtained. Respiratory syncytial virus (RSV) was the most 
commonly detected virus (73%) followed by rhinovirus (RV) (30%). In 58 samples 
(41%) more than one virus was detected, of which 41% was a dual infection with 
RSV and RV. In RSV infected children younger than 3 months, disease severity 
was not associated with the number of detected viruses. Remarkably, in children 
older than 3 months we found an association between more severe disease and 
RSV mono-infections.
Conclusion
Disease severity in children with bronchiolitis is not associated with infection 
by multiple viruses. We conclude that other factors, such as age, contribute to 
disease severity to a larger extent. 
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INTRODUCTION
In young children, bronchiolitis is a common presentation of viral lower 
respiratory tract infections (LRTI). Human Respiratory syncytial virus (RSV) is the 
most frequently identified virus with detection rates up to 40–85% in infants 
hospitalized for respiratory infections during winter epidemics.1, 2 About 1–2% 
of children infected by RSV need to be hospitalized, of which 6–11% require 
intensive care admission.3, 4 Other viruses which are frequently detected in 
young children with acute respiratory tract infections include: rhinovirus (RV), 
human metapneumovirus (hMPV), parainfluenza virus (PIV), influenza virus (IV), 
adenovirus (AdV), enterovirus (EV) and human bocavirus (hBoV).5–7
Children with bronchiolitis show a great variability in disease severity. Although 
prematurity, congenital heart diseases, chronic lung disease, and immune 
deficiencies are known risk factors for severe RSV infection, half of the children 
admitted at an intensive care unit were born at term and healthy.8 It is still 
not completely understood why some children develop a more severe course of 
disease than others. Both host and viral factors contribute to viral pathogenesis 
and disease severity is the result of a dynamic interplay between these factors.
The use of real-time polymerase chain reaction (RT-PCR) has greatly improved 
the ability to diagnose viral respiratory infections. PCR based methods are more 
sensitive than conventional detection methods such as viral culture and antigen 
detection. Furthermore, RT-PCR has enabled the identification of viruses which 
are normally difficult to detect by conventional methods and has allowed the 
simultaneous detection of multiple pathogens in one sample.9
As a result of the latter, the detection of viral co-infection in children with LRTIs 
has increased from 5 to 10% using conventional methods to 10–30%.5, 10, 11 
However, the clinical implications of these co-infections remain unclear. Some 
reports have suggested that infection with multiple viruses results in a more 
severe course of disease, while others have described that disease severity did 
not differ between infections caused by one or multiple viruses.10, 12, 13 In addition, 
the presence of viruses in asymptomatic children suggests that a positive viral 
PCR does not necessarily indicate a causative relationship.14
In this study, we aim to examine whether infection with multiple viruses results 
in increased disease severity in young children with bronchiolitis. Therefore, we 
prospectively studied the association between the detection of multiple viral 
pathogens by RT-PCR and disease severity in young children with bronchiolitis 
included during three consecutive winter seasons.
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METHODS
Patients
Children younger than 2 years of age with clinical symptoms of bronchiolitis 
presenting to the emergency department or the departments of pediatrics of the 
Radboud University Medical Center or Canisius Wilhelmina Hospital, Nijmegen, 
the Netherlands, were prospectively included between November and April (winter 
season) in the years 2006–2009. Bronchiolitis was defined as an acute infection 
of the lower airways, characterized by increased respiratory effort (tachypnea 
and/or use of accessory respiratory muscles) and expiratory wheezing and/or 
crackles and/or apnea. Medical history and demographic data were collected 
from questionnaires and medical records. The study was approved by the 
Committee on Research involving Human Subjects of the University Nijmegen 
Medical Centre and written informed consent was obtained from all parents. 
Within 24 hr after admission a nasopharyngeal aspirate was collected and stored 
at -80°C for virological characterization. Patients were classified into three 
different groups based on the severity of disease. Children without hypoxia or 
need for nasogastric feeding were allocated to the mild group. The moderate 
group included children requiring hospitalization for supplemental oxygen and/
or nasogastric feeding. Supplemental oxygen was given at oxygen saturations 
below 93% measured by pulsoximetry. Finally, children requiring mechanical 
ventilation were included in the severe group.
Collection of Nasopharyngeal Aspirates
A nasopharyngeal aspirate was collected by introducing a catheter, connected 
to a collection tube and aspiration system, through one of the nostrils into the 
nasopharyngeal cavity. Then, 1.5 ml of saline was instilled into the catheter and, 
while slowly retracting the catheter, the nasopharyngeal fluid was aspirated in 
a collection tube. Subsequently the catheter was flushed with 1 ml of saline and 
added to the collection fluid. The samples were cooled and transported to the 
laboratory. The nasopharyngeal aspirate was centrifuged at 500g for 10 min at 
4°C and the supernatant was frozen at -80°C.
Virus Detection in Nasopharyngeal Secretions
Samples were analyzed by multiplex RT-PCR as previously described.9 Briefly, upon 
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thawing, nucleic acids were extracted from each sample, using the MagNA Pure 
LC and the MagNA-Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics, 
Almere, The Netherlands) according to the instructions of the manufacturer. A 
multiplex RT-PCR assay containing 15 different viral pathogens was used. This 
assay was designed for the detection of specific viral genomes belonging to IV 
type A and B, coronavirus (CoV) 229E and OC43, hBoV, EV, AdV, parechovirus 
(PeV), PIV types 1–4, hMPV, RV, and RSV. An internal control consisting of 
Phocine Herpesvirus (PhPV, IC DNA control) and Equine Arthritis Virus (EAV, IC 
RNA control) was included in the assay. RNA was reverse transcribed to cDNA 
using the TaqMan Reverse Transcription Reagents kit (Applied Biosystems, 
Nieuwerkerk Ad Ijssel, NL) in a 50 µl reaction mix containing 20 µl of nucleic 
acid isolate and random hexamers as primers, according to the manufacturer’s 
instructions. PCRs were performed on the LightCycler 480 instrument using 
LightCycler 480 Probes Master Mix (Roche Diagnostics). Validated primer/probe-
mixes were purchased from Diagenode (Liège, Belgium) and used according to 
the manufacturer’s instructions. Cycling conditions were 95°C for 5 min, followed 
by 50 cycles of 95°C for 15 sec and 55°C for 15 sec and 72°C for 20 sec. The 
amount of virus was recorded semi-quantitatively based on the cycle threshold 
value (Ct value).
Statistical Analysis
Values are expressed as percentages for discrete/categorical variables and 
as median and interquartile range (IQR) for continuous variables. As the data 
were not normally distributed, Kruskal–Wallis tests were performed to compare 
age, birth weight, and symptoms duration. Mann–Whitney U-tests were used 
for individual comparisons between mild, moderate, and severe patients. Chi-
squared tests were performed to compare categorical data. A two sided value of 
p < 0.05 was considered statistically significant.
RESULTS 
One hundred and forty two children were included. Table 1 shows the characteristics 
of the patients. The mean age was 4.5 months. The age distribution was: 76 
children younger than 3 months (54%), 25 between 3 and 6 months (18%), 27 
between 6 and 12 months (19%), and 14 between 1 and 2 years (10%). Children 
in the severe group were younger than those in the mild and moderate group 
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(2.2 vs. 4.7 and 6.4 months, respectively; p < 0.001). Twenty-seven children (19%) 
had underlying diseases, of which 18 (13%) were born prematurely (defined by 
a gestational age of 35 weeks or less) and 9 had a congenital heart defect (6%). 
Prematurity (27% vs. 6%; P = 0.02) and maternal smoking during pregnancy (33% 
vs. 12%; P = 0.01) was more often observed in the severe group compared to 
the moderate group. The lower day care attendance in the severe group can 
be explained by the lower age in this group. No other significant differences in 
clinical parameters were found between the patient groups.
Overall, 211 viruses were detected in 142 nasopharyngeal aspirates. Data are 
summarized in Table 2. In 4 of the 142 samples (3%) no virus was detected. The 
most frequently detected virus was RSV in 104 samples (73%), followed by RV, 
which was present in 43 samples (30%).
Table 1. Patient characteristics
Total 
(N = 142)
Mild 
(N = 41)
Moderate 
(N = 64)
Severe 
(N = 37)
P-value
Age (mo), mean ± SE 4.5 ± 0.39 6.4 ± 0.81 4.7 ± 0.61 2.2 ± 0.36 p< 0.0013
Male 87 (61) 23 (56) 38 (59) 26 (70) NS
Birth characteristics
Birth weight (g), mean ± SE 3261 ± 66 3202 ± 123 3405 ± 91 3094 ± 135 NS
Prematurity1 18 (13) 4 (10) 4 (6) 10 (27) p= 0.014
Maternal smoking 22/130 (17) 5/39 (13) 7/61 (12) 10/30 (33) p= 0.035
Breastfeeding 81/138 (59) 28/41 (68) 34/61 (56) 19/36 (53) NS
Underlying diseases2
CHD 9 (6) 3 (7) 2 (3) 4 (11) NS
Environmental factors
Atopic disease 18/140 (13) 6 (15) 9 (14) 3/35 (9) NS
Atopic family history 76/136 (56) 19/40 (48) 38/62 (61) 19/34 (56) NS
Passive smoking 19/134 (14) 6/39 (15) 7/63 (11) 6/32 (19) NS
Siblings 110/141 (78) 30 (73) 47/63 (75) 33 (89) NS
Daycare attendance 25/138 (18) 10/38 (26) 14/64 (22) 1/36 (3) p = 0.026
Presentation
Days of illness before         
presentation, median (IQR)
4.0 (3.0–6.0) 4.0 (3.0–7.5) 4.0 (3.0–6.0) 5 (3.0–6.0) NS
Data are presented as number (%), unless otherwise specified. Mo, months; g, grams; IQR, interquartile range; 
CHD, congenital heart defect. 1prematurity was defined as a gestational age of 35 weeks or less.2no patients 
with chronic lung diseases or immune deficiencies were included. Individual statistical comparisons were 
as follows: 3mild versus moderate, p=0.03; mild versus severe, p<0.001; moderate versus severe, p=0.01. 
4moderate versus severe, p= p0.02. 5moderate versus severe, p=0.01. 6mild versus severe, p=0.001; moderate 
versus severe, p=0.002.
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Table 2. Distribution of viruses recovered from 142 nasopharyngeal aspirates from children 
less than 2 years of age with bronchiolitis
Virus Total 
(N = 142)
Mild 
(N = 41)
Moderate 
(N = 63)
Severe 
(N = 37)
RSV 104 (73) 29 (71) 47 (75) 28 (76)
RV 43 (30) 17 (41) 20 (32) 6 (16)
AdV 13 (9) 2 (5) 7 (11) 4 (11)
EV 10 (7) 5 (12) 5 (8) 0
hMPV 9 (6) 4 (10) 4 (6) 1 (3)
IV-A 7 (5) 1 (2) 5 (8) 1 (3)
hBoV 6 (4) 4 (10) 2 (3) 0 (0)
CoV 8 (6) 5 (12) 2(3) 1 (3)
PIV-3 6 (4) 2 (5) 4 (6) 0
PeV 5 (4) 1 (2) 4 (6) 0
No virus 4 (3) 0 0 4 (11)
1 virus 80 (56) 18 (44) 35 (56) 26 (70)
> 1 virus 58 (41) 23 (56) 28 (44) 7 (19)
       2 viruses 46 (32) 18 (44) 22 (35) 6 (16)
       3 viruses 10 (7) 3 (7) 6 (10) 1 (3)
       ≥ 4 viruses 2 (1) 2 (5) 0 0
Data are presented as number (% of samples). Total exceeds 100% because of the detection of more than 
one virus per sample. RSV, respiratory syncytial virus; RV, rhinovirus; AdV, adenovirus; EV, enterovirus; 
hMPV, human metapneumovirus; IV, Influenzavirus; hBoV, human bocavirus; CoV, coronavirus; PIV, para-
influenzavirus; PeV, parechovirus. IV-B, PIV type 1,2, and 4 were not detected and not mentioned in this table.
Other respiratory viruses were found in less than 10% of the total group. RSV 
was detected in a similar frequency in the three severity groups (71–75%), while 
RV was found in 41, 32, and 16% of children with mild, moderate, and severe 
disease, respectively.
More than one virus was found in 58 of 142 subjects (41%). Figure 1 shows the 
distribution of viruses detected as a single infection or in combination with other 
viruses. RSV was detected as a single virus infection in 61 of RSV positive subjects 
(59%), followed by hMPV which was detected as a single virus in respectively 56% 
of hMPV positive samples. RV was detected as a single virus in 9 of 43 subjects 
with RV positive samples (21%). The other viruses were less frequently detected 
as single virus infections, of which hBoV, PeV, and AdV were only detected in 
combination with other viruses.
Infection with two or more viruses was more frequently found in children with 
mild and moderate disease than in those with severe disease (56 and 44%, 
respectively vs. 19%; p = 0.003). Infection with both RSV and RV was the most 
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Figure 1. Frequencies of viruses detected as a single virus or in combination with other viruses. Numbers in 
bars represent the absolute numbers of infection per virus. RSV, respiratory syncytial virus; RV, rhinovirus; 
AdV, adenovirus; EV, enterovirus; hMPV, human metapneumovirus; IV, influenza virus; hBoV, human 
bocavirus; CoV, coronavirus; PIV, para-influenza virus; PeV, parechovirus.
common combination of viruses, detected in 24 of the 58 infections caused by 
multiple viruses (41%), followed by the combination of Adv and RSV in 9 patients 
(16%).
Table 3 depicts the clinical characteristics and disease severity in children with 
either RSV mono- and multiple infections or children infected by one or more other 
viruses than RSV. Children with RSV mono-infections were younger (2.0 months 
vs. 5.6 and 5.4 months; p = 0.001) and suffered from more severe disease than 
children with RSV multiple infections and children infected with other viruses 
than RSV. Children with RSV mono infections required more often mechanical 
ventilation compared to those with RSV and one or more other viruses (36% vs. 
14%; p = 0.002). There was a trend toward lower Ct values, implicating higher 
viral load, in more severe disease in children with RSV multiple infections, but 
not in children with RSV mono-infections.
As the differences in age between the groups may have influenced our results, 
we also evaluated the association between disease severity and the detection of 
multiple viruses in children diagnosed with RSV bronchiolitis younger and older 
than 3 months (Fig. 2). Prematurity was more often observed in RSV infected 
children older than 3 months than in those below 3 months. Other risk factors 
were not different between these two age groups. Children younger than 3 
months were less often infected by multiple viruses compared to children older 
than 3 months (25% vs. 65%). In children younger than 3 months disease severity 
was not associated with the number of detected viruses, while in children older 
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than 3 months significantly less multiple infections were detected in the severe 
group compared to the mild group (33% vs. 84%; p< 0.01).
Table 3. Comparison of patient characteristics and disease severity in patients with RSV mono-
infections, multiple infections including RSV and infections caused by other viral pathogens
RSV mono 
(N = 61)
RSV multiple 
(N = 43)
RSV negative 
(N = 38)
P-values
Age (mo), median (IQR) 2.0 ± 0.39 5.6 ± 0.84 5.4 ± 0.80 p< 0.0013
Age < 3 mo 46 (75%) 15 (35%) 15 (39%) p< 0.0013
Male 41 (67%) 25 (58%) 21 (55%)
Birth characteristics
Birth weight (grams), mean ± SD 3251 ± 778 3281 ± 700 3255 ± 817
Prematurity1 9 (15%) 6 (14%) 3 (8%)
Maternal smoking 12/59 (20%) 6/40 (15%) 4/31 (13%)
Breastfeeding 33/60 (53%) 29/41 (71%) 20/37 (54%)
Underlying diseases2
CHD 1 (2%) 2 (5%) 5 (13%) p= 0.034
Environmental factors
Atopic disease 6 (10%) 6/42 (14%) 6/37 (16%)
Atopic family history 34/59 (58%) 19/42 (45%) 23/35 (66%)
Passive smoking 9/59 (15%) 4/42 (10%) 6/33 (18%)
Siblings 50 (82%) 33 (77%) 27/37 (73%)
Daycare attendance 1 (2%) 13/41 (32%) 11/36 (31%) p < 0.0013
Viral load
RSV Ct value, mean ± SD 27.2 ± 5.1 28.3 ± 4.4
       Mild 26.5 ± 7.2 29.2 ± 4.9
       Moderate 27.2 ± 4.8 28.1 ± 3.7
       Severe 27.5 ± 4.3 26.0 ± 3.4
Disease severity p = 0.0025
       Mild 11 (18%) 18 (42%) 12 (32%)
       Moderate 28 (46%) 19 (44%) 17 (45%)
       Severe 22 (36%) 6 (14%) 9 (24%)
Data are presented as number (%), unless otherwise specified. IQR, interquartile range; SD, standard deviation; 
CHD, congenital heart defect; mo, months. 1prematurity was defined as a gestation age of 35 weeks or less.
2no patients with chronic lung diseases or immune deficiencies were included. 3RSV negative versus RSV 
mono and RSV negative versus RSV multiple. 4RSV negative versus RSV mono. 5RSV multiple versus RSV mono.
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Figure 2. Percentages of infections caused by RSV (mono) or RSV and ≥1 other viruses (multiple) in children 
(A) younger and (B) older than 3 months of age for the different severity groups. Numbers in bars are absolute 
numbers.
DISCUSSION
In the present study, we evaluated the viral etiology in young children with 
bronchiolitis during three consecutive winter seasons and examined the 
association between the detection of two or more viruses by RT-PCR and disease 
severity. Our main finding was that the detection of more than one virus is not 
associated with increased disease severity in children with bronchiolitis. These 
findings debate the cumulative effect of the detection of a certain virus on 
disease severity during co-infection. In addition, viral load in children with single 
RSV infections is not associated with disease severity.
The amount of multiple infections (41%) in this study is consistent with current 
literature.5, 10, 11 However, in 97% of our samples at least one virus was detected 
which is high compared to other studies.15, 16 This may be explained by the 
inclusion period between November and April in which virus activity as reflected 
in the number of respiratory tract infections is highest in The Netherlands in 
combination with strict inclusion criteria of bronchiolitis. Furthermore, RT-PCR 
is a sensitive method to detect viruses. As the detection of a virus by RT-PCR 
does not necessarily mean that it causes symptoms, the presence of a virus, RV 
particularly, has to be interpreted carefully. Viral RNA is reported to be detectable 
in nasopharyngeal samples 4–5 weeks after infection.17, 18 RV has been detected 
in 12–35% of asymptomatic children,19–21 while asymptomatic carriage of other 
viruses, especially RSV, is uncommon with detection rates up to 5% only.7,14,18,21,22
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In this study, infection with both RSV and RV was the most common combination 
of viral co-infections. To date there has been little agreement on the effect of 
viral co-infection on disease severity in children with bronchiolitis in which both 
RSV and RV are detected. Papadopoulos et al. demonstrated that the presence 
of RV in children with RSV bronchiolitis increased the risk for severe disease 
approximately five times.13 Although this study was supported by another study 
that also described dual viral infection as a relevant risk factor for intensive care 
admission23, others did not find an additional effect of RSV/RV dual infections on 
disease severity compared to RSV single infections.15, 24
RSV has been described as the most common pathogen causing bronchiolitis 
and is associated with increased disease severity in young children and in those 
with underlying diseases.24, 25 In our study, children with RSV mono-infections 
suffered from most severe disease. The young age of the children in the most 
severe group may have caused a bias in our results, since young age is a well-
known risk factor for severe RSV infection. This is supported by our findings 
that demonstrate that children with severe symptoms upon viral infection are 
younger than children with milder manifestations of viral infection. Correction 
for age is difficult, as age, disease severity, and multiple infections are all related 
to each other. To correct for age we performed analyses in children younger and 
older than 3 months.
In children younger than 3 months no association was found between disease 
severity and the number of detected viruses. The higher prevalence of prematurity 
in children older than 3 months compared to those below 3 months suggest that 
the youngest children are most susceptible for severe disease upon viral infection 
and that in older children other risk factors, such as prematurity, become more 
important contributors to disease severity.
Interestingly, in children older than 3 months, an association between severe 
disease and the presence of one virus was observed (Fig. 2). In line with this 
finding, Marguet et al. observed a shorter duration of hospitalization in children 
with RSV/RV dual infection compared to those with single RSV infection suggesting 
that infection with RV has no additional, and potentially a protective effect on 
disease severity.12 In addition, children with multiple viral infections including 
RSV did not suffer from more severe disease compared to those without RSV. 
This may be explained by either differences in age or type of immune response. 
The induced immune response upon viral infection may protect the host from 
infection with a second virus as has been proposed by Greer et al. who described 
a potential protective effect of RV through the stimulation of the interferon (IFN) 
stimulated genes inducing an antiviral state that prevents the patient from a 
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more severe course of disease after second infection with a new virus.26
We also observed an association between age and multiple infections. Less 
multiple infections were observed in younger children. This has been described 
before11 and possible explanations why detection of more than one virus is 
less frequently observed in the most youngest infants are; (1) less exposure to 
viruses due to less day-care attendance, (2) the development of more and earlier 
severe symptoms upon single viral infection, and (3) partial protection against 
respiratory viruses because of protective maternal antibodies which disappear 
with age.
In addition to host factors, such as young age and underlying diseases, type of 
virus and viral load have been described to play a role in disease severity.27, 28 In 
our study, a trend toward higher RSV loads in children with more severe disease 
was observed in children with RSV multiple infection but not in those with RSV 
mono-infections. Most studies have described a positive relation between higher 
RSV load and disease severity.28–31 In addition, an association of higher viral 
load with young age has been previously reported.32 Our sample size was rather 
small compared to these studies and age specific analyses for viral loads were 
therefore not performed. Finally, a number of limitations need to be considered. 
First, we only included children during the winter season, from November until 
April. This may have created a bias toward a higher incidence of RSV. While RV 
infections are present throughout the year with peaks in autumn and spring, RSV 
does rarely appear out of winter season in the Netherlands. Data from a registry 
of the Dutch Working Group on Clinical Virology showed that in 2006 and 2007 
51% of the annual RV infections were detected between November until April 
compared to 94% of the annual RSV infections (published with permission of the 
Dutch Working Group on Clinical Virology). Second, we only included children 
presenting in a hospital, which may have caused a bias. Third, we analyzed 
infections with other viruses than RSV as a group (RSV negative infections) 
instead of analyzing them separately, because the low number of samples 
infected with other viruses than RSV. To further reveal the association between 
young age, multiple infections and disease severity in children with bronchiolitis, 
more large-scale clinical studies in various health care settings are required.
To conclude, in this study we showed that disease severity in children with 
bronchiolitis is not associated with infection by multiple viruses. Remarkably, 
in children older than 3 months we found an association between more severe 
disease and RSV mono-infections. Our results suggest that other factors than 
infection with multiple viruses contributes to disease severity, of which age is the 
most important risk factor.
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ABSTRACT
Introduction
Matrix metalloproteinases (MMPs) play an important role in respiratory 
inflammatory diseases, such as asthma and chronic obstructive pulmonary 
disease. It was hypothesized that MMP-8 and MMP-9 may function as biological 
markers to assess disease severity in viral lower respiratory tract infections in 
children. 
Methods
MMP-8 and MMP-9 mRNA expression levels in peripheral blood mononuclear 
cells (PBMCs) and granulocytes obtained in both the acute and recovery phase 
from 153 children with mild, moderate, and severe viral lower respiratory tract 
infections were determined using real-time PCR. In addition, MMP-8 and MMP-9 
concentrations in blood and nasopharyngeal specimens were determined during 
acute mild, moderate, and severe infection, and after recovery using ELISA. 
Furthermore, PBMCs and neutrophils obtained from healthy volunteers were 
stimulated with RSV, LPS (TLR4 agonist), and Pam3Cys (TLR2 agonist) in vitro. 
Results
Disease severity of viral lower respiratory tract infections in children is associated 
with increased expression levels of the MMP-8 and MMP-9 genes in both PBMCs 
and granulocytes. On the contrary, in vitro experiments showed that MMP-8 and 
MMP-9 mRNA and protein expression in PBMCs and granulocytes is not induced 
by stimulation with RSV, the most frequent detected virus in young children with 
viral lower respiratory tract infections. 
Conclusion
These data indicate that expression levels of the MMP-8 and MMP-9 genes in both 
PBMCs and neutrophils are associated with viral lower respiratory tract infections 
disease severity. These observations justify future validation in independent 
prospective study cohorts of the usefulness of MMP-8 and MMP-9 as potential 
markers for disease severity in viral respiratory infections. 
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INTRODUCTION
Respiratory viral infections are an important cause of hospitalization among 
children younger than 5 years of age with estimated population-based 
hospitalization rates of 1–2%.1-3 Human respiratory syncytial virus (RSV) is the 
most commonly identified virus with detection rates up to 40–85% in infants 
hospitalized for respiratory infections during winter epidemics.4-6 The clinical 
manifestations range from a simple common cold to severe lower respiratory 
tract symptoms requiring mechanical ventilation. About 6–11% of the children 
admitted to hospital with RSV infection require intensive care admission.7, 8 
Up to 35% of the children hospitalized with bronchiolitis did not receive any 
supportive intervention.9  On the other hand, it is crucial to avoid discharge of 
those children who may experience clinical deterioration. Among children sent 
home with the diagnosis bronchiolitis, 4.6–6.8% required hospitalization later on 
during infection.10, 11 Biomarkers to assess severity of viral lower respiratory tract 
infections (LRTIs), in particular RSV infection, may be helpful to clinicians in the 
decision whether a child needs to be hospitalized.
Lung injury during severe RSV infection is thought to be mediated by both 
direct cytotoxic effects of the virus and the result of the induced inflammation. 
Pathologic features of severe RSV infection include extensive bronchiolar 
epithelial destruction, peribronchial lymphocyte infiltration, necrosis of 
bronchial epithelium, and mucus plugs in the small bronchioles.12, 13 Matrix 
metalloproteinases (MMPs) are family of zinc endopeptidases capable of 
degrading components of the cellular matrix, and consequently, are suggested to 
be important in several diseases associated with tissue remodeling. Pronounced 
increase in their expression is thought to be associated with a variety of 
inflammatory disease, including respiratory diseases.14
MMPs play a role in cellular migration of neutrophils, lymphocytes, and other 
immune cells to the lungs by degrading extracellular matrix, but also have pro- 
and anti-inflammatory properties. The activity of MMPs is regulated through 
binding to tissue inhibitor of metalloproteinases (TIMPs) leading to inactivation. 
An imbalance in production and activation, or inactivation by TIMPs might 
augment airway inflammation through direct or indirect effects upon signaling 
pathways that influence migration of leukocytes through the tissues.14,15 
Increased concentrations and activity of MMP-8 and MMP-9 have been observed 
in respiratory samples obtained from adults and children with acute lung injury 
and pneumonia16-19 as well as in chronic lung diseases such as asthma.20, 21 
In addition, a relation between MMP-9 concentrations and disease severity of 
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pneumonia16, 18 and asthma22, 23 has been described.
Yeo et al. have reported that MMP-9 protein expression is increased in human 
airway epithelial cell lines infected with RSV.24 In addition, MMP-9 gene expression 
is increased in the lungs of RSV-infected mice.25 Another study demonstrated 
that nasopharyngeal samples from infants infected with RSV and parainfluenza 
virus (PIV) contain increased MMP-9 and TIMP-1 concentrations.26
In the current study, it was hypothesized that MMP-8 and MMP-9 gene expression 
levels, and consequently, MMP-8 and MMP-9 plasma concentrations may function 
as biomarkers for disease severity in viral LRTIs.
METHODS
Study Design
Children younger than 5 years of age with laboratory confirmed viral LRTIs were 
prospectively included during three consecutive winter seasons (November–April 
in the years 2006–2009). Patients with congenital heart or lung disease, known 
immunodeficiencies or glucocorticoid use were excluded. Viral LRTI was defined 
as an acute infection of the lower airways, characterized by increased respiratory 
effort (tachypnea and/or use of accessory respiratory muscles and/or expiratory 
wheezing and/or crackles and/or apnea) in combination with a confirmed 
viral etiology by multiplex real-time polymerase chain reaction (RT-PCR) on 
nasopharyngeal washes as described previously.27 The multiplex RT-PCR assay 
detect 15 different viral pathogens; influenza virus types A and B, coronavirus 
229E and OC43, human bocavirus, enterovirus, adenovirus, parechovirus, PIV 
types 1–4, human metapneumovirus, rhinovirus (RV), and RSV.
Written informed consent was obtained from all parents and the study was 
approved by the Committee on Research involving Human Subjects of the 
University Nijmegen Medical Centre. Within 24 hr after admission a blood sample 
and nasopharyngeal aspirate was collected and parents from hospitalized children 
were asked permission to draw a second blood sample and nasopharyngeal 
aspirate 4–6 weeks after admission. Medical history, demographics, and clinical 
parameters were collected from questionnaires and medical records. Patients 
were classified into three different groups based on severity of disease. Children 
without hypoxia or severe feeding problems were allocated in the mild group, 
those requiring hospitalization for supplemental oxygen (oxygen saturations 
<93%) and/or nasogastric feeding in the moderate group and children requiring 
mechanical ventilation in the severe group.
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Sample Collection
A nasopharyngeal aspirate was collected by introducing a catheter, connected to 
a collection tube and an aspiration system, into the nasopharyngeal cavity. Then, 
1.5 ml of saline was instilled into the catheter and, while slowly retracting the 
catheter, the nasopharyngeal fluid was aspirated in a collection tube. Afterwards 
the catheter was flushed with 1 ml of saline and added to the collection fluid. 
The samples were kept cold and immediately transferred to the laboratory. The 
nasopharyngeal aspirate was centrifuged at 500g for 10 min at 4°C to spin down 
the mucus and cells, after which the supernatant was frozen at -80°C.
Five milliliters of blood was collected into sodium heparin tubes and directly 
transferred to the laboratory. A thin blood smear was prepared and stained 
with (May-Grunwald-)Giemsa to determine the percentages of granulocytes and 
PBMCs. PBMCs were obtained by density gradient centrifugation (Lymphoprep®; 
Axis Shield, Oslo, Norway) and stored in Trizol at -80°C for RNA isolation. Plasma 
samples were stored at -80°C for enzyme-linked immunosorbent assays (ELISAs).
Quantitative mRNA Expression of MMP-8 and MMP-9 in PBMCs and 
Granulocytes
RNA from PBMC and granulocytes was extracted using Trizol (Invitrogen Life 
Technologies, Bleiswijk, The Netherlands) according to the manufacturers’ 
protocol. Subsequently, a clean-up was performed on total RNA with the RNeasy 
Minikit (Qiagen, Venlo, The Netherlands) according to the manufacturers’ 
instructions. Total RNA (2 µg, measured with spectrophotometry, Nanodrop, 
Wilmington) was reverse transcribed using a high-capacity cDNA reverse 
transcription kit according to the manufacturers’ instructions (Applied 
Biosystems, Foster City, CA) and cDNA was stored at -20°. The relative gene 
expression was measured with SYBR Green PCR Mastermix (Applied Biosystems; 
P/N 4367659) on the ABI 7500 Fast Real Time PCR system using standard 
program and software. After 40 repetitions a dissociation curve was performed 
as control for the specificity of the PCR reaction. The following primers were 
used: hActin F: cgtcacacttcatgatggagttg, hActin R: cttccttcctgggcatgga; hMMP-
9 F: gccccccttgcataagga, hMMP-9 R: cagggcgaggaccatagag; and hMMP-8 F: 
ccagtttgacatttgatgctatcac, hMMP-8 R: ctgaggatgccttctccagaa. All reactions were 
performed in duplo. Actin was used as reference gene. After a quality check 
(melting temp, curve of reaction, and standard deviation Ct) the ΔCt of the MMP-
8 and MMP-9 to actin was calculated and expressed as relative expression.
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MMP-8, MMP-9, and TIMP-1 Concentrations in Plasma and 
Nasopharyngeal Washes
Concentrations of total MMP-8 and MMP-9 in plasma, nasopharyngeal aspirate, 
and supernatants of cell stimulation assay were measured by ELISA according to 
the manufacturers’ protocol (DuoSet, R&D systems, Abingdon, UK). In addition, 
TIMP-1 concentrations in plasma were determined as described above.
In Vitro Stimulation of PBMCs and Neutrophils From Healthy Volunteers
After informed consent, blood was drawn from healthy volunteers and collected 
in EDTA tubes. Blood was diluted 1:1 with pyrogene-free phosphate buffered 
saline (PBS) (Lonza, Basel, Switzerland). PBMCs and granulocytes were obtained 
by density gradient centrifugation (Lymphoprep®; Axis Shield). After washing, 
PBMCs were brought at a concentration of 5 × 106 cells/ml in serum-free RPMI 
medium (Gibco, Invitrogen, Paisley, UK) with 100 U/ml of penicilin/streptavidin 
(Gibco, Invitrogen). Granulocytes were purified by lysing the red blood cells 
(0.155 M NH4Cl, 0.0001 M Na2EDTA and 0.01 M KHCO3), and, after washing, 
granulocytes were suspended at a concentration of 5 × 106 cells/ml in RPMI 
medium supplemented with 0.5% human serum albumin (Sanquin, Amsterdam, 
The Netherlands).
Mononuclear cells (5 × 105 cells in 100 µl) were added to round-bottom 96-well 
plates and stimulated with either 100 µl culture medium (negative control), 1 ng/
ml lipopolysacharides (LPS, Escherichia coli serotype 055:B5, Sigma–Aldrich, 
purified as described previously 28 or MOI 1 of RSV A2 (kindly provided by Dr. 
R. de Swart, Erasmus MC, Rotterdam, The Netherlands). RSV A2 was cultured 
in HeLa cells and purified by ultracentrifuge over a sucrose 30% gradient. After 
incubation for 24 hr at 37°C and 5% CO2. supernatant was collected and stored 
at -80°C. Neutrophils (5 × 105 cells in 100 µl) were stimulated and incubated in the 
same way for 4 hr and supernatant was stored at -80°C. Apoptosis was determined 
on the FACScalibur by Annexin V apoptosis detection kit (BD) according to the 
manufacturers’ instructions and no differences between stimuli were found after 
4 hr.
Statistics
Values are expressed as percentages for categorical variables and as mean 
and standard error (SE) or median and interquartile range (IQR) for continuous 
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variables. For variables that were not normally distributed, Kruskal–Wallis test 
was performed to compare continuous variables followed by Mann–Whitney 
U-tests for individual comparisons. Chi-squared tests were performed to compare 
categorical data. A two-sided value of p< 0.05 was considered statistically 
significant.
RESULTS
Patient Characteristics
In total, 153 patients were included. In 109 patients (71%) RSV was detected. RSV 
positive children were significantly younger than RSV negative children. No other 
significant differences were observed between these groups (Table 1).
Table 1. Patient characteristics
Total 
(N = 153)
RSV+ 
(N = 109)
RSV- 
(N = 44)
p-value
Age (days ± SE) 206 ± 26 149 ± 20 347 ± 72 <0.001
Male 95 (62%) 70 (64%) 25 (57%) NS
Prematurity 21 (14%) 16 (15%) 5 (11%) NS
Family history of atopy 82 (57%) 56 (54%) 26 (63%) NS
Symptomatic days before 
presentation (days ± SE)
5.5 ± 0.4 5.2 ± 0.4 6.3 ± 1.1 NS
Data are presented as number (%), unless otherwise specified. For variables that were not normally distributed, 
Kruskal–Wallis test was performed to compare continuous variables followed by Mann–Whitney U-tests for 
individual comparisons. Chi-squared tests were performed to compare categorical data. A two-sided value of 
p<0.05 was considered statistically significant. NS, not significant, SE, standard error.
A total of 54, 60, and 39 children were classified as having mild, moderate, 
and severe disease, respectively. Patients with severe disease were significantly 
younger compared to those with mild disease (105 days vs. 278 days; p< 0.05). 
More prematurely born children were observed in the severe group compared 
to the mild and moderate group. No other significant differences in clinical 
parameters were found between the different severity groups (Table 2). In addition, 
total leukocytes and neutrophil counts were comparable between all groups.
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Table 2. Patient characteristics for mild, moderate, and severe infections
Total      
(N = 153)
Mild       
(N = 54)
Moderate 
(N = 60)
Severe 
(N = 39)
p-value
Age (days) 206 ± 26 278 ± 52 206 ± 38 105 ± 36 <0.01
Male (%) 95 (62%) 32 (59%) 36 (60%) 27 (69%) NS
Prematurity (%) 21 (14%) 5 (9%) 6 (10%) 10 (26%) <0.05
Family history of atopy (%) 82 (57%) 27 (52%) 36 (62%) 19 (55%) NS
Symptomatic days before 
presentation
5.5 ± 0.4 7.0 ± 1.1 4.8 ± 0.3 4.6 ± 0.4 NS
RSV (%) 109 (71%) 35 (65%) 45 (75%) 29 (74%) NS
Leukocytes counts 8.7 ± 0.7 9.8 ± 1.1 8.6 ± 1.0 8.2 ± 1.4 NS
Neutrophil counts 3.5 ± 0.5 3.1 ± 0.7 2.9 ± 0.7 4.3 ± 1.1 NS
Data are presented as percentages or mean  ± standard error (SE). Cell counts are given as 106 cells/ml ±SE. 
For variables that were not normally distributed, Kruskal–Wallis test was performed to compare continuous 
variables followed by Mann–Whitney U-tests for individual comparisons. Chi-squared tests were performed 
to compare categorical data. A two-sided value of p<0.05 was considered statistically significant. NS, not 
significant.
Disease Severity Is Associated With Increased Gene Expression Levels 
of MMP-8 and MMP-9 in Both Granulocytes and PBMCs
During acute viral infection we observed increased expression of the MMP-
8 and MMP-9 genes in both PBMCs and granulocytes compared to recovery. 
No differences in gene expression of MMP-8 and MMP-9 in both PBMCs and 
granulocytes were found between RSV positive and RSV negative children during 
acute infection. In general, gene expression of the MMP-9 gene was higher in 
granulocytes than in PBMCs. For MMP-8, the same trend was noticed (Figure 1A 
and B and figure 2A and B).
Increased disease severity was associated with higher expression levels of 
the MMP-8 and MMP-9 genes in both PBMCs and granulocytes. To determine 
whether this association was dependent on the type of virus, RSV positive and 
RSV negative children were analyzed separately. For RSV positive patients, the 
same association was found between disease severity and gene expression 
levels (Figs. 1C, D and 2 C, D). For RSV negative patients, MMP-8 and MMP-9 
gene expression was higher in children with severe disease compared to those 
with mild. In addition, RSV negative children with severe disease had higher 
expression levels of the MMP-8 gene in both PBMCs and granulocytes compared 
to those with moderate disease (data not shown).
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Figure 1. Gene expression levels of MMP-8 and MMP-9 in granulocytes from children with viral LRTIs. Relative 
gene expression levels (mean ± se) of MMP-8 (A) and MMP-9 (B) in granulocytes from children during acute 
RSV positive and RSV negative viral LRTIs and after recovery of infection. Relative gene expression levels of 
MMP-8 (C) and MMP-9 (D) for RSV positive children with mild, moderate, and severe disease. Mann–Whitney 
U-test was performed to compare children infected by RSV and other viruses. Paired analyses (Wilcoxon) were 
performed to compare acute and recovery samples. A two-sided value of P < 0.05 was considered statistically 
significant.
Disease Severity Is Associated With Increased MMP-8 Plasma Levels
The plasma concentration of MMP-8 was increased during acute RSV infection 
compared to recovery. In RSV negative patients this difference was not significant 
(Fig. 3A). Higher MMP-8 plasma concentrations were found in children with 
severe and moderate disease compared to those with mild disease (Fig. 4A). In 
nasopharyngeal washes, the concentration of MMP-8 was increased during acute 
RSV infection compared to recovery washes (Fig. 3D). No significant differences 
of MMP-8 concentrations in the nasopharyngeal washes were observed between 
the different severity groups (Fig. 4D). In both RSV positive as RSV negative 
patients MMP-9 concentrations in the nasopharyngeal washes were increased 
during infection (Fig. 3E). Children with moderate disease had increased MMP-9 
concentrations in nasopharyngeal washes compared to those with mild disease.
66
Chapter 4
Figure 2. Expression levels of the MMP-8 and MMP-9 genes in PBMCs from children with viral LRTIs. Relative 
gene expression levels (mean ± standard error) of MMP-8 (A) and MMP-9 (B) in PBMCs from children during 
acute RSV positive and RSV negative viral LRTIs and after recovery of infection. Relative gene expression levels 
of MMP-8 (C) and MMP-9 (D) for RSV positive children with mild, moderate, and severe disease. Mann–Whitney 
U-test was performed to compare children infected by RSV and other viruses. Paired analyses (Wilcoxon) were 
performed to compare acute and recovery samples. A two-sided value of p<0.05 was considered statistically 
significant.
However, no significant differences in MMP-9 concentrations were observed 
in children with severe disease compared to those with mild and moderate 
disease (Fig. 4E). TIMP-1 concentrations in plasma or nasopharyngeal washes 
were not increased during acute infection and there was no correlation with 
disease severity (Figs. 3C and 4C). The ratio between MMP-9 and TIMP-1 plasma 
concentrations, an indicator for enzyme activity, was not increased during acute 
RSV infection. This ratio was significant higher in the recovery plasma of RSV 
negative patients compared to the acute samples (Fig. 3F). No relation between 
disease severity and the plasma MMP-9 and TIMP-1 ratio was found (Fig. 4F).
No differences in plasma or nasopharyngeal levels of MMP-8, MMP-9, and TIMP-
1 plasma concentrations were observed between RSV positive and RSV negative 
children during acute viral respiratory infection. In general, MMP-8 and MMP-9 
concentrations were higher in nasopharyngeal samples compared to plasma.
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Figure 3. MMP-8 and MMP-9 concentrations in plasma and nasopharyngeal samples from children during 
acute LRTIs and after recovery. Plasma concentration of MMP-8 (A), MMP-9 (B), TIMP-1 (C), and concentration in 
nasopharyngeal washes of MMP-8 (D) and MMP-9 (E) from children during acute RSV positive and RSV negative 
viral LRTIs and after recovery of infection. Ratio’s between plasma MMP-9 and TIMP-1 (F). Concentrations (ng/
ml) are given in mean ± se. Mann–Whitney U-test was performed to compare children infected by RSV and 
other viruses. Paired analyses (Wilcoxon) were performed to compare acute and recovery samples. A two-
sided value of p<0.05 was considered statistically significant.
MMP-9 Plasma Concentrations Are Correlated With the Number of 
Granulocytes
MMP-9 plasma concentrations correlated with the number of granulocytes 
measured during acute RSV infection (Pearson’s correlation coefficient 0.33; 
P = 0.019). No correlation was found between the number of granulocytes and 
MMP-8 plasma and nasopharyngeal concentrations and MMP-9 nasopharyngeal 
concentrations (data not shown). Furthermore, there was no correlation between 
symptomatic days before presentation and levels of MMP-8 and MMP-9 gene 
expression or concentration of the protein in plasma and nasopharyngeal washes 
(data not shown).
MMP-8 and MMP-9 mRNA and Protein Expression by PBMCs and Neu-
trophils Is Not Induced by RSV In Vitro
To investigate whether the source of plasma MMP-8 and MMP-9 during RSV 
infection was the result of direct interaction of PBMCs or neutrophils with RSV, 
68
Chapter 4
Figure 4. MMP-8 and MMP-9 concentrations in plasma and nasopharyngeal samples from children with mild, 
moderate, and severe RSV infection. For RSV positive children plasma concentration of MMP-8 (A), MMP-9 (B), 
TIMP-1 (C), and concentration in nasopharyngeal washes of MMP-8 (D) and MMP-9 (E) in mild, moderate, and 
severe disease are given. Ratio’s between plasma MMP-9 and TIMP-1 (F). Concentrations (ng/ml) are given 
in mean± standard error. Mann–Whitney U-tests were performed to compare mild, moderate, and severe 
disease. A two-sided value of P < 0.05 was considered statistically significant.
PBMCs and neutrophils were stimulated with RSV in vitro. Stimulation of PBMCs 
with LPS (TLR4 agonist) induced MMP-9 secretion, whereas stimulation with 
RSV had no effect. None of the stimuli induced MMP-8 secretion by PBMC (Fig. 
5A). Stimulation of PBMCs with RSV did not result in increased gene expression 
of MMP-8 and only a moderate increase of MMP-9 expression was observed 
(Fig. 5B). Unstimulated neutrophils secreted high levels of MMP-8 and MMP-9. 
Stimulation with LPS and RSV had no effect on the release of MMP-8 and MMP-9 
by neutrophils (Fig. 5C).
DISCUSSION
This study demonstrates that disease severity of viral LRTIs in children is 
associated with increased gene expression levels of the MMP-8 and MMP-9 genes 
in both PBMCs and granulocytes. These associations were observed in children 
with lower respiratory tract infections caused by either RSV or other respiratory 
viruses. The in vitro experiments in this study show that MMP-8 and MMP-9 mRNA 
and protein expression in PBMCs and granulocytes is not induced by stimulation 
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with RSV. Consequently, other factors than direct viral interaction induce gene 
expression in PBMCs and granulocytes.
This is the first study that describes an association between MMP-8 and MMP-9 
gene expression and disease severity of viral LRTIs in children. This association 
was significant for children with a RSV infection and there was a trend for children 
with a viral LRTI caused by other viruses, indicating to a more general marker for 
disease severity during respiratory viral infections.
Several studies have shown that transcriptional analysis of peripheral blood 
cells can be used to discriminate the etiology and disease outcome.29-32 
Ramilo et al. compared the transcriptional profiles of PBMCs of children with 
infectious diseases, and identified a set of genes that could separate influenza A 
Figure 5. Stimulation of PBMCs and neutrophils by LPS 
and RSV in vitro. Human PBMC of healthy volunteers (n 
¼ 4) were stimulated with LPS (1 ng/ml) or RSV A2 (MOI 
1) and MMP-8 and MMP-9 concentrations in supernatant 
were measured after 24 by ELISA (A) or at transcriptional 
level by q-PCR (B). Neutrophils were stimulated for 4 hr 
and MMP levels were determined in the supernatant (C).
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infections from bacterial infections (Staphylococcus aureus, Escherichia coli, and 
Streptococcus pneumoniae).31 Both MMP-8 and MMP-9 were not represented in 
the selected set of classifier genes. Retrospective analysis of the microarray data 
set was performed by us, and showed that mRNA expression of MMP-8 and MMP-
9 were elevated in all groups compared to controls, indicating a more general 
marker for inflammatory disease (data not shown). No data were available on 
disease severity, so it is not possible to exclude an association with disease 
severity. In an experimental model of viral infection of the upper respiratory tract 
in adults with RSV, influenza, and RV, no up-regulation of MMP-8 and MMP-9 
was detected in whole blood transcriptional profiles.33 However, these infections 
were all mild with consequently low levels of inflammatory markers.
This study shows that in MMP-8 plasma concentrations were increased during 
acute infection with RSV. Although MMP-8 plasma concentrations were higher 
in moderate and severe disease compared to mild disease, there was no step-
wise relation with disease severity. This is in contrast with the gene expression 
data and indicates a different source of plasma proteins than the circulating cell 
population. This is in line with the study of Hartog et al. in which they found 
elevated MMP-8 concentrations in plasma and lung fluid in adults with hospital-
acquired bacterial pneumonia compared to healthy controls.16 They found 
an association between clinical severity scores and MMP-8 concentrations in 
bronchoalveolar lavage fluid, but not in plasma.
Although MMP-9 plasma concentrations were increased during acute viral 
respiratory infections in children, no association between MMP-9 plasma 
concentrations and disease severity was found in this study. Previous studies 
have described such an association for several inflammatory diseases, such 
as pneumonia16, tuberculosis infections34, septic shock35, and asthma.22 This 
may be related to the fact that, in consistence with other studies36-38, MMP-9 
concentrations were correlated to neutrophil counts, although no significant 
differences in neutrophil counts between the different severity groups were 
observed in this study.
TIMP-1 is an inhibitor of the protease activity of all known MMPs.39 Previous 
studies have described an association between an imbalance between MMP-9 
and TIMP-1 and tissue degradation and airflow obstruction in asthma and chronic 
bronchitis.37, 40 In addition, elevated MMP-9/TIMP-1 ratios have been observed in 
plasma from patients with status asthmatics.22 Furthermore, it has been shown 
that increased TIMP-1 concentrations, but not MMP-9, in nasopharyngeal washes 
of RSV-infected children correlated with disease severity and this suggests that a 
disturbed MMP-9/TIMP-1 homeostasis contributes to disease severity.26 The ratio 
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of MMP-9 and TIMP-1 concentration in plasma did not show a correlation with 
disease severity in this study and indicates that MMP-9 is differentially regulated 
at the mucosal level during infection.
Although both MMP-8 and MMP-9 concentrations in nasopharyngeal samples 
were increased during acute infection compared to recovery samples 
no association with disease severity was observed. The wide range of 
nasopharyngeal concentrations between individuals is partly due to the variation 
induced by aspiration volumes from the nasopharyngeal cavity. Currently, more 
standardized methods have been developed, such as flocked swabs, which can 
be used for viral diagnostics as well as protein analysis.41, 42 Normalization of 
protein levels to stable metabolites present in the mucus might further improve 
the use of nasopharyngeal samples for diagnostics, although these methods are 
not available yet. Further it should be taken into account that upper respiratory 
samples do not necessarily represent the situation in the lower airways and the 
systemic inflammatory response.
The in vitro experiments in this study show that MMP-8 and MMP-9 mRNA and 
protein expression in PBMCs and granulocytes were not induced by stimulation 
with RSV. Other factors than direct interaction between RSV and host cells could 
explain the increased gene expression levels of MMP-8 and MMP-9 in children 
with viral LRTIs. Influx of bone marrow-derived neutrophil precursors in blood 
from children with severe RSV infections can result in higher MMP-9 expression 
due to granule protein production, such as MMP-8 and MMP-9, during immature 
stages of neutrophil development.43  Also inflammatory mediators, such as 
growth factors, pro-inflammatory cytokines, oxidative stress upon viral infection 
can induce elevated gene expression levels of MMPs.14 It has also been shown that 
the lung injury caused by mechanical ventilation has resulted in increased MMP-
8 and MMP-9 expression.44 However, in this study, the last mentioned cannot 
completely explain the differences in gene expression since also differences 
in gene expression between patients with mild and moderate disease were 
observed, all non-ventilated patients.
The results of this study indicate that neutrophils are the major source of MMP-
9 production. The higher MMP-8 and MMP-9 concentrations in nasopharyngeal 
samples compared to plasma may therefore reflect the influx and degranulation 
of neutrophils in the airways during infection.
This is in contrast to observations made by others that suggest that airway 
epithelial cells are the primary source of MMPs. It has been shown that MMP-9 
gene expression is increased in human airway epithelial cell lines infected with 
RSV.24 However, another study indicated that infected human airway epithelial 
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cells are not the primary source of MMPs and TIMP-1 and that infiltrating 
leukocytes are responsible for MMP-9 in airway samples.26 Also in a RSV infection 
model in mice, of which it is known that the epithelial cells are not infected, it 
was demonstrated that gene expression of MMP-9 is elevated in the lungs most 
likely by infiltrating cells.25 For MMP-8, no correlation with neutrophil counts was 
observed and gene expression levels in granulocytes and PBMCs were comparable 
indicating that MMP-8 transcription and secretion was different regulated than 
MMP-9. This is supported by differences in the degranulation of subcellular 
neutrophilic granules, in which MMP-8 and MMP-9 are stored and differences 
in transcriptional events that induce MMP-8 and MMP-9 mRNA expression.45 For 
example, it has been shown that pro-inflammatory cytokines, particularly IL-1ß 
play a central role in the modulation of MMP-8 expression.46, 47 Future studies 
may reveal the role for MMP-8 plasma concentrations as a potential biomarker 
to assess disease severity in viral lower respiratory tract infections in children.
The relation of MMP-8 and MMP-9 with viral load in the nasopharyngeal cavity 
have not been investigated in this study. In experimental respiratory viral 
infection models, inflammatory markers such as cytokines correlated with viral 
load and the symptom scores, indicating that the amount of virus is the driving 
force for inflammation.48 Also in children, disease severity has been associated 
with high viral titers.49, 50 Further research might reveal the role of inflammatory 
mediators in the pathogeneses of severe respiratory viral infections.51 In this 
light, it is interesting to consider inflammatory mediators, such as MMPs, as 
potential targets for therapy.
Some limitations of this study need to be considered. First, the younger age of 
the children with the most severe lower respiratory tract infections may have 
caused a bias in the results. However, age was not correlated with MMP-8 and 
MMP-9 plasma concentrations, which suggests that age alone cannot explain the 
observed differences. According to these results, Thrailkill et al. did not found 
significant differences in MMP-8 and MMP-9 serum concentrations in children, 
2–18 years of age.52 Second, multiple viruses were detected in 40% children 
with lower respiratory tract infections and it cannot be entirely exclude that the 
presence of multiple viruses have induced a different inflammatory response.
The results of this study suggest that the expression of MMP-8 and MMP-
9 genes are potential marker candidates for diagnostic use to assess disease 
severity in children with viral LRTIs. Markers for disease severity do not have 
clinical implication at present, because currently antiviral treatment is not 
available. However, new antiviral treatment of patients will be based most likely 
on diagnostics predicting disease severity and susceptibility.53, 54 Furthermore, 
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markers for disease severity are also important for research purposes to study 
effects of interventions, such as treatment. Although currently no biomarkers 
at transcription level are available in the clinic, because the processing is time 
consuming, innovative techniques may enable rapid analysis of the expression 
of multiple genes at transcriptional level in the near future.55
In conclusion, increased expression of the MMP-8 and MMP-9 genes was 
observed in PBMCs and granulocytes obtained from children with severe viral 
lower respiratory tract infections. MMP-8 and MMP-9 gene expression levels in 
circulating cells may be useful markers to support clinical evaluation of disease 
severity in viral respiratory infections. These results justify future follow-up, that 
is, the validation in independent prospective study cohorts of the usefulness of 
MMP-8 and MMP-9 as a potential markers for disease severity in viral respiratory 
infections.
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ABSTRACT
Background
Current tools to predict the severity of respiratory syncytial virus (RSV) infection 
might be improved by including immunological parameters. We hypothesized 
that a combination of inflammatory markers would differentiate between severe 
and mild disease in RSV-infected children. 
Methods 
Blood and nasopharyngeal samples from 52 RSV-infected children were collected 
during acute infection and after recovery. Retrospectively, patients were 
categorized into three groups based on disease severity: mild (no supportive 
treatment), moderate (supplemental oxygen and/or nasogastric feeding), and 
severe (mechanical ventilation). Clinical data, number of flow-defined leukocyte 
subsets, and cytokine concentrations were compared. 
Results
Children with severe RSV infection were characterized by young age; 
lymphocytopenia; increased interleukin (IL)-8, granulocyte colony-stimulating 
factor (G-CSF), and IL-6 concentrations; and decreased chemokine (C-C motif) 
ligand (CCL-5) concentrations in plasma. The combination of plasma levels of 
IL-8 and CCL-5, and CD4+ T-cell counts, with cutoff values of 67 pg/ml, 13 ng/
ml, and 2.3 × 106/ml, respectively, discriminated severe from mild RSV infection 
with 82% sensitivity and 96% specificity. 
Conclusion
This study demonstrates that the combination of CD4+ T-cell counts and IL-8 
and CCL-5 plasma concentrations correlates with disease severity in RSV-infected 
children. In addition to clinical features, these immunological markers may be 
used to assess severity of RSV infection and guide clinical management.
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INTRODUCTION
Respiratory syncytial virus (RSV) is a common cause of bronchiolitis in young 
children.1, 2 The clinical manifestations of RSV infection range from a common 
cold to severe lower respiratory tract infections requiring mechanical ventilation. 
About 1–2% of RSV-infected children are hospitalized3–5, of which 6–11% require 
intensive care admission.3, 6 Although young age, prematurity, congenital heart 
diseases, chronic lung diseases, and immune deficiencies are risk factors for 
severe RSV infection, more than half of the RSV-infected children requiring 
intensive care admission were otherwise healthy.3, 7 It has been reported that 
35% of children hospitalized with bronchiolitis did not receive any supportive 
intervention.8 On the other hand, it is crucial that those children who may 
experience clinical deterioration are not discharged. Among those sent home 
with a diagnosis of bronchiolitis, 4.6–6.8% required hospitalization later on 
during infection.9,10 Clinical prediction models may help clinicians to distinguish 
RSV-infected children requiring hospitalization from those who can be safely 
sent home. To date, mainly clinical parameters have been used to predict the 
severity of disease in RSV infection.11,12 Several studies have associated severity 
of RSV disease with particular cytokines such as interleukin (IL)-8, IL-6, IL-4, and 
interferon (IFN)-γ. 13–16 A change in plasma or nasopharyngeal levels of these 
cytokines in an early phase of the host response can be used as early markers for 
severity of disease. The addition of inflammatory parameters may improve the 
prediction of disease severity in children with RSV infections. To examine whether 
a combination of these inflammatory mediators can differentiate between severe 
and mild RSV infection, we characterized immune cells (CD4+ and CD8+ T cells, 
natural killer (NK) cells, monocytes, and B cells) and measured concentrations of 
16 cytokines and chemokines in young children with RSV bronchiolitis. 
METHODS
Study Design 
Children below 2 years of age with RSV bronchiolitis were prospectively included 
during three consecutive winter seasons (from November to April 2006–2009). 
Bronchiolitis was defined as an acute infection of the lower airways, characterized 
by increased respiratory effort and expiratory wheezing and/or crackles and/or 
apnea. The study was approved by the Committee on Research Involving Human 
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Subjects of the University Nijmegen Medical Center, and written informed 
consent was obtained from all parents. Within 24hr after presentation, blood 
and nasopharyngeal samples were collected; and from hospitalized children, 
permission was asked of the parent or guardian for a recovery sample 4–6 wk 
later. Clinical data were collected from questionnaires and medical records. 
Retrospectively, based on the clinical course, patients were classified into three 
different groups: children without supportive interventions were allocated to the 
mild group; those requiring hospitalization for supplemental oxygen (oxygen 
saturations below 93%) and/or nasogastric feeding were allocated to the 
moderate group; and children requiring mechanical ventilation were allocated 
to the severe group.
 
Sample Collection 
Nasopharyngeal aspirates were collected by introducing a catheter into the 
nasopharynx. Then, 1.5 ml saline was instilled into the nose and, while slowly 
retracting the catheter, the nasopharyngeal fluid was aspi-rated in a collection 
tube. Subsequently, the catheter was flushed with 1 ml saline, which was added 
to the collection tube. The samples were cooled and immediately transported to 
the laboratory. The nasopharyngeal aspirate was centrifuged and the supernatant 
was frozen at -80 °C. A total of 5 ml of blood was collected into sodium heparin 
tubes and processed within 2 h. Blood smears were stained with May-Grunwald-
Giemsa to determine the percentages of granulocytes. PBMCs were obtained 
by density gradient centrifugation (Lymphoprep, Axis Shield, Oslo, Norway) 
and stored in liquid nitrogen after cryopreservation. Immunophenotyping was 
performed on either fresh blood cells or on viably frozen PBMCs to determine the 
leukocyte subsets. Plasma samples, diluted 1:1 with phosphate-buffered saline 
(PBS), were stored at -80 °C for cytokine analyses. 
Virus Detection 
Multiplex real-time reverse transcription PCR was performed on nasopharyngeal 
aspirates as previously described.39 The multiplex RT-PCR assay detects 15 
different viral pathogens: influenza virus type A and B, coronavirus 229E and 
OC43, human bocavirus, enterovirus, adenovirus, parechovirus, parainfluenza 
virus types 1–4, human metapneumovirus, rhinovirus, and RSV. The amount of 
virus was recorded semiquantitatively based on the cycle threshold (Ct) value.
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Immunophenotyping 
Erythrocytes were eliminated from heparinized blood by using ammonium 
chloride lysis; the remaining leukocytes were washed with PBS and resuspended 
in PBS with 0.5% bovine serum albumin (BSA). Leukocyte subsets were analyzed 
using immunofluorescence-labeled monoclonal antibodies (mAb) determined 
in multicolor flow cytometry. Depending on the number of cells, 50 µl of cell 
suspension containing maximally 1 × 106 nucleated cells was incubated with 
50 µl fluorochrome-labeled monoclonal antibodies (final dilution 1:20) for 15 
min in the dark at room temperature. Combinations of mAb conjugates were 
used for CD3, CD4, CD8, CD56, CD45, CD14, and CD19 (Beckman Coulter, 
Miami, FL). Cells were enumerated by using flow-count counting beads (Beckman 
Coulter). Staining of cells was determined by using a Fc500 flow cytometer 
(Beckman Coulter). Data were analyzed using the CXP software (Beckman 
Coulter). Immunophenotyping of cryopreserved PBMCs and intracellular 
cytokine staining were performed after thawing. The following combinations of 
markers and fluorescent antibodies were used: CD14–fluorescein isothiocyanate 
(FITC), CD16.56–phycoerythrin (PE), IL-4–PE, CD3–peridinin chlorophyll protein, 
CD19–allophycocyanin (APC), IFN-γ–APC, CD4–PE–Cy7, and CD8–APC–Cy7. 
Extracellular staining of surface markers CD14, CD16.56, CD3, CD4, and CD8 
was performed in 96-well microtiter plates. For intracellular cytokine staining (IL-
4 and IFN-γ), PBMCs were stimulated with β-mercapto-ethanol, phorbol myristate 
acetate (10 ng/ml), golgistop, and ionomycin at 37 °C for 4 h. Then, staining 
of surface markers CD3, CD4, and CD8 was performed. Thereafter, cells were 
fixed, permeabilized with 0.5% saponin and 0.5% BSA in PBS, and stained for 
intracellular IL-4 and IFN-γ. Samples were acquired immediately after staining on 
a BD FACSCanto (Becton Dickinson, Heidelberg, Germany) and analyzed using 
flow cytometry analysis soft-ware (FlowJo analyses 7.6, Three Star, Ashland, OR). 
Cytokine Concentrations 
Concentrations of the cytokines IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, IL-
17, G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, 
and tumor necrosis factor (TNF) and the chemokines IL-8 (chemokine CXC ligand 
8), IFN-γ–inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-
1), and CCL-5 were measured by flow cytometry using the BD CBA Human Soluble 
Flex Set system (Becton Dickinson) according to the manufacturer’s instructions. 
Briefly, cytokine-specific antibody–coated beads were incubated for 1 h with 
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25 µl plasma, supernatant of nasopharyngeal aspirates, or standard solution. 
Thereafter, samples were incubated with the corresponding PE-labeled detection 
antibodies for 2 h. After washing, samples were measured by flow cytometry. 
Analysis of data and quantification of cytokines were per-formed using FCAP 
Array software (Becton Dickinson). The detection limits were 2.3 pg/ml for IL-1β, 
11.2 pg/ml for IL-2, 1.4 pg/ml for IL-4, 1.6 pg/ml for IL-6, 0.13 pg/ml for IL-10, 
0.6 pg/ml for IL-12p70, 0.6 pg/ml for IL-13, 0.3 pg/ml for IL-17a, 1.6 pg/ml for 
G-CSF, 0.2 pg/ml for GM-CSF, 0.8 pg/ml for IFN-γ, 1.2 pg/ml for TNF, 1.2 pg/ml 
for IL-8, 0.002 pg/ml for CCL-5, 1.3 pg/ml for MCP-1, and 0.5 pg/ml for IP-10. 
Statistics 
Values are expressed as percentages for categorical variables and as mean and 
SE or median and interquartile range for continuous variables. For variables 
that were not normally distributed, the Kruskal–Wallis test was performed to 
compare continuous variables, followed by Mann–Whitney U-tests for individual 
comparisons. χ2 tests were performed to compare categorical data. A two-sided 
value of P < 0.05 was considered statistically significant. A receiver operating 
characteristic curve was plotted for those markers that were statistically different 
between severe and mild RSV infection. An optimal cutoff value for individual 
markers was then deter-mined with a sensitivity approaching 100% and specificity 
>85%. If the diagnostic marker was unable to meet the abovementioned criteria, 
the optimal cutoff value was adjusted so that both sensitivity and specificity 
approached 75%. With these optimal cutoff values, the sensitivity, specificity, 
and positive and negative predictive values of these markers or combination of 
markers were calculated. All statistical tests were performed by SPSS (Release 16; 
SPSS, Chicago, IL). 
RESULTS 
Severity of RSV Infection Is Associated With Young Age 
Demographics and clinical features of the 52 included infants are presented 
in Table 1. Children with severe disease were significantly younger than those 
with mild or moderate disease (1.0 vs. 2.0 and 5.3 mo; P < 0.01 and P = 0.04, 
respectively). No other significant differences in clinical parameters were 
observed.
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RSV Monoinfection Is Associated With Disease Severity, Irrespective of Viral Load 
An examination of the nasopharyngeal samples detected RSV in all the samples. 
In 21 of 53 samples (40%), one or more other viruses than RSV were detected, 
of which rhino- virus was most frequently detected (n = 17). Viral coinfection 
occurred more often in children with mild RSV infection (73%) as compared with 
those with moderate (46%) and severe disease (16%; P < 0.01). No differences in 
RSV load were observed between the severity groups or between children with 
RSV monoinfections and those infected by multiple viruses. 
Table 1. Demographics of children diagnosed with an RSV infection and categorized by severity 
of disease
Mild 
(N=11)
Moderate 
(N=22)
Severe
(N=19)
p-value
Age (mo), median (IQR) 5.3 (2.0–8.9) 2.0 (1.4–6.7) 1.0 (0.7–3.9) 0.006*
Age <3 mo 4 (36) 14 (64) 14 (74) NS
Male (%) 7 (64) 15 (68) 14 (74) NS
Birth weight (g), mean ± SE 3,312 ± 186 3,262 ± 157 3,167 ± 191 NS
Prematurity ≤35 wk 1 (9) 2 (9) 6 (32) NS
Breastfeeding 8 (73) 12 (63) 8 (44) NS
Smoking during pregnancy 1 (9) 3 (15) 5 (28) NS
Congenital heart disease 0 1 (5) 1 (5.3) NS
Atopic disease 2 (18) 2 (9) 2 (11) NS
Siblings 7 (64) 13 (59) 17 (90) NS
Day care 3 (38) 3 (14) 1 (5) NS
Passive smoking 2 (20) 2 (10) 3 (18) NS
Family history of atopy 7 (64) 13 (65) 12 (67) NS
Onset of symptoms in days, median (IQR) 6 (4–8) 4 (3–5.25) 5 (3–6) NS
Ct value RSV, mean ± SE 29.7 ± 1.6 28.5 ± 0.9 28.7 ± 0.9 NS
Coinfection 8 (73) 10 (46) 3 (16) 0.007**
Data are presented as number (%), unless otherwise specified. Kruskal–Wallis tests were performed and 
results are presented; P < 0.05 was considered to be statistically significant. If differences were significant, a 
Mann–Whitney U-test was performed for one-to-one comparisons: *p=0.04: mild vs. moderate; p=0.003: mild 
vs. severe; and **p=0.002: mild vs. severe. Ct, cycle threshold; IQR,interquartile range; NS, not significant; 
RSV, respiratory syncytial virus.
Severity of RSV Infection Is Associated With Lymphocytopenia 
No differences were found in the numbers of granulocytes, monocytes, or B cells 
between the severity groups (Figure 1). Severe RSV infection was associated with 
lower CD4+ T-cell, CD8+ T-cell, and NK-cell counts as compared with mild or 
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Figure 1. Absolute cell counts of leukocyte subsets in blood from children with an RSV infection categorized 
by disease severity. Cell counts of (a) granulocytes, (b) monocytes, (c) B cells, (d) NK cells, (e) CD4+ T cells, 
and (f) CD8+ T cells are expressed as 106 cells/ml. Data are plotted as medians with the 25th–75th percentile 
range. Mann–Whitney U-tests were performed, **p<0.01. NK, natural killer; RSV, respiratory syncytial virus.
moderate infection. During recovery, the number of NK cells, CD4+ T-cells, and 
CD8+ T-cells in children with severe RSV infection increased to normal values for 
age (Supplementary Figure S1). No differences were found in immunophenotyping 
of fresh or cryopreserved PBMCs (data not shown) .
Severity of RSV Infection Is Associated With High IL-8, IL-6, and G-CSF, 
and Low CCL-5 Plasma Concentrations
Cytokine concentrations in plasma and nasopharyngeal aspirates in the three 
patient groups are summarized in Table 2 and Supplementary Table S1. Cytokines 
that were present in less than 30% of the acute blood and nasopharyngeal 
samples were excluded from further analyses (Supplementary Tables S2 and S3). 
In children with severe disease, IL-8, IL-6, and G-CSF plasma concentrations were 
higher than in those with mild or moderate disease (Table 2). In contrast, severe 
disease was associated with lower CCL-5 plasma concentrations as compared 
with mild or moderate disease (p<0.01). Whereas CCL-5 concentrations were 
higher during acute infection as compared with those during recovery in the 
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moderate group (p=0.03), CCL-5 plasma levels were lower during acute infection 
as compared with those during recovery in the severe group (p=0.01). 
In addition, CCL-5 plasma concentrations during recovery were significantly 
higher in the moderate group than in the severe group (p=0.03). No significant 
differences in the percentage or absolute numbers of IL-4– and IFN-γ–producing 
CD4+ and CD8+ T cells were observed in children with severe RSV infection as 
compared with those with mild or moderate RSV infection (Supplementary Table 
S4).
Table 2. Cytokine and chemokine concentrations (pg/ml) in plasma of children with mild, 
moderate, or severe RSV infection
Mild (N=11) Moderate (N=20) Severe (N=19) p-value
IL-8 48.1 (36.0–76.8) 55.7 (40.5–106.6) 127.8 (79.0–321.9) <0.0001*
CCL-5 25507 (19971–35204) 25235 (11264–45161) 8632 (3895–12155) 0.007**
IL-6 20.4 (11.0–35.6) 10.1 (0.0–69.8) 72.9 (21.9–122.4) 0.025***
IL-1 21.7 (0.0–37.0) 6.0 (0.0–38.9) 0.0 (0.0–23.6) NS
MCP-1 220.0 (168.1–296.4) 138.4 (106.7–229.9) 174.6 (103.9–481.0) NS
G-CS 51.9 (21.2–180.8) 47.0 (12.9–111.1) 129.9 (85.6–362.7) 0.021†
IP-10 575.6 (418.9–902.8) 395.7 (331.9–666.5) 660.4 (347.3–1,184.9) NS
Data are presented as median values (25th–75th percentile). Kruskal–Wallis tests were performed and the 
results are presented; p<0.05 was considered to be statistically significant. If differences were significant, a 
Mann–Whitney U-test was performed for one-to-one comparisons: *p<0.01: mild vs. severe and moderate vs. 
severe; **p<0.01: mild vs. severe and moderate vs. severe; ***p=0.02: moderate vs. severe; and †p=0.01: 
moderate vs. severe. CCL, chemokine (C-C motif ) ligand; G-CSF, granulocyte colony-stimulating factor; IL, 
interleukin; IP, inducible protein; MCP, monocyte chemoattractant protein; NS, not significant; RSV, respiratory 
syncytial virus.
Severity of RSV Infection Is Associated With High IL-6 Nasopharyngeal 
Concentrations
Overall, nasopharyngeal cytokine concentrations were higher during acute 
infection than after recovery (Supplementary Table S3 online). Higher IL-6 
concentrations were found in nasopharyngeal samples from children with 
moderate or severe disease as compared with those with mild disease (P < 0.05). 
No other significant differences in nasopharyngeal cytokine levels were found 
between the patient groups (Supplementary Table S1). 
Inflammatory Markers in RSV Infection Inflammatory Parameters 
Distinguish Disease Severity in RSV-Infected Infants Younger Than 3 
months and in Children With Single RSV Infection 
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Given that severe disease was associated with younger age, we also performed 
analyses in infants younger than 3 months. Because of the small numbers, we 
categorized these infants into two groups: ventilated (N=15) and nonventilated 
(N=18). In this young age group, higher IL-8, IL-6, and G-CSF plasma 
concentrations, lower CCL-5 plasma concentrations, and lower NK cell and CD4 
T-cell counts were observed in ventilated as compared with nonventilated RSV-
infected infants (Table 3). 
Table 3. Significant differences in clinical and inflammatory parameters between ventilated and 
nonventilated RSV-infected infants younger than 3 months
Ventilated (N=15) Nonventilated (N=18) p-value
Age (days) 31.0 (19.0–48.7) 53.4 (45.0–59.7) 0.01
Plasma IL-8 127.8 (87.4–137.8) 57.3 (40.2–43.9) <0.01
Plasma IL-6 66.4 (3.2–98.0) 12.9 (3.2–43.8) 0.03
Plasma G-CSF 114.5 (3.2–157.3) 34.3 (6.1–144.6) 0.03
Plasma CCL-5 8,874.2 (8,193.6–38,503.2) 12,529.0 (5,863.3–15,769.5) 0.01
Nasopharyngeal IL-6 291.7 (152.0–522.1) 335.1 (229.7–368.8) 0.03
NK cells 0.12 (0.06–0.27) 0.41 (0.20–0.58) <0.01
CD4+ T cells 1.67 (1.24–2.25) 2.80 (2.32–3.56) <0.01
CD4/CD8 ratio 2.60 (2.60–3.78) 5.28 (3.31–7.91) 0.01
Numbers are presented as median values (25th–75th percentile). Cytokine concentrations are given in pg/
ml and cell numbers in 106 cells/ml. Mann–Whitney U-tests were performed; p<0.05 was considered to be 
statistically significant. CCL, chemokine (C-C motif ) ligand; G-CSF, granulocyte colony-stimulating factor; IL, 
interleukin; NK, natural killer; RSV, respiratory syncytial virus.
As infection by multiple viruses may have influenced our results, we analyzed 
inflammatory parameters in 16 ventilated and 15 nonventilated children with RSV 
single infections. No significant differences in age and clinical parameters were 
found. Significantly higher IL-8, IL-6, and G-CSF and, although not significant, 
lower CCL-5 plasma concentrations (p=0.06) were observed in ventilated children 
as compared with nonventilated children. In addition, CD4+ T-cell and NK cell but 
not CD8+ T-cell counts were lower in ventilated children than in nonventilated 
children. 
Combination of IL-8, CCL-5, and CD4+ T-cell Count Discriminates Severe 
RSV Infection From Mild RSV Infection 
Clinical and inflammatory parameters that were significantly different between 
the patient groups (Table 4) were selected for further analyses. On the basis of 
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Table 4. Comparison of sensitivity, specificity, PPVs, NPVs, and AUC for different inflammatory 
markers in ventilated versus nonventilated children with RSV bronchiolitis
Marker Cutoff value Sensitivity Specificity PPV (%) NPV (%) AUC
CCL-5 ≤13 ng/ml 0.79 0.74 65 85 0.782
IL-8 ≥67.2 pg/ml 0.89 0.77 68 92 0.844
IL-6 ≥28.7 pg/ml 0.75 0.67 60 80 0.718
G-CSF ≥82.7 pg/ml 0.80 0.67 62 83 0.723
Age ≤2 mo 0.65 0.57 48 73 0.718
CD4+ cells ≤2.29 × 106/ml 0.87 0.74 87 74 0.859
NK cells ≤0.28 × 106/ml 0.87 0.63 87 63 0.812
Performance of combined markers
IL-8 and CD4
CCL-5 and CD4
≥2 of IL-8, CCL-5,and CD4a
0.80
0.91
0.82
0.89
0.84
0.96
80
67
93
89
96
89
Cutoff values are based on optimal sensitivity and specificity for each marker. AUC, area under the curve; 
CCL, chemokine (C-C motif ) ligand; G-CSF, granulocyte colony-stimulating factor; IL, interleukin; NK, natural 
killer; NPV, negative predictive value; PPV, positive predictive value; RSV, respiratory syncytial virus. The 
combination of IL-8, CC L-5, and CD4+ T-cell counts discriminated ventilated from nonventilated children 
under the condition that two or more cutoff values of IL-8 and CC L-5 concentrations and CD4+ T-cell counts 
were exceeded.
the receiver operating characteristic (ROC) curves, cutoff values were calculated 
(67 pg/ml, 13 ng/ml, and 2.3 × 106 cells/ml for IL-8 and CCL-5 plasma levels 
and CD4 T-cell counts, respectively). 
IL-8 plasma levels and CD4+ T-cell counts showed high sensitivity (89% and 87%, 
respectively) and specificity (77% and 74%, respectively), followed by CCL-5 with 
a sensitivity of 79% and specificity of 74%. We explored the possibility of using a 
combination of markers to predict disease severity. The combination of IL-8 and 
CCL-5 levels and CD4+ T-cell counts predicted disease severity with a sensitivity 
of 82% and specificity of 96%, if two of three cutoff values within a patient were 
above or below the threshold. Positive and negative predictive values were 93% 
and 89%, respectively, for this combination of markers. 
DISCUSSION
This study demonstrates that CD4+ T-cell counts and IL-8 and CCL-5 plasma 
concentrations may be a useful set of markers for distinguishing disease severity 
in young children with RSV bronchiolitis. Therefore, by including immunological 
inflammatory parameters, current clinical prediction models for severity of RSV 
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infection may be improved. 
In our study, young age, lymphocytopenia, and IL-8, IL-6, G-CSF, and CCL-5 
plasma levels were associated with severe RSV infection. Young age is a known 
risk factor for severe RSV infection. An immature immune system, in combination 
with the lack of in utero sensitization to RSV and small airways, indicates that 
severe RSV infections are predominantly observed in young infants.17 However, 
age alone cannot explain the observed differences in inflammatory parameters 
because our analyses in infants younger than 3 months still showed significant 
differences in inflammatory parameters between the severity groups. 
In line with previous studies, lower T-cell and NK-cell counts were observed 
during severe RSV infection as compared with milder infections.18-20 Given that 
young infants have normally higher T-cell and NK-cell counts than older children, 
the degree of lymphocytopenia may even have been underestimated in this 
patient group.21,22 This lymphocytopenia can be explained by either migration of 
lymphocytes into the airways or apoptosis.13,18,19,23 Another hypothesis may be 
that infection-induced immune suppression results in lower lymphocyte counts.
As previously described15, our results show that RSV infections induce a systemic 
response reflected by changes in cytokine plasma concentrations. Despite 
the significantly higher IL-8, IL-6, and G-CSF and lower CCL-5 concentrations 
in plasma during severe RSV infection as compared with milder infection, in 
nasopharyngeal aspirates, only IL-6 was significantly higher during severe RSV 
infection. Given that nasopharyngeal samples do not necessarily reflect local 
inflammation in the lower airways, and sampling methods and correction for 
dilutional effects differ between studies, the use of cytokines in nasopharyngeal 
samples as biomarkers is complicated.24 Because blood samples are relatively 
easy to obtain in a uniformly established manner, and cytokine plasma levels 
were all normalized at the time of recovery, cytokine levels in plasma are potential 
biomarker candidates for diagnostic use. 
In contrast to increased IL-8, IL-6, and G-CSF levels, CCL-5 plasma concentrations 
were decreased during severe RSV infection as compared with those after 
recovery and milder manifestations of RSV infection. Although our results differ 
from some studies that observed increased CCL-5 concentrations in respiratory 
samples24, 25 and blood26 during acute RSV infection as compared with healthy 
controls, they are consistent with others showing lower CCL-5 concentrations 
in blood during acute infection as compared with recovery samples.27,28 The fact 
that not all studies examined recovery samples or evaluated disease severity may 
explain these differences. 
Although CCL-5 is initially produced by local innate immune cells to attract T 
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cells and monocytes to the site of infection, CD4+ and CD8+ T cells have been 
described as the main source of the second peak of CCL-5, which occurs 5–7 d 
after infection.29 A decrease in T cells may therefore result in lower CCL-5 levels. 
However, the discrepancy between T-cell counts and CCL-5 levels during recovery 
in the moderate and severe groups suggests that the lower T-cell counts cannot 
completely explain the lower CCL-5 levels during severe RSV infection. Other 
mechanisms such as an inadequate or suppressed T-cell response may play a 
role. Infection-induced immune suppression is a well-established phenomenon 
and has been described in sepsis, measles, and chronic viral infections.30-32 
The immature immune system of infants can also result in a reduced immune 
response. Controversial results have been published on changes in CCL-5 levels 
during the first months of life, and we cannot exclude that higher CCL-5 levels 
reflect functional maturation of the immune system.33, 34 However, in infants 
younger than 3 months, we still observed significantly lower CCL-5 concentrations 
in ventilated infants than in non-ventilated infants. 
The inflammatory response during severe RSV infection has been associated 
with atopy and asthma, although the precise mechanism behind this relation 
is still unclear.35 It has been suggested that an IL-4–induced Th2 response 
during primary RSV infection might play a role in the development of atopic 
disease, although this could also be due to a shared etiology of bronchiolitis and 
asthma.36 If this had played a role in our study, one would expect differences in 
IL-4–producing T-cell subsets or differences in the prevalence of atopic disease. 
However, no differences between severe and nonsevere patients were found. 
Therefore, it is unlikely that the inflammatory markers found to be associated 
with disease severity can be explained by the existing atopy or the development 
of atopic disease. 
Some limitations of our study need to be considered. Multiple viruses were 
detected in 40% of the samples, and these co-infections were associated with 
less severe RSV infection. Although comparing single RSV infections between 
ventilated and non-ventilated children gave results similar to those of the analyses 
in which multiple infections were included, the possibility that the presence 
of other viruses induced a different inflammatory response cannot be entirely 
excluded. Another important consideration regarding markers for disease 
severity is that they do not have clinical implications at this moment, because 
currently no antiviral treatment is available. However, newly developed antiviral 
treatment of patients will be based most likely on diagnostics predicting disease 
severity and susceptibility.37,38 For the evaluation of intervention studies, such as 
vaccination and antiviral treatment, markers for disease severity will be valuable. 
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Furthermore, given that we focused on the discrimination between ventilated 
and nonventilated children, studies need to be undertaken to determine whether 
this set of biomarkers could also discriminate between children requir-ing 
hospitalization and those who can be discharged. 
In summary, we demonstrate the usefulness of a combination of immunological 
markers to distinguish disease severity in young RSV-infected children. We 
conclude that prediction models of RSV infection in young children may be 
improved by including immunological parameters, such as IL-8 and CCL-5 
concentrations and CD4+ T-cell counts. Future studies have to be performed to 
validate our findings to see whether the use of these parameters may contribute 
to early recognition of children developing severe RSV infection. This may guide 
clinicians to decide whether a child needs to be hospitalized and to initiate 
symptomatic therapy in an early phase of disease. 
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SUPPLEMENTARY DATA
Supplementary Figure S1. Absolute cell counts during acute infection and after recovery in mechanically 
ventilated children. Cell counts of NK-cells (A), CD4+ T-cells (B) and CD8+ T-cells (C) are expressed as 106 
cells/ml. Data are plotted s medians with 25th-75th percentile range. Paired analyses using Wilcoxon signed-
rank test were performed, ** p<0.01.
Supplemental Table S1. Cytokine and chemokine concentrations (pg/ml) in nasopharyngeal 
aspirates of children with mild, moderate and severe RSV infection. 
mild (N=9) Moderate (N=13-15) Severe (N=14-15) p-value
IL-8 9106 (7599-18947) 11908 (10672-20307) 17773 (11917-67609) NS
CCL-5 116.8 (52.6-179.9) 74.0 (57.5-208.5) 48.0 (0.0-199.8) NS
IL-1β 552.4 (206.5-944.4) 1670.4 (763.5-3150.9) 1093.7 (545.3-5932.5) NS
IL-6 1475.20 (1136.6-1908.4) 2593.3 (1641.6-4492.8) 4801.2 (1520.3-8186.6) p=0.031*
IL-10 28.9 (0.0-49.6) 101.7 (0.0-207.8) 22.7 (0.0-139.4) NS
MCP-1 140.7 (60.4-251.2) 394.1 (202.6-394.1) 539.9 (89.2-1865.7) NS
TNF 216.1 (168.4-356.0) 649.3 (266.2-1990.1) 431.2 (251.1-2290.9) NS
G-CSF 4940.4 (3416.0-8715.8) 5001.6 (3220.8-8403.7) 3242.7 (1437.1-5780.9) NS
IP-10 11788 (7168-24024) 14633.9 (5289.1-24037.4) 5016.0 (775.9-11538.9 NS
Data are presented as median (25th-75th percentile). Kruskal-Wallis tests were performed and presented in 
the table, p<0.05 was considered to be statistically significant. If differences were significant a Mann Whitney 
U test was performed for one to one comparisons:  * p<0.05: Mild vs. severe and moderate vs. severe 
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Supplemental Table S2. Paired analyses of cytokine and chemokine plasma concentrations 
(pg/ml) during acute RSV infection and after recovery in moderate and severe disease groups.
moderate acute moderate recovery N p-value
IL-8 60.7 (49.7-126.2) 9.9 (6.3-14.0) 12 <0.01
CCL-5 20312 (11846-45161) 12872 (9583-32677) 12 0.03
IL-6 22.6 (2.7-76.9) 0.0 (0.0-0.0) 11 0.02
IL-10 30.7 (0.0-54.7) 0.0 (0.0-0.0) 12 0.01
MCP-1 159.2 (106.7-296.1) 146.4 (87.0-198.8) 12 0.05
G-CSF 47.0 (13.1-136.0) 5.8 (0.0-14.5) 11 0.05
IP10 413.5 (365.2-794.0) 191.5 (128.8-246.2) 11 <0.01
severe acute severe recovery N p-value
IL-8 130.7 (90.7-326.5) 12.2 (1.4-25.0) 16 <0.001
CCL-5 8874 (3314-20488) 34351 (21253-61944) 15 <0.01
IL-6 79.4 (9.7-146.1) 0.0 (0.0-0.0) 15 <0.01
IL-10 7.4 (0.0-23.5) 0.0 (0.0-0.0) 16 0.01
MCP-1 176.1 (107.1-482.4) 232.4 (148.6-358.4) 16 NS
G-CSF 129.9 (85.6-371.7) 3.9 (0.0-10.5) 15 <0.01
IP10 660.4 (437.3-1286.7) 187.6 (133.8-292.3) 15 <0.01
Data are presented as median (25th-75th percentile). Wilcoxon signs ranks test were performed for paired 
analyses between acute and recovery samples, p<0.05 was considered to be statistically significant.N=number 
of subjects, NS= not significant.
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Supplemental Table S3. Paired analyses of cytokine and chemokine nasopharyngeal 
concentrations (pg/ml) during acute RSV infection and after recovery in moderate and severe 
disease groups. 
 moderate acute moderate recovery N p-value
IL-8 14971 (11314-24860) 8758.2 (1449.8-15201.0) 7 0.03
CCL-5 74.0 (40.7-176.5) 23.3 (0.0-60.1) 5 0.04
IL-1B 1743.0 (763.5-3236.5) 68.4 (24.0-868.6) 5 0.04
IL-6 2001.6 (1616.3-3518.4) 215.9 (64.4-559.7) 7 0.02
IL-10 103.8 (21.1-412.8) 0.0 (0.0-51.2) 5 NS
MCP-1 302.8 (159.0-373.9) 32.3 (7.0-65.7) 4 NS
TNF-a 823.5 (200.4-1944.9) 2.4 (0.0-70.7) 4 NS
G-CSF 6090.0 (3623.1-9296.7) 3590.1 (449.1-4922.1) 7 NS
IP-10 18229 (8009-28110) 3321.0 (1897.8-9194.0) 7 0.02
 severe acute severe recovery N p-value
IL-8 16072 (10196-41044) 7528.3 (2973.5-14524.0) 10 0.05
CCL-5 48.0 (3.0-435) 20.8 (0.0-107.5) 9 NS
IL-1B 1033.0 (604.5-9572.0) 204.4 (144.5-880.0) 8 0.05
IL-6 4069.3 (1159.2-9814.7) 363.5 (78.4-657.3) 10 0.01
IL-10 7.7 (0.0-355) 0.0 (0.0-80.2) 5 NS
MCP-1 781.0 (68.8-3412.2) 61.3 (0.0-162.3) 7 0.02
TNF-a 431.2 (288.5-5475.3) 144.0 (0.0-378.6) 8 NS
G-CSF 3246.1 (1431.9-7609.3) 3038.1 (1327.2-5827.4) 10 NS
IP-10 3930.5 (424.5-18245.6) 1326.4 (489.1-2806.1) 10 NS
Data are presented as median (25th-75th percentile). Wilcoxon signs ranks test were performed for paired 
analyses between acute and recovery samples, p<0.05 was considered statistically significant.N=number of 
subjects, NS= not significant.
Supplemental Table S4. IL-4 and IFN-γ producing CD4 and CD8 positive T-lymphocytes from 
children with severe and non-severe RSV infection measured by intracellular cytokine staining.
CD4+ T-lymphocytes CD8+ T-lymphocytes
IFN-γ (%) IL-4 (%) IFN-γ/IL-4 IFN-γ (%) IL-4 (%) IFN-γ/IL-4
Non severe
(N=9)
0.17 
(0.07-0.26)
0.29 
(0.26-0.47)
0.43 
(0.30-0.69)
2.17 
(1.15-2.94)
0.48
(0.29-0.56)
3.15 
(2.74-6.75)
Severe
(N=10)
0.11 
(0.06-0.18)
0.33 
(0.22-0.51)
0.39 
(0.14-0.56)
2.14 
(1.04-3.24)
0.59 
(0.52-0.63)
2.73 
(1.85-5.46)
P-value NS NS NS NS NS NS
Cell numbers are given in 106/ml, data are presented as median (25th-75th percentile). Mann-Whitney U tests 
were performed, p<0.05 was considered to be statistically significant.NS= not significant.
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ABSTRACT
Background
Respiratory viral infections follow an unpredictable clinical course in young 
children ranging from a common cold to respiratory failure. The transition 
from mild to severe disease occurs rapidly and is difficult to predict. The 
pathophysiology underlying disease severity has remained elusive. There is an 
urgent need to better understand the immune response in this disease to come 
up with biomarkers that may aid clinical decision making. 
Methods
In a prospective study, flow cytometric and genome-wide gene expression 
analyses were performed on blood samples of 26 children with a diagnosis of 
severe, moderate or mild respiratory syncytial virus (RSV) infection. Differentially 
expressed genes were validated using quantitative PCR (qPCR) in a second cohort 
of 80 children during three consecutive winter seasons. FACS analyses were also 
performed in the second cohort and on recovery samples of severe cases in the 
first cohort.
Results
Severe RSV infection was associated with a transient but marked decrease in 
CD4+ T, CD8+ T, and NK cells in peripheral blood. Gene expression analyses 
in both cohorts identified Olfactomedin4 (OLFM4) as a fully discriminative 
marker between children with mild and severe RSV infection, giving a PAM cross-
validation error of 0%. Patients with an OLFM4 gene expression level above -7.5 
were 6 times more likely to develop severe disease, after correction for age at 
hospitalization and gestational age. 
Conclusion
By combining genome-wide expression profiling of blood cell subsets with 
clinically well-annotated samples, OLFM4 was identified as a biomarker for 
severity of pediatric RSV infection. 
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INTRODUCTION 
Respiratory viral infections are an important cause of hospitalization among 
children younger than 5 years of age. Human respiratory syncytial virus (RSV) is 
the most common (40-85%) identified virus in infants hospitalized for respiratory 
infections during winter epidemics, with hospitalization rates between 1 and 2%.1-
6 Clinical manifestations range from common colds to severe lower respiratory 
tract infections (LRTIs) requiring mechanical ventilation. Risk factors for a severe 
course are known, but the majority of patients admitted to an intensive care 
unit were previously healthy.7-9 Since transition from mild to severe disease can 
occur within hours, one of the key challenges for clinicians is to differentiate 
children who need hospitalization for supportive care from those who can safely 
be discharged. Currently, young infants with mild bronchiolitis, especially those 
younger than 3 months of age, are often admitted to a hospital since they have 
an increased risk of severe disease. However, up to 35% of children hospitalized 
with bronchiolitis do not receive any supportive intervention.10 Conversely, it is 
crucial to avoid early discharge of those children who may experience clinical 
deterioration. Among children sent home with the diagnosis bronchiolitis, 4.6-
6.8% require hospitalization later on.11, 12
Much research has been done on the immune response against RSV in humans. 
Several reports suggested an important role for the innate immune system, 
while others found an inadequate adaptive immune response especially in 
young children and in individuals who present with a severe clinical picture.13 
The uncertainty in the nature of the immune response against RSV is reflected 
in the unpredictable clinical course of the infection as well as in the difficulty 
of developing an adequate vaccine. We, as well as others, previously reported 
that T-lymphocytes can be markedly decreased in the more severe cases of the 
disease. We reported that in severe cases both CD4 and CD8 T-cell numbers, as 
well as NK-cells were reduced in peripheral blood.14 However, it remains unclear 
whether this indicates an inadequate immune response against RSV, for instance 
by massive apoptosis or decreased production of T-cells, or that peripheral blood 
poorly reflects an ongoing immune response that might be very active.
The detection and application of biomarkers to assess severity of viral  LRTIs, in 
particular RSV infection, may assist clinicians in the prediction of severe disease 
in children with bronchiolitis and may help to reduce the number of unnecessary 
hospitalizations or clinical deterioration after discharge. Furthermore, markers 
for disease severity are important research tools to study effects of interventions 
by new therapies or to stratify patients by disease severity.15, 16 Several studies 
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have shown that transcriptional analysis of peripheral blood cells may be used to 
define different etiologies of disease and disease outcomes.17-20 In a seminal proof-
of-concept study, Ramilo et al. (2007) compared the transcriptional profiles of 
PBMCs of children with infectious diseases and identified a set of genes that can 
separate influenza A infections from bacterial infections (Staphylococcus aureus, 
Escherichia coli and Streptococcus pneumoniae).20 Recently this group also 
reported that these transcriptome profiles also contained information regarding 
viral etiology (influenza, rhinovirus and RSV) and the course of disease.21 
This study was initiated to obtain insight into the changes occurring in adaptive 
and innate immune cells during RSV infection and to identify possible biomarkers 
of disease severity. To identify transcriptional biomarkers to separate mild from 
severe disease, genome-wide gene expression analyses were performed on 
blood samples of 26 children with a diagnosis of severe, moderate or mild RSV 
infection in two winter seasons.  A validation cohort of 80 children spanning 
three other consecutive winter seasons by flow cytometry and q-PCR was used to 
validate various candidate biomarkers. 
METHODS
Study Design
In this prospective cohort study, 3 ml of sodiumheperanized blood and 
nasopharyngeal samples were obtained from two cohorts of patients with viral 
bronchiolitis within 24 hours after first contact with the hospital. Medical history, 
demographic data, and clinical assessments were collected from questionnaires 
and medical records. Presence of 15 different viral pathogens was tested by 
multiplex RT-PCR on nasopharyngeal samples as previously described.22 Patients 
were classified retrospectively into three groups based on severity of disease. 
The mild group included children without hypoxia or severe feeding problems. 
The moderate group included children requiring hospitalization for supplemental 
oxygen (oxygen saturations <93%) and/or nasogastric feeding. Children requiring 
mechanical ventilation were included in the severe group. Recovery samples 
were obtained 4-6 weeks after acute infection from children with moderate and 
severe disease. The first cohort consisted of 31 patients with RSV infections, 
divided into mild (n=9), moderate (n=11) and severe (n=11) disease. This cohort 
was used for micro-array analysis and initial qPCR validation of genes of interest. 
The second cohort comprised 80 children with viral LRTIs also divided into three 
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groups: mild (n=14), moderate (n=42) and severe (n=24). This cohort was meant 
for validation purposes. All subjects were recruited at two hospitals in Nijmegen, 
the Canisius Wilhelmina Hospital and the Radboud University Medical Center, 
The Netherlands. The study protocols were approved by the Regional Committee 
on Research involving Human Subjects Arnhem-Nijmegen (serving as the IRB) and 
were conducted in accordance with the principles of the Declaration of Helsinki. 
Written informed consent was obtained from the parents of all children.
RNA Isolation and Microarray Gene Expression Analyses
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation (Lymphoprep®, Axis Shield, Norway), counted and subsequently 
stored in Trizol® reagent (Invitrogen, The Netherlands) at -80°C in the same 
laboratory by the same team for both cohorts. RNA from PBMC and granulocyte 
fractions was extracted using Trizol (Invitrogen Life Technologies) according to 
the manufacturer’s protocol. Total RNA was isolated using the RNeasy Minikit 
(Qiagen). RNA integrity and quality was assessed using capillary electrophoresis 
[RNA 6000 Nano LabChip (Agilent)] on an Agilent Bioanalyzer 2100 system. RNA 
processing, target labeling and hybridization to gene expression arrays was 
performed by standard methods as described. 23 Biotin labeled cRNA was obtained 
using the One-Cycle Eukaryotic Target Labeling Assay (Affymetrix), after which 15 
µg of fragmented, biotin labeled cRNA was hybridized to Affymetrix® GeneChip® 
Human Genome U133 plus 2.0 arrays according to standard Affymetrix protocol 
(Affymetrix Inc, Santa Clara, CA).
Flow Cytometry
Whole blood was stained with monoclonal antibodies (mAbs) to identify the 
following subsets: CD4+ T-cells (CD4+CD3+CD8-), CD8 T-cells (CD8+CD4-
CD3+), NK-cells (CD3-CD56+), B-cells (CD45+CD19+), monocytes (CD14+) and 
granulocytes (CD14-CD45+CD15+). Samples were acquired immediately after 
staining on a BD FACS CANTO and analyzed using FlowJo software. 
Data Analysis
Quality control analyses were performed as previously described.23, 24 Scanned 
images were inspected for artifacts, percentage of calls present (<25%) and 
controls of RNA degradation. This led to some arrays being discarded. On each 
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remaining array, probes labelled outliers by the Affymetrix scanning software 
and overexposed probes (with maximum PM intensity level >63.000) were 
removed. Subsequently, probesets with less than 8 probes remaining were 
discarded. For each comparison, robust multichip analysis (RMA) was used for 
background removal, quantile normalization of probe intensity levels and probe 
set summarization. The resulting values were log2-transformed for further 
analysis, giving probeset expression levels between 0 and 16. We then selected 
only those probesets that showed at least a two-fold difference (up or down) on 
a minimum of two arrays with respect to the median expression over all arrays 
in that particular comparison.24, 25 Finally, Significance Analysis of Microarrays 
(SAM)26 was applied to find differentially expressed probesets with a significance 
level of q <0.05. To select only biologically relevant changes, we demanded 
additionally that the difference in absolute expression levels between groups 
was larger than log2(200) and that the absolute difference was >2 fold.
In a subsequent supervised analysis, we trained a PAM classifier (“Prediction 
Analysis of Microarrays”)27, attempting to find a minimum number of discriminative 
genes that yielded an optimal cross-validation error (i.e. the predicted test error). 
For visualization purposes, samples were clustered based on selected probesets 
by complete linkage hierarchical clustering with 1-correlation as a distance 
measure, using the Matlab Bioinformatics toolbox (Mathworks, Natick, MA). 
The original and processed data were deposited in the NCBI Gene Expression 
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo). All microarray experiments 
were performed according to the MIAME guidelines.
RT-PCR
Real-time quantitative PCR was used to measure the expression of genes of 
interest. Initial validation of gene expression of OLFM4 detected in the first 
cohort was performed with SYBR Green PCR Mastermix (Applied Biosystems; 
P/N 4367659) with forward 5`- atcaaaacacccctgtcgtc- 3`and reverse 5`- 
gctgatgttcaccacaccac-3` primers for OLFM4. Actin was used as a reference 
gene with forward primer 5`- cgtcacacttcatgatggagttg-3` and reverse primer 
5`-cttccttcctgggcatgga-3`. After validation of the microarray, the second cohort 
was analyzed with commercially available Taqman primers (OLFM4 Hs00360669_
m1 and GAPDH Hs99999905_m1). All samples were run for 40 cycles in duplicate. 
Ct values of OLFM4 were normalized against the reference gene GAPDH. 
OLFM4 Plasma Measurement
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OLFM4 concentrations were measured in randomly selected plasma samples of 
49 patients from the validation cohort by a commercial ELISA kit (E90162Hu, 
Uscn Live Science Inc., China) according to the instructions of the manufacturer.
Published Microarray Data Mining
A data mining search was performed in NCBI GEO and in EBI Arrayexpress, online 
databases with datasets and profiles of previously performed microarray studies 
to validate our results.28, 29 Terms for searching were: OLFM4, Affymetrix, whole 
blood children, RSV and/or homo sapiens. More than 90 microarray studies were 
found. Based on the population (children/infants), sample size, disease type 
and available information per sample, 18 studies were selected. From the series 
matrix files, the results were log transformed and OLFM4 gene expression was 
selected and analyzed to gain insight in its behavior in different disease states 
and ages. 
Statistics
The distributions of categorical variables are presented as percentages per 
category. Numerical variables are reported as means with standard deviation 
(SD) or medians with interquartile ranges (IQR) depending on whether or not 
the variables were normally distributed (Kolmogorov-Smirnov’s test, p>0.05). 
To determine whether OLMF4 was independently associated with receiving 
mechanical ventilation, multivariable log-binomial regression analyses were 
performed in the validation cohort resulting in adjusted Relative Risks (RR).30  
RESULTS 
We previously reported that RSV infection, especially in severe cases, was 
associated with lymphopenia. This was not only visible in NK- and CD8+ T-cells, 
known to be directly involved in anti-viral immunity, but surprisingly also in 
CD4+ T-cells, whereas B-cells were unaffected.14 In the current study, we analyzed 
recovery samples of 6 severe patients after clearance of the infection (on average 
4 weeks after discharge) and found that the numbers of NK cells as well as CD4+ 
and CD8+ T-cells had returned to normal, indicating that the lymphopenia was 
transient (data not shown). 
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Table 1. Patient characteristics
Mild (N=9) Moderate (N=9) Severe (N=8) p-value
Age (months) 8.7 [3.6-9.3] 1.9 [1.5-8.3] 2.4 [1.1-4.9] NS
Gender (male) 6 (67%) 8 (89%) 6 (75%) NS
Gestational age (wks) 40 [36.9-41.0] 38.6 [37.2-40.0] 35.1 [33.1-39.8] NS
Length of stay (days) 0 [0-3] 5 [2-9] 13 [6.3-19.8] p<0.001*
Values are given in numbers (percentages) and median with inter quartile range (IQR). P-values are based on 
Kruskall Wallis tests, followed by Mann Whitney U tests for individual comparisons: *mild vs moderate p<0.01, 
moderate vs severe p<0.05, mild vs severe p<0.001
Initially, genome-wide expression analyses were done on the 31 patients of 
the first cohort. Two and three patients from the moderate and severe groups, 
respectively were excluded due to insufficient RNA quality and labelling. 
Therefore, clinical, laboratory and microarray data of 9 patients with mild disease, 
9 with moderate disease and 8 with severe disease were analysed. Patients with 
a clinical diagnosis of mild disease were older at time of admission to hospital 
than those with severe disease. The length of stay in hospital increased with 
increasing disease severity. No statistically significant differences were seen in 
gender, number of premature infants and duration of symptoms (Table 1). 
Figure 1. Venn diagram with differentially expressed genes between groups. Differentially expressed genes 
(q<0.05; >2 fold difference; absolute expression value >200) in patients with RSV infections comparing 
patients with mild vs severe disease and during acute infection vs recovery in patients with moderate and 
severe disease.
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Microarray analyses point to OLFM4 as a marker gene to classify disease severity
The microarray analysis of PBMC of children with mild versus severe disease 
showed that 564 probesets were expressed differentially (428 upregulated and 
136 downregulated genes) under conditions as described in material and 
methods (q <0.05; >2 fold difference; absolute expression value >200). 
As biomarkers should discriminate between non-disease and disease, the genes 
expressed differentially in children with mild versus severe disease as well as 
during acute severe RSV infection versus recovery were selected. The analysis 
of paired acute and recovery samples of children with severe RSV infection 
resulted in 808 differentially expressed probesets (647 upregulated and 161 
downregulated). Of these 808 probesets, 448 showed overlap with the 564 
probesets in the comparison of mild versus severe disease, 365 genes being 
upregulated and 83 genes being downregulated (Figures 1 and 2). 
Figure 2. Discriminating mild disease from severe disease in children with RSV infection. Mi, mild; Mo, 
moderate; S, severe. 448 differentially expressed probesets were selected based on overlap in the comparison 
mild vs severe disease in RSV infected children and acute samples vs recovery samples of children with severe 
RSV infection. Samples were clustered based on these selected probesets by complete linkage hierarchical 
clustering with 1-correlation as a distance measure. 
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Table 2 shows the top 25 of up- and downregulated genes, of which Olfactomedin 
4 (OLFM4) was the most upregulated gene with a factor of over 40 fold. Since 
children in the severe group were younger compared to those with mild disease, 
a paired age-matched subanalysis was performed among 7 severe patients 
versus 7 patients with mild or moderate disease. 
Table 2. Top 25 up- and downregulated genes differentially expressed in PBMCs during severe 
RSV infection.
Upregulated 
genes
Fold change
mild vs severe
Fold change 
severe acute vs 
recovery
Downregulated 
genes
Fold change
mild vs severe
Fold change
severe  acute vs 
recovery
OLFM4 49.7 43.2 GNLY -4.8 -4.0
MMP8 24.2 37.2 GZMH -4.5 -3.2
CAECAM8 18.4 19.3 GNLY -4.5 -3.7
ARG1 16.9 24.2 FGFBR2 -4.5 -5.1
ANXA3 16.6 16.2 TRAC -3.9 -2.9
DEFA4 15.1 16.1 KLRF1 -3.8 -3.3
CA1 14.9 17.5 LGALS2 -3.7 -2.0
CHI3L1 13.9 11.0 KLRC1 -3.7 -3.2
LTF 13.0 12.6 KLRD1 -3.7 -3.0
SELENBP1 12.8 15.8 TRAC -3.4 -2.8
CRISP3 12.3 12.3 THOC4 -3.4 -3.1
ELANE 11.2 10.6 GZMB -3.4 -2.3
HP 11.0 11.9 KLRD1 -3.4 -2.7
CEACAM6 11.0 10.1 IGHM -3.3 -2.0
HBM 10.5 26.0 GZMK -3.3 -2.4
CHI3L1 10.3 9.2 PRF1 -3.2 -2.2
MPO 10.2 9.9 TRAC -3.1 -2.3
ALAS2 10.2 21.7 ITPKB -3.0 -3.5
IL1R2 10.2 10.5 SH2D1B -3.0 -2.6
EPB42 10.1 15.3 SPON2 -3.0 -2.8
CEACAM6 10.1 9.7 PRF1 -3.0 -2.4
LCN2 10.1 10.3 TGFBR3 -2.9 -2.4
MPO 9.8 9.9 FCER1A -2.9 -3.9
MMP9 9.8 11.6 KLRB1 -2.9 -3.9
BPI 9.6 8.9 GPR56 -2.9 -2.9
Genes that showed overlap in both the comparisons mild vs severe disease and severe acute vs recovery 
samples are shown
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This analysis resulted in 287 differentially expressed probesets, all upregulated. 
The gene list of upregulated probesets did not differ substantially from the main 
analysis. 
A supervised analysis (PAM) also identified OLFM4 as a fully discriminative marker 
between children with mild and severe RSV infection, giving a cross-validation 
error of 0%. As both SAM and PAM analyses revealed OLFM4 as a potentially 
important marker for disease severity in children with RSV infection and OLFM4 
has -to the best of our knowledge- not been associated with respiratory tract 
infections before, this gene was chosen for further analysis. Interestingly, there 
was no marked upregulation of apoptosis genes in the severe group, indicating 
that the observed lymphopenia was not caused by increased apoptosis.
Validation of Microarray Findings by QPCR
To confirm our findings in the microarray analyses, qPCR was performed for 
OLFM4 in PBMCs of the same patients. One patient in the moderate group was 
excluded since insufficient material was left. OLFM4 expression was statistically 
significantly higher in patients with severe disease compared to those with mild 
and moderate disease (Figure 3). 
OLFM4 Gene Expression in PBMCs is Increased during Acute Viral 
Respiratory Infection and Correlates with Disease Severity in a Validation 
Cohort
The validation cohort consisted of 80 children with viral LRTIs, among which 
47 had a confirmed RSV infection. The characteristics of these patients differed 
Figure 3. qPCR of patients from the micro-
array cohort. OLFM4 gene expression levels 
were significantly higher in patients with 
severe disease compared to those with mild 
and moderate disease. Expression levels are 
presented as ΔCt and median with inter quartile 
range (IQR). Statistics were performed by 
Kruskall Wallis tests (p<0.001), followed by Mann 
Whitney U tests for individual comparisons: 
mild vs moderate p=0.26, moderate vs severe 
p<0.05, mild vs severe p<0.001.
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from those of the patients in the discovery cohort, especially for age, gender, 
preterm birth, duration of symptoms, and RSV Ct value (Table 3). In total, 115 
PBMC samples were available for qPCR analysis, subdivided in 80 acute and 35 
recovery samples. OLFM4 gene expression levels in PBMCs obtained during acute 
infection were higher compared to those obtained after recovery (p<0.001). In 
agreement with our microarray analyses, expression of OLFM4 in PBMCs was 
higher in patients with severe disease compared to those with mild and moderate 
disease (Figure 4). For the confirmed RSV+ patients only, OLFM4 expression also 
served as a discriminating marker, similar to the full validation cohort (data not 
shown). Length of stay (LOS) in hospital, another measure for severity, was also 
correlated positively with gene expression levels of OLFM4 (ρ=0.402, p<0.001).
OLFM4 Expression Correlates with Disease Severity in PBMCs but Not in 
Plasma
Since biomarkers in plasma are more easily obtained and processing is less time-
consuming, we measured protein levels of OLFM4 in plasma of 49 randomly 
selected patients of the validation cohort. Although OLFM4 plasma concentrations 
during acute infection were statistically significantly higher compared to those 
in recovery samples, no association with disease severity was observed (Figure 
5). No correlation between protein levels and relative gene expression was found 
either (ρ=0.270, p=0.088). 
Table 3. Patient characteristics of validation cohort
Mild
(N=14)
Moderate  
 (N=42)
Severe
(N=24)
p-value
Age (months) 3.2 [1.1-10.3] 4.9 [2.0-14.5] 1.2 [0.6-2.8] p<0.01*
Gender (male) 8 (57%) 22 (52%) 12 (50%) NS
Gestational age (wks) 36.8 [39.1-40.0] 38.0 [37.0-40.0] 38.9 [37.0-40.5] NS
Length of stay (days) 3 [2-3] 6 [4-9] 11 [10-13] p<0.001**
Confirmed RSV infection 3 (21%) 29 (69%) 15 (63%) <0.01***
Values are given in numbers (percentages) and median and inter quartile range (IQR). *mild versus severe 
p=0.05, moderate versus severe p<0.001 **mild versus moderate and severe p<0.001, moderate versus 
severe p<0.001 ***mild versus moderate p<0.01, mild versus severe p<0.05.
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In a Multivariable Model OLFM4 Gene Expression is a Statistically 
Significant Marker for Severe Disease
Relative OLMF4 gene expression, gender, gestational age, and age at time 
of hospital admission (in weeks) were included as determinant and potential 
confounders, respectively in a multivariable model for mechanical ventilation. 
For OLMF4, a cut-off value of > -7.5 was chosen, which corresponds with an 
OLFM4 expression level greater than 0.5% that of GAPDH. The unadjusted RR 
of mechanical ventilation was 8.6 with a 95% confidence interval (CI) of 2.2 – 
34.0. After adjustment for age and gestational age, the RR was 6.1 (95%CI: 1.5 
– 24.4), which indicates that children with OLMF4 gene expression levels above 
-7.5 have a 6-fold increased risk of severe RSV infection requiring mechanical 
ventilation. Gender did not add substantially to the final model. Including OLMF4 
gene expression in the model as a continuous variable resulted in an age and 
gestational age adjusted RR of 1.20 (95%CI: 1.04 – 1.38), meaning that the risk 
of receiving mechanical ventilation increased by 20% with every step increase in 
expression level (range -12.6 through -1.33). 
Figure 4. OLFM4 gene expression values in 
PBMCs from infants during acute mild, moderate 
and severe viral lower RTI and after recovery. 
Expression levels are presented as ΔCt and 
median with inter quartile range (IQR). Statistics 
were performed by Kruskall Wallis tests 
(p<0.001), followed by Mann Whitney U tests 
for individual comparisons: mild vs moderate 
p=0.38, moderate vs severe p<0.001, mild vs 
severe p<0.05. 
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Figure 5. Plasma levels of OLFM4 in patients with viral RTI. (A) OLFM4 plasma levels are statistically significantly 
higher during acute (n=41) infections compared to recovery samples (n=25). (B) However, there are no 
statistically significant differences among the three severity groups. Plasma levels (ng/ml) are presented as 
median with inter quartile range (IQR). Statistics were performed by Mann Whitney U tests for comparison 
acute vs recovery (p<0.05), and Kruskall Wallis tests for comparison mild vs moderate vs severe (p=0.29). 
DISCUSSION
In this study we demonstrated that OLFM4 gene expression in PBMC is a previously 
unidentified classifier for severe disease in children with viral LRTIs. OLFM4 
expression was significantly increased during acute viral respiratory infections 
compared to recovery samples. Moreover, an association was found between 
OLFM4 gene expression in PBMCs and disease severity; in a multivariable model 
OLFM4 showed its power as a significant marker for severe disease. Children 
with mechanical ventilation have almost 10 times more often an increased 
OLFM4 expression in PBMC (greater than 0.05% of the GAPDh levels). Therefore, 
OLFM4 fulfills the criteria as a biomarker for disease severity, in particular to 
discriminate mild from severe cases in young infants. For OLFM4 to formally be 
used as prognostic marker, a more extensive, prospective study will be required.
To the best of our knowledge, the OLFM4 gene has not been described in the 
context of viral respiratory infections. To test its behaviour during infectious 
disease we data-mined other micro-array studies that described pediatric and 
adult patient cohorts with infections. In a study by Ioannidis et al. (GSE 34205), 
we found that OLFM4 gene expression was higher in PBMCs obtained from 
patients with RSV (n=51) or influenza virus (n=27) infections compared to the 
gene expression in healthy infants (n=22), p<0.01 and p<0.0001, respectively.31 
No differences were found in OLFM4 gene expression between children under or 
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above three months of age with either infection by RSV or influenza. In contrast, 
two other studies did not observe upregulation of OLFM4 in PBMCs from children 
during infection by measles or rotavirus (GSE 5808 and 2729).32, 33 Zaas et 
al. performed microarrays on whole blood obtained from adult volunteers at 
baseline and at the peak of their symptoms after being experimentally infected 
with RSV, influenza or rhinovirus (GSE 17156).34 Although their data showed an 
upregulation of OLFM4 in RSV infected adults (p=0.01), there were no differences 
in OLFM4 gene expression between the baseline and during symptomatic 
influenza or rhinovirus infections.34 Data of Ramilo et al. (GSE 6269-1) showed 
a statistically significant upregulation of OLFM4 in children, aged 0-16 years, 
diagnosed with influenza virus or bacterial infections (E. coli, S. aureus or S. 
pneumoniae) compared to healthy controls.20 In this cohort, children with S. 
aureus or S. pneumoniae infections had statistically significantly higher OLFM4 
gene expression compared to influenza A infected patients.20. Thus, other 
studies have also seen upregulation of OLFM4 expresion after bacterial or viral 
infection. However, none of the studies looked at disease severity. 
OLFM4, also known as hGC-1 and GW112, was first cloned from G-CSF–stimulated 
human myeloid precursor cells and is mainly expressed in bone marrow, gastro-
intestinal tract, prostate and pancreas.35 Earlier studies have shown that OLFM4 
is involved in multiple cellular functions e.g. cell growth, differentiation and 
apoptosis.27 OLFM4 expression has been reported as one of several (prognostic) 
markers in oncology.27 In addition, its involvement in the immune response to 
inflammation has been described. OLFM4 expression is upregulated in some 
inflammatory diseases, such as chronic inflammatory bowel diseases36 and in 
Helicobacter pylori-infected patients.37 Liu et al. showed an enhanced immune 
response and inflammation in OLFM4-/- mice upon Helicobacter pylori infection. 
Their results indicate that OLFM4 inhibits NOD1 and NOD2-mediated NF-κB 
activation, suggesting that OLFM4 plays an important role in regulating innate 
immune responses.38 In another study, Liu et al. demonstrated that neutrophils 
from OLFM4 -/- mice have increased capability to kill S. aureus and E. coli and 
are more resistant to systemic sepsis.39 These data suggest that OLFM4 may be 
an important regulator of host innate immunity against a broad array of bacterial 
infections. Data mining of gene expression profiling datasets (www.immgen.
org) indicates that OLFM4 is besides being expressed in neutrophils, also highly 
expressed in Th1 cells. Therefore the increased OLFM4 expression seen in 
the severe subgroup may indicate an highly active ongoing Th1 response. In 
summary, OLFM4 was upregulated in several viral and bacterial infections in 
many (but not all) previously published studies investigated. 
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Although OLFM4 mRNA has been described to be selectively expressed in normal 
human myeloid lineage cells, OLFM4 protein concentrations have been measured 
in PBMCs, B-lymphocytes, neutrophils and monocytes.40 This is in agreement with 
our results and those from the reanalyzed microarray studies, in which high and 
significantly different OLFM4 mRNA expression was found in PBMCs obtained 
from children with different severity of viral lower respiratory infections. 
Clemmensen et al. showed that OLFM4 was present at protein level in only 20–
25% of peripheral blood neutrophils, whereas mRNA for OLFM4 was present in 
all myelocytes and metamyelocytes, indicating post-transcriptional regulation as 
a basis for the heterogeneous expression of OLFM4 protein.41 This may explain 
why we did not find differences between gene expression levels in granulocytes 
during acute infection and after recovery in our larger patient cohort. 
In this study we did not find an association between OLFM4 plasma concentrations 
and disease severity. The advantage of measuring markers in plasma is the 
ease of implementation, speed, reproducibility and standardization. However, 
innovative techniques enable rapid analysis of the expression of multiple genes 
at transcriptional level in the near future.42
The severe CD4, CD8 and NK cell lymphopenia that we and others described 
before, can now be better explained. Together with the up regulation of activation 
markers on PBMC in the severe group and lack of apoptosis, the observed 
lymphopenia likely results from recruitment of T cells to the site of infection, 
i.e the lungs with an parent lower cell count in peripheral blood. In this respect 
peripheral blood may not reflect the situation in all parts of the body. OLFM4 is 
associated with Th1 responses, an active or even overaggressive Th1 response 
may underlie the severe clinical manifestations in this group. This is reminiscent 
of interpretations in the early RSV vaccine trails. Nevertheless, more accurate 
measurements at the site of infection will be needed to determine whether in the 
severe cases an inadequate adaptive immune response or a hyper responsive 
reaction (for instance by excessive production of cytokines) is responsible for 
the severe manifestations of RSV infection.
Notwithstanding this uncertainty, in this study we are the first to show that 
OLFM4 transcription is associated with severity of disease in children with viral 
lower respiratory tract infections, also after correcting for age. These results 
emphasize the role of OLFM4 in innate and adaptive immunity and encourages 
further research into the presence of OLFM4 in PBMCs and the pathogenesis of 
RSV infections. Moreover, it could lead to the development of a new diagnostic 
tool to predict a severe course of viral respiratory disease and aid the physician 
in clinical decisions. 
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ABSTRACT
Background
Respiratory virus infections are among the primary causes of morbidity 
and mortality in humans. Influenza virus, respiratory syncytial virus (RSV), 
parainfluenza (PIV) and human metapneumovirus (hMPV) are major causes of 
respiratory illness in humans. Especially young children and the elderly are 
susceptible to infections with these viruses. In this study we aim to gain detailed 
insight into the molecular pathogenesis of respiratory virus infections by studying 
the protein expression profiles of infected lung epithelial cells.
Methods
A549 cells were exposed to a set of respiratory viruses (RSV, hMPV, PIV and 
Measles virus (MV)) using both live and UV-inactivated virus preparations. 
Cells were harvested at different time points after infection and processed for 
proteomics analysis by 2-dimensional difference gel electrophoresis (2D-DIGE). 
Samples derived from infected cells were compared to mock-infected cells to 
identify proteins that are differentially expressed due to infection.
Results
We show that RSV, hMPV, PIV3, and MV induced similar core host responses 
and that mainly proteins involved in defense against endoplasmatic reticulum 
(ER) stress and apoptosis were affected which points towards an induction of 
apoptosis upon infection. 
Conclusion
By 2-D DIGE analyses we have gathered information on the induction of apoptosis 
by respiratory viruses in A549 cells.
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INTRODUCTION
Respiratory viruses are a major cause of lower respiratory tract infections (LRTIs) 
and are among the primary causes of morbidity and mortality in humans. These 
infections are a major public health problem. Especially infants and young children 
as well as the elderly are prone to severe and even fatal outcome of infections 
with respiratory viruses such as Influenza virus, RSV, PIV, and human hMPV.1-5 
In young children and infants, RSV is the primary etiologic agent of epidemic 
lower respiratory tract infections being responsible for 80% of cases of acute 
bronchiolitis.6, 7 For RSV extensive vaccine-related research has been performed, 
but so far no efficient and widely applicable vaccine has been developed yet. Also 
for the recently discovered hMPV8, which is closely related to RSV, no vaccine is 
currently available. Only for MV an effective vaccine is available and for classical 
Influenza vaccines are available but these need further improvement.
RSV, hMPV, PIV and MV belong to the Paramyxoviridae family of viruses These 
are all enveloped viruses and have a linear, non-segmented, single stranded 
negative sense RNA of ~15,000 nucleotides containing 10 genes encoding 10 
(RSV) proteins, 13 kb containing 8 genes (hMPV), ~15,500 nucleotides containing 
6 genes (PIV), and 15.9 kb containing 6 genes (MV), respectively.9 All these 
viruses enter the host via the respiratory tract by infecting airway epithelial cells 
that line the nose as well as the large and small airways and induce inflammation 
associated with the disease at the site of infection with the exception of MV that 
disseminates beyond the respiratory tract.9 
Although respiratory cells are the first targets of respiratory virus infection, 
they are also the first line of defense in the innate immune response that is 
generated upon infection.10 Epithelial cells form a direct physical barrier between 
the host and the environment, the epithelial cells are able to detect invading 
pathogens and actively participate in the innate immune response to invading 
viruses e.g. by producing acute phase proteins and inflammatory cytokines 
and chemokines.10-12 Depending on the location in the lung, there are different 
types of epithelial cells that respond to invading pathogens in a cell type specific 
manner due to varying expression of pattern recognition receptors, cell-specific 
protein expression, or to differences in susceptibility to injury. These responses 
can result in killing of the pathogen by recruitment of phagocytes that can not 
only directly kill the invading pathogens but also shape the adaptive immune 
response to viral infection
However, little is known about the exact mechanisms underlying the induction 
and maturation stages of innate and adaptive anti-viral immune responses. 
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Also the interaction between the virus and the host at the molecular level is 
not well understood. A better understanding of these events is required for the 
development of new strategies for treatment and prevention of these infectious 
diseases. In this study we describe the effect of respiratory virus infection (RSV, 
hMPV, PIV and MV) on protein expression levels in type II alveolar A549 human 
epithelial cells by 2-D DIGE analyses at different time points after infection to gain 
detailed insight into the interaction between the viruses and the host cells and 
to explore differences in induced protein expression changes between different 
respiratory viruses. A549 cells are frequently used for in vitro infection with 
RSV and all four viruses are capable of infecting these cells making it a suitable 
in vitro model for comparing protein expression profiles between RSV, hMPV, 
PIV, and MV.12-17 We show that a similar core host response was induced by the 
different viruses that were studied, and that RSV, hMPV, PIV3, and MV mainly 
affect proteins involved in defense against ER stress and apoptosis which points 
towards an induction of apoptosis upon infection.
MATERIALS AND METHODS
Chemicals and Reagents 
Fluorescent minimal labeling CyDyes and IPG buffer pH3–10 were purchased 
from GE Healthcare (Roosendaal, The Netherlands). Urea, thiourea, Tris, 
iodoacetamide, trifluoroacetic acid (TFA), phosphoric acid, acetone, glycerol, 
acetonitrile, ammonium bicarbonate, CHAPS, l-lysine, and porcine modified 
trypsin were all from Merck (Amsterdam, The Netherlands), DTT from Sigma-
Aldrich (Zwijndrecht, The Netherlands), DHS from Fluka, Trizol from Invitrogen 
(Breda, The Netherlands), TEMED, low melting temperature agarose (LMT), 
ammoniumpersulphate and Coomassie Brilliant Blue R-250 from BHD (Amsterdam, 
The Netherlands), and acrylamide from Nation Diagnostics (Hessle, UK).
Cells and Viruses
The human lung adenocarcinoma epithelial cell line A549 and (American Type 
Culture Collection (ATCC; CCL-185), Manassas, VA, USA) and the Vero-118 cell 
line (a gift from B.G. van den Hoogen) were cultured at 37 °C with 5% CO2 in 
respectively HAM F12 medium (GIBCO) supplemented with 3% heat-inactivated 
fetal calf serum (FCS, Hyclone) and Iscove’s Modified Dulbecco’s Medium (IMDM, 
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GIBCO) supplemented with either 0.02% trypsin and 3% bovine albumin fraction 
V medium (for hMPV infection) or 10% FCS (for RSV, PIV, and MV infections). 
All media were also supplemented with penicillin (100 U/ml; BioWhittaker), 
streptomycin (100 µg/ml; BioWhittaker) and l-glutamin (2 mM; BioWhittaker). 
High titer stocks from hMPV (NL/1/00, a gift from B.G. van den Hoogen), 
RSV-A2 (ATCC; VR1540), PIV3 (ATCC; VR-93), and MV-Edm (ATCC; VR-24) were 
grown on Vero-118 cells using a serial limiting dilution protocol according to 
Gupta et al. and used to infect A549 cells.18 From all virus stocks inactivated 
virus preparations were produced by UV-irradiation using an Uvitec ultraviolet 
transilluminator (312 nm wavelength).
In Vitro Infection Experiments
A549 cells were seeded at a density of 3 × 105 cells/well in a 6-well plate and 
were allowed to adhere overnight. Live or UV-inactivated virus preparations 
(same dilution from the original high tittered stocks) were added to the cells at a 
multiplicity of infection of 3 to 10. At 60 min after infection the virus-containing 
serum free medium was removed and replaced by a fresh HAM F12 medium 
(containing 3% FCS) and cells were incubated at 37 °C. For the mock-infected 
cells a medium containing no virus was added to the cells. At 6, 12, and 24h 
after infection the cells were washed once with pre-warmed PBS and the cells 
were lysed in 1 ml Trizol and stored at -80 °C. These infection experiments were 
performed in duplicate on different days for analysis of biological replicates.
Protein Isolation
Proteins were isolated from the remaining interphase and organic phase that 
remain after RNA extraction from Trizol samples. Four volumes of ice-cold 
(-20 °C) acetone were added to these fractions and incubated at -20 °C for 1 
h. Precipitated proteins were then centrifuged at maximum speed for 5 min. 
The protein pellet was washed twice with ice-cold 80% acetone. The pellet was 
air-dried and suspended in milliQ. Protein concentration in each sample was 
determined using a 96-well plate based BCA assay (Pierce) according to the 
manufacturer’s instructions.
Protein Labeling
A total amount of 25 µg protein was taken from each sample and dried in a 
130
Chapter 7
vacuum concentrator. The protein pellets were dissolved in 10 µl lysis buffer (30 
mM Tris, 7 M urea, 1 M thiourea, and 4% CHAPS) and were snap frozen five times 
to completely dissolve the protein pellet. Per 25 µg protein 200 pmol fluorescent 
minimal labeling CyDye was added according to the scheme depicted in Table 
1 and incubated on ice for 30 min in the dark. 1 µl 10 mM l-lysine was added 
to each sample and was incubated for 15 min in the dark to stop the labeling 
reaction. Labeled samples were stored at -20 ° until use.
Table 1. Experimental setup for 2-D DIGE experiments1.
Gel number Cy3 Cy5 Cy2
1–2 Mock t = 0 Mock t = 6 A549 mock
3–4 Mock t = 12 Mock t = 24 A549 mock
5–6 RSV + UV t = 6 RSV - UV t = 6 A549 mock
7–8 RSV + UV t = 12 RSV - UV t = 12 A549 mock
9–10 RSV + UV t = 24 RSV - UV t = 24 A549 mock
11–12 hMPV + UV t = 6 hMPV - UV t = 6 A549 mock
13–14 hMPV + UV t = 12 hMPV - UV t = 12 A549 mock
15–16 hMPV + UV t = 24 hMPV - UV t = 24 A549 mock
17–18 PIV + UV t = 6 PIV - UV t = 6 A549 mock
19–20 PIV + UV t = 12 PIV - UV t = 12 A549 mock
21–22 PIV + UV t = 24 PIV - UV t = 24 A549 mock
23–24 MV + UV t = 6 MV - UV t = 6 A549 mock
25–26 MV + UV t = 12 MV - UV t = 12 A549 mock
27–28 MV + UV t = 24 MV - UV t = 24 A549 mock
150 µg protein from each sample was labeled with fluorescent CyDyes as indicated.
2-D Gel Electrophoresis
Samples to be run on the same gel were combined (Table 1) and used for 
rehydration of 18 cm Immobiline Dry Strips pH4–7 (GE Healthcare). A volume of 
310 µl rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 1.2% IPG buffer 
pH3–10, and 2 mg/ml DTT) was added to the combined samples and applied to 
the strips using a rehydration tray. After an overnight rehydration the proteins 
were separated in the first dimension using a Multiphor II (3 h 300 V followed 
by a gradual increase by 300 V every 20 min until a final voltage of 2200 was 
reached). After complete focusing (± 30 kVh), the strips were equilibrated in 
0.5% DTT in equilibration buffer (100 mM Tris pH8.8, 6 M urea, 30% glycerol, 
and 2% SDS) for 10 min followed by 4.5% iodoacetamide in equilibration buffer 
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for 10 min. The strips were then applied to a 12–20% gradient polyacrylamide gel 
that had been made the day before using low-fluorescent glass plates. The strips 
were fixed using a 1% LMT solution and the proteins were directly separated 
overnight in the second dimension using an Ettan Dalt Six (GE Healthcare) at 10 
°C and 2 W per gel.
Scanning and Image Analysis
Gels were scanned on a Typhoon 9410 (Amersham Biosciences) at excitation 
wavelengths of 488, 532, and 633 nm and 520BP40, 580BP30, and 670BP30 
emission filters Cy2, Cy3, and Cy5, respectively. For the comparative analyses 
per time point only those protein spots were included that were present in all of 
the gels to be compared for a certain virus or time point. Statistical analysis and 
quantitative protein expression were done using Decyder Analysis BVA software 
(Amersham Biosciences) and protein spots were considered significantly 
differential at a p-value of < 0.01 and a fold change of at least 2.5.
Mass Spectrometry and Protein Identification
For identification of protein spots a preparative gel containing 500 µg protein was 
run as described earlier and stained with Coomassie Brilliant Blue R-250. Protein 
spots of interest were manually excised from the gel and digested with trypsin. 
Peptides were extracted using 2% TFA and were desalted and concentrated using 
C18 StageTips. Peptide mixtures were purified and desalted using C18 StageTips. 
Peptide separation and sequence determination were performed with a nano-high 
performance liquid chromatography system (Agilent 1100 series, Amstelveen, 
The Netherlands) connected to a 7-T linear quadrupole ion trap-ion cyclotron 
resonance Fourier transform mass spectrometer (Thermo Electron, Breda, The 
Netherlands). Peptides were separated on a 15-cm 100-µm-inner-diameter 
PicoTip emitter for online electrospray (New Objective, Woburn, MA) packed with 
3 µm C18 beads (Reprosil, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) 
with a 60-minute linear gradient from 2.4 to 40% acetonitrile in 0.5% acetic 
acid at a 300 nl/min flow rate. The four most abundant ions were sequentially 
isolated and fragmented in the linear ion trap by applying collisionally induced 
dissociation. Proteins were identified using the MASCOT search engine (Matrix 
science, London, UK) against the human protein NCBI database using the following 
search criteria: 20 ppm peptide tolerance, a maximum of 2 missed cleavages, a 
fixed carbamidomethyl modification of cysteines, and variable oxidation (M) and 
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deamidation (NQ) modification.
Molecular Network Analyses
The global protein–protein interaction (PPI) network used (herein referred to 
as galaxy 6) was built from an accumulation of human-curated PPIs obtained 
from the Biomolecular Interaction Network Database (BIND) (data downloaded 
in October 2006), the Human Protein Reference Database (HPRD) (data of 
release 6th of January 2007), the IntAct database (downloaded in May 2007), 
the Molecular Interactions Database (MINT) (downloaded in May 2007), and the 
PDZBase database (downloaded in May 2007). All PPI networks were drawn using 
Cytoscape. The Gene Ontology (GO) database used was downloaded from NCBI 
in February 2008. Gene enrichment analyses were done using BINGO.19 Protein 
enrichment analyses were done using in-house python scripts.
RESULTS AND DISCUSSION
2-D DIGE analyses
To study the epithelial responses upon respiratory virus encounter and infection, 
A549 cells were exposed to different respiratory viruses (RSV, hMPV, PIV and 
MV). Both live and UV-inactivated virus preparations were used thus allowing 
distinction between live, replicating, virus-induced changes in protein expression 
and changes induced upon contact with or uptake of non-replicating virus 
particles. At different time points after infection, the cells were lysed and used 
for protein expression analysis by 2-D DIGE and quantitative and comparative 
DeCyder analyses. Approximately 1000 spots were detected in the individual 
gels. Of these, 325 were present in at least 20 out of 28 gels and could be 
used for statistical and comparative analyses. For the comparative analyses 
per time point only those protein spots were included that were present in all 
of the gels to be compared for a certain virus or time point. Upon infection 
with either one of the respiratory viruses or mock, a total of 70 spots showed 
differential expression in at least one of the time points after infection (Fig. 1A). 
Differentially expressed spots were manually excised from a preparative gel and 
were analyzed by nano-LC FT-ICR-MS to identify the proteins. Of the 70 spots 
that were picked for analysis we were able to identify the corresponding protein 
in 63 samples. 
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Figure 1. Preparative gel image (A) and functional classification (B) of protein spots that showed differential 
expression upon respiratory virus infection of A549 cells compared to mock at 6, 12 or 24 h after infection.
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This resulted in the positive identification of 55 unique proteins (Table 2). These 
proteins were shown to be mostly involved in cellular structures, stress respon-
ses, protein biosynthesis and modification, transcription, and trafficking (Fig. 
1B).
Respiratory Virus-Induced Changes in Protein Expression
Upon infection of A549 cells with the 4 different respiratory viruses, there were 
21, 18, 19 and 17 spots that showed differential expression upon infection 
with RSV, hMPV, PIV or MV, respectively, compared to mock-infected cells at 
6, 12 or 24 h after infection (Table 2). RSV, hMPV, PIV and MV belong to the 
family of the Paramyxoviridae and are related to each other yet inducing distinct 
disease phenotypes. What became apparent from the 2-D DIGE analyses is that 
RSV and hMPV infected cells showed slightly more induced changes in protein 
expression than the PIV and Measles virus-infected cells. Also no clear differences 
were found in direct comparisons between protein samples from live and UV-
inactivated virus-infected cells, indicative for a predominating general response 
upon virus encounter by A549 cells with no apparent effect of the replication on 
the proteome within the time frame of the experiment. In addition, only proteins 
with a high turn-over rate will show differential expression at earlier time points. 
Figure 2. Functional classification of proteins that showed differential expression upon infection of A549 cells 
with respiratory viruses RSV (A), hMPV (B), PIV (C), and MV (D).
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Table 3. Molecular and cellular functions of differentially expressed proteins.
Molecular and cellular functions Number of proteins1
All RSV hMPV PIV MV
Cellular organization, morphology, 
function and proliferation
26 8 12 13 11
Cell death 22 7 14 10 10
Metabolism 11 4 5 6 7
Small molecule biochemistry 14 4 6 4 6
Molecular transport 8 3 5 4 5
Post-translational modification and folding 8 2 5 5 4
Cellular compromise 3 3 5 4 1
DNA replication, recombination, and repair 6 2 5 3 2
Cell-to-cell signaling and interaction 5 3 3 2 2
Gene expression 5 2 3 2
Protein synthesis 4 2 3 1 1
Cellular development 2 2 3
Infection mechanism 3 1 2 2
Cell signaling 1 1 3
Cell-mediated immune response 4 4
Protein Degradation 3 1 3
RNA post-transcriptional modification 3 1 1 1
RNA trafficking 1 1 1 1
Inflammatory response 3 1 1
Cellular movement 1 1 1
RNA damage and repair 2 1 1
Cellular response to therapeutics 1 1
Energy production 1 1
Free radical scavenging 1 1
1Only significant changes are shown.
An additional caveat regarding a non-ambiguous interpretation of the differential 
protein responses measured by 2-D DIGE is an accumulation of virus-induced 
changes in addition to host cellular defense responses upon encounter with 
the virus particles. Given the observation that there were not many differences 
between live and UV-inactivated virus particles, the most likely effect is that of 
the cell upon encounter with the virus particles instead of the activity of the 
live replicating viruses. Upon infection of A549 cells with RSV, eleven proteins 
were more abundant, 9 less abundant, and 1 more abundant at 6 h while less 
abundant at 24 h compared to mock-infected cells (Table 2). Most of these 
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proteins are known to be involved in protein biosynthesis and modification, 
and cellular structures (Table 2 and Fig. 2A). A total of 18 protein spots were 
differentially expressed in A549 cells upon encounter with hMPV, of which 7 
were more abundant and 11 less abundant (Table 2 and Fig. 2B). A major part 
of the differentially expressed proteins are known to be involved in protein 
biosynthesis and modification, cellular stress responses, transcription or 
are cytoskeleton- or structural proteins. PIV infection showed more abundant 
expression in 12 protein spots, less abundant expression in 6 spots and 1 spot 
that was more abundant in live virus particles infected cells while less abundant 
in UV-inactivated virus-infected cells (Table 2 and Fig. 2C). Finally, MV showed 
less abundant expression in 8 spots and more abundant expression in 9 spots 
(Table 2 and Fig. 2D).
In addition to functional annotations, we also used Ingenuity for functional 
analyses on these differentially expressed proteins and identified 34 molecular 
and cellular functions for these proteins. Most functions include cell death, cellular 
organization and function and morphology, post-translational modifications and 
folding, and metabolism (Table 3, Fig. 1B). 
Table 4. GO enrichment analyses of respiratory virus altered proteins in A549 cells.
Case                                                    Virus-
                                                           perturbed
Random 
input
Virus-
perturbed 
recovered
Average 
random 
recovered
Fold en-
richment
p-value1
RSV tx in original network 8 8 7 1.43 4.89 < 0.001
RSV tx in apoptosis network 8 8 1 0.14 7.25 0.007
RSV tx apoptosis enriched 8 8 8 0.47 16.88 < 0.001
RSV tx apoptosis–cytokine enriched 8 8 3 0.47 6.33 0.002
hMPV tx in original network 17 17 11 3.11 3.54 < 0.001
hMPV tx in apoptosis network 17 17 3 0.27 11.07 < 0.001
hMPV tx apoptosis enriched 17 17 17 1.05 16.19 < 0.001
hMPV tx apoptosis–cytokine enriched 17 17 8 1.05 7.62 < 0.001
PIV tx in original network 14 14 10 2.53 3.95 < 0.001
PIV tx in apoptosis network 14 14 1 0.23 4.39 0.013
PIV tx apoptosis enriched 14 14 14 0.85 16.45 < 0.001
PIV tx apoptosis–cytokine enriched 14 14 6 0.85 7.05 < 0.001
MV tx in original network 12 12 7 2.15 3.25 0.001
MV tx in apoptosis network 12 12 2 0.20 10.20 0.001
MV tx apoptosis enriched 12 12 12 0.72 16.55 < 0.001
MV tx apoptosis–cytokine enriched 12 12 3 0.72 4.14 0.005
1P-value refers to how likely random recovered number is higher than virus-perturbed recovered.
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These analyses also showed that all 4 viruses affect these cellular processes 
similarly (Table 3).
Molecular Network Analyses
Results from the original GO network analysis (Fig. 3, arrow 1, result 1) show 
that many of the identified proteins (viral perturbed) are involved in apoptosis. 
To further explore the involvement of respiratory virus-induced or repressed 
proteins in the apoptosis pathway we performed a GO enrichment analysis as 
schematically depicted in Fig. 3A (arrows 2, 2a, and 3, result 2). The apoptosis 
network was extracted from the original GO network and was enriched for 
proteins known to interact with proteins involved in apoptosis resulting in the 
apoptosis N1 protein network (arrow 2b, Fig. 3A). When virus-perturbed proteins 
were analyzed using this database 100% of the proteins were recovered (arrow 4, 
result 3), thus indicating the involvement of these proteins in apoptosis, either 
directly or indirectly by interacting with proteins that are directly involved in 
apoptosis (Table 4).
Since cytokines have been shown to be of great importance in respiratory virus 
infection and are known to be involved in apoptosis as well, we generated a 
new network from the apoptosis N1 network and the cytokine network from the 
original GO database together with the virus-perturbed proteins (cytokine and 
virus-perturbed network) and extracted the virus-perturbed N1 network (arrow 6, 
result 4). Analysis of the virus-perturbed proteins in this database revealed that 
25–55% of these proteins are either proteins involved in apoptosis themselves or 
cytokines known to interact with these apoptosis proteins (Fig. 3B).
A substantial part of the proteins that were differentially expressed upon infection 
with either one of the different viruses are involved in apoptosis. To check 
whether this observation was not based on coincidence we performed another 
GO enrichment procedure for randomly selected proteins. Table 4 shows that 
the number of recovered proteins was significantly higher in the virus-perturbed 
than for the randomly selected proteins, indicating that the proteins that were 
found differentially expressed are indeed mostly involved in apoptosis.
Functional Pathway Analyses
Ingenuity functional pathway analyses showed that a total number of 22 
differentially expressed protein spots is considered to be involved in cell death 
and 26 in cellular organization, function and proliferation (Table 3). Ingenuity 
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Figure 3. GO enrichment analysis procedure (A) and protein–protein interactions (B) of differentially expressed 
proteins in respiratory virus-infected A549 cells. The numbers on arrows in figure A represent the order in 
which the GO enrichment procedure was performed. Triangles in figure B represent proteins involved in 
apoptosis, nodes with dark bold borders are cytokines. Green nodes are proteins that were more abundant 
upon infection, while red nodes represent less abundant proteins. 
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function analyses revealed that there is a great overlap between these molecular 
and cellular functions, since similar proteins were categorized in these two 
functional categories. Both categories include VCL, RDX, HSPA5, T-complex 
protein 1, HSPA90AA1, NDUFS1, NCL, PNPT1, XRCC5, ALDH3A1, PDCD6IP, and 
NPM1 and proteins that are cell death associated only LMNB1, TUBB3, RAD23B, 
EEF2, P4HB, VCP, HSPA8, and PEA15 (Table 5). The process of virus-induced 
apoptosis can be divided into 4 processes based on these proteins, namely, virus 
uptake and infection, stress response, disruption of cellular structures and cell 
death by apoptosis.
Virus Uptake and Infection
XRCC5 is the 86 kDa subunit of the Ku complex that is abundant in the nucleus 
and binds to DNA.20 Ku was postulated to have a role in DNA repair or replication 
as it has been shown to bind to the termini of DNA fragments. It was shown 
previously that Ku86 has a role in HIV1 and SV40 infection and our data suggest 
a role for this protein in RSV infection of A549 cells as well.21-23
HSPA8 is a member of the HSP70 family of heat shock proteins and has been 
shown to be virus inducible showing highest expression during the S-phase of 
cell cycle and is necessary for the entry of HTLV-I into its target cells.24, 25 In hMPV 
and PIV infected A549 cells, HSPA8 is more abundant at 6 and 12 h respectively. 
This shows that hMPV is inducing expression in A549 cells early in infection 
while this response is somewhat slower in PIV infected cells.
Stress Response Proteins
Of the set of differentially expressed proteins described above, HSPA5, HSP90AA1, 
TUBB3, P4HB and VCP are all proteins that are involved in cellular stress responses 
preceding apoptosis. All these proteins were shown to be less abundant at 24 h 
after infection except for TUBB3, a member of the tubulin family of microtubule 
proteins that is also known to be involved in adaptation to oxidative stress and 
cellular survival.26-28 More abundant expression of TUBB3, as observed in hMPV 
infected cells at 12 h suggests an initial mechanism for defense against oxidative 
stress which might eventually fail at 24 h after infection or points towards the 
blocking of cell cycle progression and induction of apoptosis.26, 29, 30
Less abundant expression of the other 4 proteins also points towards apoptotic 
processes in A549 cells at 24 h after infection. The molecular chaperones 
HSPA5 and HSP90AA1 are involved in the ER stress response upon accumulation 
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of unfolded proteins in the ER.31 When the unfolded protein response is not 
correctly activated, cells die by apoptosis.32 In contrast to some other viruses, 
hMPV induces a less abundant expression of HSPA5 protein expression in A549 
cells at 24 h after infection33-36, suggesting that the ER stress response is not 
correctly induced thus resulting in the subsequent induction of apoptosis in 
these cells.
HSP90AA1 has a very important function in the folding of cell regulatory 
proteins and the refolding of stress-denatured polypeptides.37-39 In hMPV 
infected A549 cells we observed an initial increase in HSP90AA1 expression 
at 12 h after infection which suggests a cellular response to hMPV-induced ER 
stress initiated by an increase of unfolded or misfolded proteins. Recently, an 
association between HSP90 protein complex and lamin A/C has been observed 
after oxidative stress.40 Also in our hMPV and PIV infected A549 cells we observe 
an increase in HSP90AA1 as well as lamin A/C suggesting a damaging oxidative 
stress response in these cells. The HSP90AA1-associated protein lamin A/C has 
been shown to be involved in viral infections being required for repressing HSV 
replication and more abundant expression in hMPV and PIV infected A549 cells 
supports such a response upon infection.41
The other lamin that was found to be differentially expressed upon hMPV 
infection is lamin B1 although in contrast to lamin A/C it was less abundant 
upon infection. Lamin B1 also plays an important role in the cellular response to 
oxidative stress.42 As a consequence of less abundant expression of lamin B1, 
hMPV infected cells might become more susceptible to oxidative stress and may 
result in subsequent cell death.
The molecular structure of P4HB is identical to that of the enzyme protein 
disulfide isomerase (PDI) which is known to protect cells against ER stress and 
inhibition of the protein will result in ER stress and subsequent induction of 
apoptosis.43-45 P4HB is less abundant at 24 h after infection with RSV suggesting 
the induction of apoptosis in these cells. In hMPV and PIV infected cells this 
protein is more abundant at 6 h after infection suggesting the initiation of a 
protective response against ER stress.
VCP is involved in many cellular processes such as protein degradation and 
membrane fusion and has chaperone activity. Less abundant expression of VCP 
expression has been shown to cause ER and oxidative stress and thereby induces 
apoptosis through caspase activation while more abundant expression results 
in anti-apoptotic responses.46 VCP shows less abundant expression at 24 h after 
infection with hMPV and suggests the induction of apoptosis.
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Disruption of Cellular Structures
CCT3, CCT5, and CCT6 are all part of the T-complex protein 1 that is involved in 
the folding of actin and tubulin as well as many other newly synthesized proteins. 
47, 48 Less abundant expression of CCT5 as observed in the hMPV, PIV and MV 
infected A549 cells has also been described for enterovirus 71 infected cells and 
a role in the disruption of the cytoskeletal structure to aid viral replication was 
suggested.49 A supportive finding for this disruption of cytoskeletal structure 
is that the F-actin cross-linking protein ACTN4 expression is less abundant 
at 24 h after infection thus facilitating viral replication.50 A similar result was 
observed for PDCD6IP, a protein that has been shown to play a role in infection 
with enveloped viruses, like human immunodeficiency virus type 1 (HIV-1).51-54 
In addition, PDCD6IP/AIP1 can associate with different cytoskeleton elements 
such as focal adhesion kinase and other cytoskeletal elements.55 Less abundant 
expression of PDCD6IP as observed at 24 h after infection with RVS, hMPV and 
MV suggests the inhibition of cytoskeleton assembly.56
Vinculin (VCL) is a key regulator of focal adhesions that directly interacts with 
talin and actin and controls cell adhesion and migration. Interaction between 
VCL and the plasma membrane is essential for these processes.57 Several 
viruses are known to disrupt or limit the function of these focal adhesions.58-60 
In glioblastoma cells, less abundant VCL expression is associated with induced 
apoptosis showing that disruption of the actin-VCL-cytoskeleton matrix is a 
major component of induced apoptosis in these cells.61 Decreased expression of 
VCL by RSV infection in our experiment could suggest that the A549 cells have 
decreased adhesive and increased migratory capacities upon RSV infection, but 
might also suggest that apoptosis is induced in these cells.
Radixin (RDX) forms a complex with ezrin and moesin (ERM complex) that 
regulate membrane protein dynamisms and cytoskeleton rearrangements, are 
determinants in viral susceptibility, and are involved in apoptosis.62-64 In RSV, PIV 
and MV infected A549 cells, expression of RDX was shown to be more abundant 
at 6 h after infection suggesting an initial defense response to the virus. At 24 
h after RSV infection, however, RDX expression was less abundant suggesting 
increased apoptosis in RSV infected A549 cells.
Nucleolin (NCL) is an abundant nucleolar protein that has been implicated in 
chromatin structure, rDNA transcription, rRNA maturation, ribosome assembly 
and nucleo-cytoplasmic transport.65 NCL is also involved in the stabilization of 
the apoptosis suppressor BCL-2. Reduced expression of NCL results in BCL-2 
mRNA instability and decreased levels of BCL-2 protein resulting in increased 
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apoptosis.66-68 NCL expression is less abundant upon infection with hMPV and 
thus also points towards induction of apoptosis in A549 cells.
Elongation factor 2 (EEF2) is a conserved monomeric GTPase involved in protein 
synthesis and translation elongation. This protein has been shown to have a role 
in HIV1 infection as a regulator of apoptosis and host innate cellular responses 
against viral factors as over expression of the protein induces protection against 
HIV1 induced apoptosis. In RSV and hMPV infected A549 cells, EEF2 is strongly 
less abundant at 24 h post-infection suggesting that induced apoptosis is no 
longer being suppressed by this protein.69
PEA15 is a 15-kDa phosphoprotein that can inhibit proliferation and that regulates 
the ability of BCL-2 to suppress Fas-induced apoptosis in a phosphorylation-
dependent manner. In addition, PEA-15 phosphorylation is mediated by the 
PTEN/PI3K pathway.70-71 PEA15 is less abundant in MV infected cells at 6 h after 
infection, which suggests that proliferation and BCL-2-mediated suppression of 
Fas-induced apoptosis is intact and proliferation is not suppressed yet.
CONCLUSIONS
The respiratory viruses RSV, hMPV, PIV and MV altered the expression of proteins 
involved in cell death that points towards an induction of apoptosis upon 
infection. Induction of apoptosis in epithelial cells by RSV and hMPV has been 
described before and our findings of induced ER stress, Bcl-2 and p53-dependent 
apoptosis support these data.13-16 In addition, we newly identified proteins that 
are altered by the viral infection and induce apoptosis in A549 cells. For some 
of the identified proteins a role in virus-induced apoptosis has been previously 
described for viruses other than the respiratory viruses that were used in this 
experiment. However, several proteins have been newly identified, which are 
considered to be involved in respiratory virus infection-induced apoptosis. This 
list of proteins is likely to be further extended by improving the 2-D DIGE analysis, 
i.e. by increasing the number of replicates in the analysis or by using a different 
internal standard. This might allow the analysis of additional proteins and might 
also reliably allow the identification of spots with minor changes in protein 
expression (FC<2.5). In addition, complementary (semi-)quantitative proteomics-
based techniques such as ICAT, ITRAQ or label-free MS analyses are also expected 
to confirm and are likely to complement our current findings. These proteins 
are of interest for further exploration of respiratory virus-induced apoptosis 
and might be interesting targets for the development of future therapeutics or 
prevention strategies against these severe disease causing viruses.
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ABSTRACT
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract 
infections in infants. Despite over 50 years of research, to date no safe and 
efficacious RSV vaccine has been licensed. Many experimental vaccination 
strategies failed to induce balanced T-helper responses and were associated with 
adverse effects such as hypersensitivity and immunopathology upon challenge. 
In this study we explored the well-established recombinant vaccinia virus RSV 
F/G vaccination-challenge mouse model to study phenotypically distinct vaccine 
mediated host immune responses at the proteome level. Mass spectrometry-
based spectral count comparisons enabled us to identify seven host proteins for 
which expression in lung tissue is associated with an aberrant T-helper 2 (Th2) 
skewed response characterized by the influx of eosinophils and neutrophils. 
These proteins are involved in processes related to the influx of eosinophils 
directly (Epx), chemotaxis and extravasion processes (Chil3) as well as eosinophil 
and neutrophil homing signals to the lung (Itgam). In addition, the increased 
protein levels of Arg1 and Chil3 point at a functional and regulatory role for 
alternatively activated macrophages and type 2 innate lymphoid cells in Th2 
cytokine driven RSV vaccine-mediated enhanced disease. 
IMPORTANCE
RSV alone is responsible for 80% of acute bronchiolitis cases in infants and 
substantial mortality in developing countries. Clinical trials with formalin-
inactivated RSV vaccine preparations in the 1960s failed to induce protection 
upon natural RSV infection, and even predisposed for enhanced disease. Despite 
the clinical need, to date no safe and efficacious RSV vaccine has been licensed. 
Since RSV vaccines have a tendency to prime for unbalanced responses associated 
with an exuberant influx of inflammatory cells and enhanced disease, a detailed 
characterization of primed host responses has become a crucial element in RSV 
vaccine research. We investigated the lung proteome of mice challenged with RSV 
upon priming with vaccine preparations known to induce phenotypically distinct 
host responses. Seven host proteins have been identified which expression 
levels associated with vaccine mediated enhanced disease. The identified protein 
biomarkers support the development, as well as the detailed evaluation of next 
generation RSV vaccines.
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INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory 
tract infections (LRTIs) in children, being responsible for 80% of cases of acute 
bronchiolitis and subsequent hospital admission. 1, 2 It has been estimated that RSV 
causes 33.8 million acute LRTIs globally each year, resulting in 66,000 – 199,000 
deaths among children under 5 years of age, 99% of which occur in developing 
countries.3  In addition to young children, immunocompromised individuals and 
the elderly are at increased risk for severe RSV disease and hospitalization. A 
licensed RSV vaccine is currently not available and the development of a vaccine 
against RSV infection has proven to be very difficult. Formalin-inactivated RSV 
(FI-RSV) vaccine trials in the 1960s failed to induce protection upon natural RSV 
infection, and even predisposed for enhanced disease resulting in two deaths and 
hospitalization of 80% of the vaccinated subjects.4-7  Experimental inactivated- 
and subunit vaccines tend to prime for the induction of unbalanced, Th2 type, 
host responses that result in enhanced disease accompanied with an influx of 
inflammatory cells.8 On the other hand, development of live attenuated RSV 
vaccines that are more likely to induce balanced host responses appear difficult 
to tune and these live vaccines tend either to be over- or under-attenuated.9, 
10 Several RSV infection animal models have been developed and these are 
exploited for vaccine research and studies on virus induced (immuno)pathology. 
Multiple virological and immunological parameters are assessed in these studies 
to monitor the virus-host interaction. More recently “high-resolution” genomics 
tools have also been applied, in particular to characterize the host response. 
Previously, the FI-RSV mouse model has been used to characterize the host 
lung response in enhanced disease by mRNA profiling and several host gene 
expression correlates of enhanced disease have been identified.11 To avoid the 
non antigen specific component at the basis of the host response and induced 
enhanced disease in the FI-RSV model12 we extended this approach by exploring 
the recombinant vaccinia virus  rVV-F/G vaccination-challenge model of enhanced 
disease. For this model it has been shown that vaccination of mice with rVV-G 
results in the production of neutralizing antibodies and subsequent reduction 
in RSV replication upon challenge infection.13,14 However, these mice develop 
severe illness and pulmonary eosinophilia. Therefore, this model is ideally suited 
to study vaccine-enhanced disease upon RSV infection. As for rVV-G, priming 
with rVV-F results in the production of neutralizing antibodies but induces a 
more effective immunity against viral replication than rVV-G13, no pulmonary 
eosinophilia is observed in rVV-F primed animals upon RSV challenge.
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Using this mouse model of vaccine-enhanced disease and by applying mass 
spectrometry-assisted protein profiling we studied the molecular mechanism 
underlying vaccine induced RSV specific enhanced disease. With a comparative 
proteomics approach we identified seven proteins as biomarkers of enhanced 
disease. These proteins include Epx, Chil3 and Itgam, representing proteins 
specific for the infiltrating eosinophils. In addition, proteins that are postulated 
to play a role in the preceding stages of induction and establishment of skewed 
vaccine-induced hypersensitivity response, ArgI, Clca3, PurB, and Hk3, have also 
been identified. These seven protein biomarkers can be used to support the 
development, as well as the detailed evaluation, of next generation RSV vaccines.
MATERIALS AND METHODS
Cells and Viruses
HEp-2 and RK-13 cells were cultured in DMEM and RPMI1640, respectively 
(both BioWhittaker, Verviers, Belgium), supplemented with 10% heat-inactivated 
fetal bovine serum (FBS; Greiner, Frickenhausen, Germany), penicillin (100 U/
ml; BioWhittaker), streptomycin (100 µg/ml; BioWhittaker), L-glutamine (2 mM; 
BioWhittaker) and b-mercaptoethanol (10-5 M; Merck, Darmstadt, Germany) at 
37°C and 5% CO2. RSV-A2 (a kind gift from P.J.M. Openshaw, National Heart 
and Lung Institute, Centre for Respiratory Infection, Imperial College London, 
London, UK) was propagated on HEp-2 cells. Stocks of the parental vaccinia virus 
(VV-wt) and recombinant vaccinia viruses expressing the RSV fusion protein 
(rVV-F) and attachment protein (rVV-G) were produced on RK-13 cells. Infectivity 
of all virus stocks was checked on the corresponding cell line by serial 10-fold 
dilutions and titers were calculated using the method of Reed and Muench.15 
Mouse Vaccination and Challenge Studies
 
Six-to-eight weeks old female BALB/c mice (Netherlands Vaccine Institute, 
Bilthoven, The Netherlands) were vaccinated by scarification at the tail base 
with 106 PFU wt-VV, rVV-F or rVV-G virus as described before.14, 16 Three weeks 
after vaccination, the mice were challenged by intranasal inoculation with 
5x106 tissue culture infectious dose50 (TCID50) RSV-A2. Weight was measured 
on a daily basis and mice were sacrificed by exsanguination under isoflurane 
anesthesia at 1, 2, 3, 5, and 7 days after RSV challenge (10 animals per group 
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per day). Five animals from each group were used for broncho-alveolar lavage 
(BAL). Subsequently, lungs were inflated with 10% neutral-buffered formalin 
(formalin; Klinipath, Duiven, The Netherlands) and stored in 10% formalin for 
histopathological examination. The other five animals per group were used to 
dissect the lungs. Half of the lungs were transferred to virus transport medium 
for virus isolation, while the other half was stored in RNAlater (Ambion, Austin, 
USA) for RNA and protein isolation. To obtain control samples, naïve age-matched 
animals were sacrificed and processed identically. The study was approved by 
the Animal Ethics Committee, and was carried out in accordance with animal 
experimentation guidelines.
BAL Phenotyping
Cells in BAL were analyzed by flow cytometry as described before.17 In short, 
BAL samples were centrifuged and residual red blood cells were lysed using red 
blood cell lysis buffer (Roche Diagnostics GmbH, Mannheim, Germany) for 20’ 
at room temperature. Cells in BAL were counted and labeled with fluorescent 
monoclonal antibodies in phosphate buffered saline (PBS) supplemented with 
3% HI-FBS for 60 minutes on ice. Next, cells were washed once with PBS and 
analyzed by fluorescence activated cell sorting (FACS).
Virus Isolation
Virus was isolated from lung tissue by homogenizing half of the lung in 1ml 
virus transport medium in the Fastprep-24 instrument (MPbio, Illkirch, France) 
using 1/4” ceramic spheres (VWR, Radnor, USA) according to the manufacturer’s 
protocol (20’ and 10 m/s). The homogenate was clarified by centrifugation 
and the supernatant was applied on a monolayer of HEp-2 cells in serial 2-fold 
dilutions. Cells were screened microscopically for cytopathic effect (cpe) and 
TCID50 was calculated as described above.
Protein Isolation
After removal of the RNAlater, the lungs were homogenized and lysed in 
Trizol and proteins were isolated from the interphase and organic phase that 
remained after RNA extraction from Trizol samples. Four volumes of ice-cold 
(-20°C) acetone were added to these fractions and incubated at -20°C for 1 hour. 
Precipitated proteins were then centrifuged at maximum speed for 5 minutes. 
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The protein pellet was washed twice with ice-cold 80% acetone. The pellet was 
air-dried and suspended in 40µl lysis buffer (30mM Tris, 7M urea, 1M thiourea, 
and 4% CHAPS). Protein concentration in each sample was determined using the 
2-D Quant kit (GE Healthcare, Amersham, UK) according to the manufacturer’s 
instructions.
Mass Spectrometry  
A total amount of 25mg protein was loaded onto a 12% SDS-PAGE gel and run 
at 100V until the front reached the bottom of the gel. The gel was stained 
overnight with Coomassie Blue Silver. Each lane was divided into 5 slices and 
each slice was cut into smaller pieces and prepared for protein digestion 
with trypsin. Peptides were extracted using 2% trifluoroacetic acid (TFA) and 
buffer B (80% acetonitrile (ACN), 0.5% acetic acid, 1% TFA), and subsequently 
desalted and concentrated using C18 StageTips and buffer A (0.5% acetic 
acid, 1% TFA). Peptide mixtures were purified and desalted using C18-stage 
tips. Peptide separation and sequence determination was performed with a 
nano-high performance liquid chromatography system (Agilent 1100 series, 
Amstelveen, the Netherlands) connected to a 7-T linear quadrupole ion trap-
ion cyclotron resonance Fourier transform mass spectrometer (Thermo Electron, 
Breda, the Netherlands). Peptides were separated on a 15-cm 100-µm-inner-
diameter PicoTip emitter for online electrospray (New Objective, Woburn, MA) 
packed with 3µm C18 beads (Reprosil, Dr Maisch GmbH, Ammerbuch-Entringen, 
Germany) with a 60-minute linear gradient from 2.4 to 40 percent acetonitrile 
in 0.5% acetic acid at a 300nl/min flow rate. The four most abundant ions 
were sequentially isolated and fragmented in the linear ion trap by applying 
collisionally induced dissociation. Proteins were identified using the MASCOT 
search engine (Matrix science, London, UK) against the human International 
Protein Index (IPI) database (forward and reverse sequences) using the following 
search criteria: 20 ppm peptide tolerance, a maximum of 2 missed cleavages, a 
fixed carbamidomethyl modification of cysteines, and variable oxidation (M) and 
deamidation (NQ) modification. UniProt KB mapping table was used to map IPI 
IDs to UniProt identifiers (ftp://ftp.uniprot.org/pub/databases/uniprot/current_
release/knowledgebase/idmapping/). Differentially expressed proteins were 
functionally classified using GO-slim identifiers18 and Ingenuity Pathway Analysis 
(Qiagen, Redwood City, USA).
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Validation of Peptides and Proteins
Mascot database search files were further processed using MSQuant 1.4.3 to 
generate first ranked peptide lists. A validation filter was applied to these lists 
using the reverse database searches. First the mass accuracy cut-off was set at 
the mass relative error (parts per million (ppm)) at which 95% of all identified 
peptides were still included. Then the reverse database search was used to 
set the peptide cut-off score at which only 10% of the identified peptides were 
still included in the reverse database search list. Then the number of peptide 
sequences per protein was calculated and the list was further validated by the 
following criteria; proteins that were identified based on 3 peptides or more 
were accepted. If 2 peptides were identified, these peptides were not allowed 
to contain any modifications. If only 1 peptide was identified, no modifications 
were accepted, peptide scores needed to be above 40 and the peptide delta 
score should be above 10. This resulted in false positive rates of 11% for proteins 
identified with 1 or 2 peptides and 0.9% for proteins identified with 3 or more 
peptides. After internal calibration of peptides masses by MSQuant and validation 
as just described, the absolute mass accuracy of all identified peptides was below 
15ppm for all samples with an average of ~2ppm. To remove redundancy at the 
protein level and to uniquely assign peptides to one protein, the peptides were 
remapped using Protein Coverage Summarizer (http://ncrr.pnl.gov/software/).
 
Comparative Protein Expression Analyses 
For each protein in the validated list of proteins, the number of unique parent ions 
(spectral count) was calculated based on peptide sequences and modifications. 
The number of spectra matched to peptides from a protein is used as a surrogate 
measure of protein abundance.19 A negative binomial model that handles 
overdispersion caused by few biological replicates is used to estimate the per-
protein counts.20,21 To test for differential expression between two conditions, 
the mean of the normalized per-protein counts in each condition is computed 
and compared for equality. An exact type p-value defined as the probability of a 
pair of observed counts is computed as previously described.22 After computing 
the normalized mean counts in each condition and the corresponding p-values, 
we controlled for multiple testing by controlling the false discovery rate (FDR) 
defined as expected proportion of false rejection among the rejected hypotheses, 
using the Benjamini and Hochberg (BH) procedure.
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RESULTS
Induction of Skewed Immune Responses in an RSV Vaccination-Challen-
ge Mouse Model 
BALB/c mice were primed with rVV-F, rVV-G, or VV-wt and challenged with RSV. 
Bodyweight, viral titers in the lungs, cellular composition of BAL samples were 
measured, and histopathological examination of the lungs was performed for 
a period of seven days. Bodyweight measurements showed that VV-wt primed 
animals remained at starting weight upon challenge with RSV (Figure 1A). In 
contrast, animals that have been primed with the RSV fusion protein (rVV-F) 
or the RSV attachment protein (rVV-G) showed a reduction in body weight to 
approximately 85% of starting weight in 4 to 5 days. Subsequently, the rVV-F 
primed animals returned to starting weight whereas the rVV-G primed animals 
remained low at 85% of starting weight until the end of the study at day 7 (Figure 
1A).
Virus could be isolated from lung homogenates from all animals in the VV-
wt group. Virus titers from VV-wt primed mice that mount a primary immune 
response to RSV peaked at day 3 to a level of 106 TCID50/gram lung tissue. At 
any time point, the highest titers obtained in rVV-F or rVV-G primed mice were at 
least 10-fold lower than those obtained for the VV-wt primed mice. In addition, 
the virus titers in these groups of mice showed an earlier and much lower peak 
(day 2) than VV-wt primed mice, pointing at partial protection from challenge in 
rVV-F and rVV-G primed mice (Figure 1B).
Figure 1. Relative body weight (panel A) and replication competent virus titers in the lung (panel B) from VV-wt 
(black dots), rVV-F (white dots), and rVV-G (black triangles) vaccinated mice up to seven days following RSV 
challenge. Average numbers with standard error are indicated.
163
                        
Vaccine mediated proteome changes upon RSV challenge 
BAL samples were obtained at day 1, 2, 3, 5, and 7 after challenge and the 
cellular composition was analysed by FACS analysis. Mice primed with VV-wt 
displayed a typical primary response to RSV infection with a relatively late and 
modest influx of cells during the experiment. Mice primed with rVV-F displayed 
the highest numbers of T-cells, B-cells, and dendritic cells in the BAL samples, 
while neutrophils and eosinophils were more abundant in BAL samples obtained 
from rVV-G primed animals (Figure 2). In fact eosinophil numbers in BAL samples 
contrasted most between rVV-F and rVV-G mediated secondary responses: high 
numbers were found for rVV-G primed animals while eosinophils were virtually 
absent in BAL samples from rVV-F primed animals (Figure 2D).
Figure 2. Cellular composition of BAL fluid. 
Total numbers of T-cells (panel A), B-cells 
(panel B), neutrophils (panel C), eosinophils 
(panel D), and dendritic cells (panel E) in BAL 
fluid from VV-wt (black dots), rVV-F (white 
dots), and rVV-G (black triangles) vaccinated 
mice were determined by FACS analyses. 
Average numbers with standard error are 
indicated.
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Figure 3. Proteome analysis of lung samples. Distribution of the number of proteins identified in each group 
of vaccinated mice upon RSV challenge (panel A). PCA analysis of all lung proteome samples on the basis 
of normalized spectral counts (panel B). The number of identified and validated proteins, up-regulated 
(black numbers) or down-regulated (grey numbers) upon RSV challenge in response to VV-wt, rVV-F or rVV-G 
vaccination compared to naive mice (panel C).
Histopathological examination of lung slides obtained from animals that were 
sacrificed at day 5 after challenge revealed that both VV-wt and rVV-F primed mice 
experienced interstitial pneumonia characterized by marked peribronchiolar and 
perivascular infiltrates. Conversely, rVV-G primed animals experienced a more 
severe broncho-interstitial pneumonia, in some animals even leading to foci of 
necrosis associated with the presence of viral antigen. Interestingly, rVV-G primed 
animals accounted for the highest positive staining of viral antigen of all groups. 
While eosinophils were virtually absent in VV-wt and rVV-F primed animals, these 
cells were readily detectable in rVV-G primed animals. Most eosinophils were 
located in the perivascular and peribronchiolar infiltrates and to a lesser degree 
in the alveolar walls and lumina (data not shown).
In line with the original observations obtained with this RSV vaccination and 
challenge model13, 14 the data collectively demonstrate that the rVV-F and 
rVV-G priming regimes indeed mediate the induction of distinct host response 
phenotypes upon RSV challenge. The collected lung samples are a good substrate 
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to monitor protein expression profiles and to search for differences between the 
different priming regimes. 
Mass Spectrometry-Assisted Protein Profiling of Phenotypically Distinct 
Host Responses
Lungs collected 5 days after RSV challenge, were homogenized, and proteins 
were isolated and subjected to FT-ICR-MS/MS analysis. The collected sample set 
was complemented with identical lung samples obtained from naïve mice. Raw 
FT-ICR-MS/MS data were processed and validated. Between 2,247 and 2,547 
distinct proteins were detected for each group of mice. When comparing the 
different experimental groups of mice, a large overlap in detected proteins was 
observed (Figure 3A). Principal component analysis (PCA) on the normalized 
protein expression data (spectral counts) revealed two major clusters. One cluster 
consists of VV-wt primed and naïve mice derived lung samples while the other 
consists of rVV-F and rVV-G lung samples, indicating that protein expression in 
the two latter groups is similar but different from naïve and VV-wt primed mice 
(Figure 3B). 
Next, we applied spectral count analysis to identify differentially expressed 
proteins between the vaccination groups and naïve mice. First, spectral counts 
between VV-wt, rVV-F and rVV-G vaccinated mice and naïve control mice were 
compared. Lungs from VV-wt vaccinated mice displayed least changes in protein 
expression with only 3 down- and 3 up-regulated proteins compared to naive 
mice (Figure 3C). 
Table 1. Differentially expressed proteins in rVV-G vs rVV-F primed mice upon challenge with 
RSV
UniProt ID gene Protein name rVV-G rVV-F rVV-G vs rVV-F             
spectral 
count
spectral 
count
fold change adjusted 
p-value
Q3U1U4 Itgam Integrin alpha-M 3.8 0 up 0.002
P49290 Epx Eosinophil peroxidase 12.2 1.0 12.1 0
Q61176 Arg1 Arginase 1 18.2 3.1 6.0 0.002
Q9D7Z6 Clca3 Calcium-activated chloride 
channel regulator 1
6.9 0 up 0
O35744 Chi3l3 Chitinase-like protein 3 5.7 0 up 0
Q3TRM8 Hk3 Hexokinase 3 2.8 0 up 0.041
O35295 Purb Transcriptional activator 
protein Pur-beta
0 3.5 down 0.024
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Vaccination with rVV-F or rVV-G induced higher numbers and more pronounced 
changes in protein expression (129 and 97 differentially expressed proteins, 
respectively). The magnitude of these total lung proteome changes reflects a 
relatively slow developing primary immune response (VV-wt primed animals) 
and a much faster developing secondary response in the RSV specific primed 
mice (rVV-F and rVV-G). Only 3 proteins were differentially expressed in all 3 
vaccination groups (Figure 3C). As expected based on the PCA data, a large 
overlap was observed between the rVV-F and rVV-G vaccinated mice where 50%-
67% of the identified differentially expressed proteins were also found in the 
other group. The rVV-F and rVV-G primed responses are indeed highly similar: 
only 7 proteins (Epx, Chil3, Itgam, Arg1, Clca3, PurB and Hk3) are significantly 
differentially regulated in a direct comparison of rVV-F and rVV-G primed lung 
tissue samples (Table 1). Six of these proteins are more abundantly present in 
lung tissue of rVV-G primed mice: 2 proteins are up-regulated (Arg1 and Epx) 
and 4 are unique for the rVV-G primed samples (Itgam, Chi3l3, Clca3, and Hk3). 
One protein (Purb) was expressed in rVV-F primed mice only.
rVV priming and RSV challenge RSV challenge after VV-wt priming leads to only 
a few differentially expressed proteins in lung tissue at day 5: Eif2s1, Gpd1l, 
and Armc10 are up-regulated compared to naïve mice while Msra, Hba-a1/2 and 
Figure 4. Functional classification of differentially expressed proteins. Proteins were grouped by functional 
category derived from GO slim and UniProt (http://www.uniprot.org/uniprot/). The graph shows the absolute 
number of differentially expressed proteins in VV-wt (green bars), rVV-F (blue bars), and rVV-G (red bars) 
vaccinated mice upon RSV challenge compared to naïve mice.
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Krt34 are down-regulated. These proteins are involved in responses to stress 
and metabolic processes (Figure 4). PCA analysis also showed that protein 
expression in lungs from VV-wt and naïve mice is highly similar and explains 
why only 6 differentially expressed proteins were observed (Figure 3C).
There were many similarities in the alteration of protein expression between 
rVV-F and rVV-G primed animals (Figure 3). A total number of 65 proteins were 
differentially expressed in both groups of mice compared to naïve mice and these 
mainly included proteins involved in metabolic processes and response to stress 
(Figure 4). A total of 63 proteins were differentially expressed in rVV-F only and 
32 in rVV-G vaccinated mice only. In both groups, the majority of differentially 
expressed proteins were up-regulated involving similar numbers and biological 
processes (Figures 3 and 4). 
Table 2. Differentially expressed proteins involved in immune system processes
UniProt 
ID
gene Protein name  rVV-F vs naive
           
rVV-G vs naive rVV-G vs rVV-F
FC          adj.   
             p-value
FC       adj.  
           p-value
FC       adj.  
          p-value
P04187 Gzmb Granzyme B up 0.000 up 0.033
Q02357 Ank1 Ankyrin-1 -5.2 0.000 -5.9 0.015
P15508 Sptb Spectrin beta chain, erythrocytic -6.2 0.000 -30.7 0.011
Q8R2Q8 Bst2 Bone marrow stromal antigen 2 11.7 0.000 11.2 0.004
Q9R233 Tapbp Tapasin up 0.000 up 0.002
P08032 Spta1 Spectrin apha chain, erythrocytic 1 -7.1 0.000 -10.6 0.002
P36371 Tap2 Antigen peptide transporter 2 up 0.001 Up 0.001
Q64282 Ifit1 Interferon-induced protein with 
tetratricopeptide repeats 1
up 0.001 up 0.001
Q60766 Irgm1 Immunity-related GTPase family M 
protein 1
up 0.000 up 0.000
Q5I2A0 Serpina3g Serine proteasse inhibitor A3G up 0.000 up 0.000
Q64345 Ifit3 Interferon-induced protein with 
tetratricopeptide repeats 3
up 0.000 up 0.000
Q9QZ85 Iigp1 Interferon-inducible GTPase 1 130.7 0.000 98.4 0.000
Q01514 Gbp1 Interferon-induced guanylate-binding 
protein 1
52.3 0.000 44.2 0.000
O35955 Psmb10 Proteasome subunit beta type-10 35.1 0.000 37.2 0.000
P42225 Stat1 Signal transducer and activator of 
transcription 1
30.0 0.000 30.0 0.000
P21958 Tap1 Antigen peptide transporter 1 up 0.000
P01029 C4b Complement C4-B 38.4 0.000
P01863 Ighg Ig gamma-2A chain C region, A allele 8.6 0.000
P29351 Ptpn6 Tyrosine-protein phosphatase non-re-
ceptor type 6
up 0.001 up 0.000
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UniProt 
ID
gene Protein name rVV-F vs naive rVV-G vs naive rVV-G vs rVV-F
FC        adj.   
            p-value
FC      adj.
          p-value
FC     adj.  
         p-value
P11835 Itgb2 Integrin beta-2 up 0.001 up 0.000
P47941 Crkl Crk-like protein up 0.001
Q61646 Hp Haptoglobin 4.4 0.001
Q9Z0E6 Gbp2 Interferon-induced guanylate-binding 
protein 2
10.0 0.002 8.3 0.038
Q62418 Dbnl Drebrin-like protein 28.5 0.002
Q06318 Scgb1a1 Uteroglobin -23.0 0.002
Q61107 Gbp4 Guanylate-binding protein 4 up 0.004
Q8CFB4 Gbp5 Guanylate-binding protein 5 up 0.006 up 0.001
P97290 Serping1 Plasma protease C1 inhibitor 9.1 0.006
Q64112 Ifit2 Interferon-induced protein with 
tetratricopeptide repeats 2
up 0.007
O89053 Coro1a Coronin-1A 2.8 0.012 3.2 0.012
P02089 Hbb-b2 Hemoglobin subunit beta-2 -2.0 0.018
P10711 Tcea1 Transcription elongation factor A 
protein 1
up 0.020
P04441 Cd74 H-2 class II histocompatibility antigen 
gamma chain
up 0.022 up 0.007
Q9EPB4 Pycard Apoptosis-associated speck-like 
protein containing a CARD
10.2 0.023 13.5 0.005
P31230 Aimp1 Aminoacyl tRNA synthase com-
plex-interacting multifunctional 
protein 1
16.4 0.023
P00493 Hprt Hypoxanthine-guanine phosphoribo-
syltransferase
3.0 0.024
Q60710 Samhd1 Deoxynucleoside triphosphate trip-
hosphohydrolase SAMHD1
2.2 0.027 2.3 0.030
P18468 H2-Eb1 H-2 class II histocompatibility anti-
gen, I-A beta chain
up 0.028 up 0.018
Q99JB2 Stoml2 Stomatin-like protein 2, mitochond-
rial
up 0.028
P01027 C3 Complement C3 2.0 0.042
Q64339 Isg15 Ubiquitin-like protein ISG15 up 0.045
P09470 Ace Angiotensin-converting enzyme -1.8 0.048 -3.9 0.002
Q9EQH2 Erap1 Endoplasmic reticulum aminopepti-
dase 1
15.7 0.044
Q61233 Lcp1 Plastin-2 2.1 0.040
P16110 Lgals3 Galectin-3 3.5 0.037
P01915 H2-Eb1 H-2 class II histocompatibility anti-
gen, E-D beta chain
17.5 0.032
P49290 Epx Eosinophil peroxidase 34.0 0.007 12.0 0.000
Q3U1U4 Itgam Integrin alpha-M up 0.001 up 0.000
Table 2. (continued) 
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Proteins are known to be involved in multiple pathways, and hence, are likely to 
have multiple functions. Pathway analysis (Ingenuity) was performed for further 
functional classification of differentially expressed proteins, and to investigate 
the presumed interactions between these proteins within specific functional 
categories. A substantial proportion of the differentially expressed proteins in 
rVV-F and rVV-G primed mice appeared to play a role in antigen presentation 
(7.2%), biosynthesis (6.6%) or metabolism (7.8%), but the majority is involved in 
immune and defence responses (16.3%). Within the latter group of differentially 
expressed proteins five (Npm1, Snd1, Kars, Krt18, and Eif4a1) have been 
reported to be involved in host-virus interactions and another seven (Bst1, Bst2, 
Gbp3, Ifit1, Ifit2, Ifit3, Ddx21, and Gbp1) have shown to be active in antiviral 
immune responses. Within this group of proteins involved in antiviral immune 
responses Gbp3, Ifit2, and Ddx21 were found to be up-regulated compared to 
naïve mice in rVV-F primed mice only, while Bst2, Ifit1, Ifit3 and Gbp1 were up-
regulated in both rVV-F and rVV-G primed mice. A first line of defense against 
virus infections is formed by the type I interferon induced proteins. Five proteins 
in the list of differentially expressed proteins were involved in this defense 
response. Ifit1, Ifit2, and Ifit3 are members of the interferon-induced protein 
with tetratricopeptide repeats (IFITs) family and Gbp1 and Gbp3 are members 
of the IFN-induced guanylate-binding proteins which are all involved in anti-viral 
responses.23, 24 Ifit1 and Ifit3 were differentially expressed in rVV-F and rVV-G 
primed mice while Ifit2 was only found differentially expressed in rVV-F primed 
mice. All three proteins are expressed in the cytoplasm and mitochondria but 
Ifit2 is expressed in microtubules as well and interacts with the cytoskeleton that 
may explain the difference observed.
DISCUSSION
Vaccines aim to induce antigen specific memory responses that mediate safe 
and effective secondary responses when the host is exposed to the pathogen. 
Many live-attenuated and inactivated virus vaccines have been developed and 
have collectively reduced the incidence of disease. However, for RSV and several 
other viruses, classical formalin-inactivated vaccine production approaches 
failed as they prime for unbalanced, skewed Th2 type immune responses upon 
challenge.7, 25, 26 These hypersensitivity responses are associated with immune 
pathology and are marked by peribronchiolar monocytic infiltration including 
neutrophils and eosinophils.27 In this study we explored the well-established 
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rVV-RSV vaccination-challenge mouse model to identify protein markers and 
regulatory mechanisms that are associated with or are underlying vaccine induced 
aberrant host responses. When comparing lung tissue samples from rVV-F 
and rVV-G primed animals with control samples from naïve mice we identified 
many differentially regulated proteins. These proteins are involved in metabolic 
processes and stress, but a significant part was identified as host immune 
response related proteins (Table 2). By directly comparing vaccine induced host 
responses, we were able to uncover subtle but highly relevant lung proteome 
differences between phenotypically distinct Th1- and Th2-like host responses. 
Direct comparison of protein expression in lung tissue from RSV challenged mice 
upon vaccination with rVV-F and rVV-G resulted in differential expression of 7 
proteins only: Epx, Chil3, Itgam, Arg1, Clca3, PurB and Hk3. These proteins are of 
particular interest as their biological functions can be linked to the vaccination-
induced host response phenotype and immunopathology.
An important feature of RSV vaccine primed Th2 skewed host responses is a 
marked increase of eosinophils into the lungs. As expected, rVV-G primed mice 
indeed accumulated significant numbers of eosinophils in the lungs (BAL) upon 
RSV challenge (Figure 2). Eosinophil peroxidase (Epx) is expressed by eosinophils 
and is localized in the cytoplasmic granules. Against a background of many other 
cells present in lung tissue samples, we could easily detect increased levels of the 
Epx protein in the lungs of rVV-G primed animals (Table 1). Upon RSV challenge, 
the Epx protein was present at much lower levels (12 fold) in the lungs of rVV-F 
primed animals. The Epx protein functions as an oxidant that has been shown to 
be released at sites of infection to mediate lysis of protozoa or parasitic worms. 
Lung histology from the two fatal cases of the FI-RSV trial in the sixties revealed a 
pronounced inflammatory lung infiltrate including eosinophils and neutrophils.7, 
28 This result has subsequently been reproduced in RSV vaccination-challenge 
animal models.29 Especially the association of lung eosinophilia with enhanced 
disease has attracted much attention but is most likely a secondary event; rVV-G 
primed eosinophil deficient mice also display enhanced disease upon challenge 
with RSV.30 Nevertheless, vaccine-primed eosinophilia reflects an unbalanced 
host response to be avoided as influx of these cells is regulated by Th2 type 
cytokines including IL-4, Il-10, and IL-13.31 In the context of RSV infection, the 
Epx protein can be used for vaccine evaluation purposes. Increased Epx mRNA 
levels have not been observed in rodent RSV vaccination-challenge models of 
enhanced disease.11 (unpublished observation).
The Chil3 protein levels are also up-regulated in rVV-G-primed animals relative 
to those primed with the F protein. Chil3, chitinase-like-protein 3, is a secretory 
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protein (also known as Ym1) with in vitro chemotactic activity for T-lymphocytes, 
bone marrow polymorphonuclear leukocytes and eosinophils. In addition, it has 
been demonstrated that Chil3 specifically triggers extravasion of eosinophils. 
The Chil3 protein shares conserved amino acid residues with the chitinase family 
of proteins, but also harbors a conserved CXC chemokine motif near the NH2 
terminus.32 This hybrid type protein is mainly produced by macrophages and 
is localized in the lumen of the rough endoplasmic reticulum and the nuclear 
envelope of these cells and of neutrophils.33 In a murine model of airway 
hyper responsiveness (AHR) Chil3 mRNA was also up-regulated in the lungs. 
Interestingly, up-regulation preceded the onset of airway inflammation in this 
model and specific inhibition of Chil3 mRNA expression suppressed the induction 
of eosinophilia supporting a critical role for Chil3 in eosinophilic inflammation 
processes.34 Up-regulation of Chil3 protein in the rVV-G primed mice upon RSV 
challenge suggests a role for Chil3 in the observed eosinophilia in these mice.
Homing of effector cells in inflamed tissue is facilitated by many cell adhesion 
factors. In line with the pronounced influx of different cell types into the lungs 
of rVV-F and rVV-G primed animals upon challenge with RSV, we identified Itgam, 
Itgb2, Lgals3bp, Lama5 and Tns1 as being differentially expressed relative to 
naïve animals. However, only the Itgam protein expression level was significantly 
increased in lung tissue obtained from rVV-G vaccinated mice when comparing 
rVV-G- and rVV-F-primed animals directly. Itgam appeared to be induced in 
rVV-G-primed and not in rVV-F-primed mice. The Itgam gene encodes for the 
CD11b-integrin (alphaM) polypeptide, which pairs with the polypeptide integrin 
beta-2 (Itgb2 = CD18-integrin) to form a functional integrin also known as the 
complement receptor type 3 (CR3) or macrophage-1 antigen (Mac-I). Itgb2 was 
also up-regulated in rVV-G primed mice and indicates an increased expression 
of the functional integrin. In contrast to Itgam, which was only detected in rVV-G 
primed mice, Itgb2 was also found to be up-regulated in rVV-F primed mice 
compared to naïve mice and with no statistical difference in expression compared 
to rVV-G primed mice (Table 2). Indeed, Itgam binds to multiple ligands and 
is involved in other biological processes in addition to cell adhesion.35 Itgam 
expression was originally reported to be specific for neutrophils and monocytes/
macrophages. However, Itgam expression was also induced by IL-5 and IL-33 in 
eosinophils.36 In a rVV-G-primed Th2 skewed host response, Itgam expression 
can thus mediate the recruitment of neutrophils as well as eosinophils to the 
lungs. The concerted action of up-regulated Chil3 and Itgam proteins may 
account for the high influx level of eosinophils in the lungs of the rVV-G-primed 
animals.
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Arginase-I (ArgI) catalyzes the hydrolysis of arginine to ornithine and urea, and 
is constitutively expressed in hepatocytes37 but has also been recognized as 
an enzyme involved in the iNOS pathway in myeloid cells that is predominantly 
regulated by exogenous stimuli.37, 38 In cells isolated from human blood, 
Arg1 expression has so far only been found in neutrophils.39 In mice, Arg1 
expression has been reported for alternatively activated macrophages (AAM). 
AAM play an important role in Th2 driven pathological conditions like asthma 
and express Arg1 together with Chil3, suggesting that these macrophages help 
to orchestrate the Th2 skewed responses in rVV-G-primed enhanced disease.40 
In addition, the elevated Arg1 levels in lungs from rVV-G-primed compared to 
rVV-F-primed mice may also point at a role for type 2 innate lymphocytes since 
these cells constitutively express Arg1.41 Participation of the latter cell type may 
also be dependent on IL-33. This cytokine was not detected in our proteome 
screen. However, microarray analysis of lung tissue samples obtained from 
the same experiment showed that IL-33 mRNA level was increased for rVV-G-
primed samples when compared with naïve lung samples. In a direct comparison 
between rVV-G- and rVV-F-primed lung tissue samples, the rVV-G-primed IL-33 
lung mRNA signal was higher but did not reach statistical significance (data not 
shown).
Members of the chloride channels, calcium-activated (CLCA) family of proteins 
including the murine Clca3 (mClca3, alias gob-5) and its human ortholog 
hCLCA1 have been identified as relevant molecules in diseases with secretory 
dysfunctions, including asthma and cystic fibrosis.42 mClca3 is also up-regulated 
in rVV-G-primed animals relative to rVV-F-primed animals. Biochemical analysis 
of the posttranslational processing and intracellular trafficking of the mClca3 
protein showed that it does not form an anion channel as suggested by the 
protein name, but is cleaved in two sub-units that are fully secreted as a 
glycosylated protein complex into the extracellular environment.42 Interestingly, 
it has been demonstrated that hCLCA1 mRNA levels and protein expression are 
significantly increased in the airway epithelium of asthmatic patients43, 44, and 
overexpression of mClca3 in mice resulted in goblet cell metaplasia and mucin 
overproduction.45 Targeting the mClca3 protein with antibodies inhibited these 
processes in asthmatic mice.46 Collectively, the data suggest that CLCA proteins 
may also play an important role in the Th2 driven RSV vaccine induced enhanced 
lung disease and that detection of Clca3 protein expression could be used to 
guide RSV vaccine design and evaluation.
Hexokinase III (Hk3) and purine-rich element-binding protein Beta (PurB) both 
do not have an obvious function in the host response to infection. Hexokinases 
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catalyze the first step in glucose metabolism. Hk3 expression is relatively low 
in most tissues, with the highest levels reported in lung, kidney, and liver. Hk3 
may play a role in protecting against cell death, and its overexpression decreases 
the oxidant induced production of reactive oxygen species (ROS).47 In addition 
to a protein expression level that changes due to the influx of specific immune 
cells, the metabolic function of Hk3 can only be indirectly related to the observed 
host responses. PurB is the only protein that is expressed at lower levels in 
rVV-G-primed animals relative to rVV-F-primed animals. PurB is a sequence-
specific, single-stranded DNA-binding protein implicated in the control of both 
DNA replication and transcription. Defects in this gene are associated with the 
development of acute myelogenous leukemia in which some hematopoietic 
precursors are arrested in an early stage.48 A non-equal role for PurB in cell 
division for the distinct immune cell types present in the RSV challenged lungs 
may contribute to the skewed cell composition as observed for the different 
vaccine priming regimes. 
In summary, by proteome analysis we have identified a set of host proteins that are 
differentially expressed between two phenotypically distinct secondary immune 
responses each evoked upon challenge with RSV after priming with closely related, 
but distinct, RSV vaccine preparations: rVV-F and rVV-G. Vaccination of mice with 
rVV-G- but not rVV-F- prior to RSV challenge induces typical vaccine mediated 
enhanced disease that is characterized by a marked influx of eosinophils and 
neutrophils. The identified differentially expressed host proteins between the 
two vaccination dependent conditions are involved in processes related to the 
influx of eosinophils directly (Epx), chemotaxis and extravasion (Chil3) as well 
as homing to the lungs of these cells and neutrophils (Itgam). In addition, the 
increased protein levels of Arg1 and Chil3 point at a functional and regulatory 
role for alternatively activated macrophages and type 2 innate lymphoid cells 
in Th2 cytokine driven RSV vaccine mediated enhanced disease. The identified 
proteins support research on regulatory aspects of vaccine induced skewed host 
responses, as well as the evaluation of next generation RSV vaccines.
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GENERAL DISCUSSION
One third of children hospitalized with bronchiolitis do not require supportive 
interventions and 4.6-6.8% of the patients initially discharged home, require 
hospitalization later on during infection due to deterioration.1-3 One may therefore 
conclude that the predictive value of the currently available clinical assessment 
tools for severity of bronchiolitis is limited. Clinical prediction rules to predict safe 
discharge, length of hospitalization and ICU admission for children with acute 
viral lower respiratory tract infections (LRTIs) are based on demographic criteria 
including age, birth weight, having older siblings, and clinical symptoms such 
as respiratory and heart rate, oxygen saturation and duration of symptoms.4-11 
Although these prediction rules have the potential to improve clinical judgment, 
validation in other cohorts is often lacking and implementation in daily practice is 
difficult due to subjective criteria.  A more objective and reproducible prediction 
of disease severity may be achieved by the use of additional biochemical and 
hematological markers. 
In this thesis we evaluated the role of viral factors and host immune responses 
that contribute to disease severity in young children with viral LRTIs, especially 
respiratory syncytial virus (RSV) infections, and aimed to identify potential 
biomarkers to assess disease severity in young children with these infections. 
We performed a prospective study in two hospitals in which 154 children under 
the age of 5 years with viral LRTIs were included during three consecutive winter 
seasons. Clinical data, blood samples and nasopharyngeal aspirates were obtained 
during acute infection and at recovery from previously hospitalized children. One 
of the strengths of this approach was that all patients were included by a single 
investigator, thus resulting in a low percentage of parental refusals, few missing 
clinical data and uniformly collected samples. This “respiratory tract infection 
biobank” was used for several studies in this thesis and follow-up studies are 
ongoing. In addition to the clinical study we also performed in vitro work using 
proteomic and transcriptomic technologies to assess the immune response of 
infected respiratory epithelial cell lines, and employed an experimental murine 
model to obtain insight in the pathogenesis of RSV infection and to identify leads 
for biomarkers, new treatment strategies and vaccine development. 
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The most important findings of the studies presented in this thesis are:
• Disease severity in young children with viral bronchiolitis is not associated 
with infection caused by multiple viruses or viral load 
• Several inflammatory markers measured at the transcriptional level (MMP-
9 and MMP-8) and in plasma (combination of IL-8, CCL-5 and CD4+ T-cell 
counts) discriminate severe from mild RSV infection
• Transcriptome analyses of patient material resulted in the identification of 
novel biomarkers for disease severity such as olfactomedin-4 
• Proteome analyses of material obtained from in vitro and in vivo (mice) 
experimental models revealed several host proteins which are involved in 
innate immune responses
I VIRAL FACTORS 
Multiple Infections
The use of molecular detection techniques has facilitated the simultaneous 
detection of pathogens in respiratory specimens. The prevalence of co-infections 
ranges between 19 to 35% in young children with viral respiratory tract infection 
admitted to hospital or evaluated at the emergency department.12-14 Although 
many studies evaluated the association between infection with multiple viral 
pathogens and disease severity, the clinical impact of multiple virus infections on 
clinical presentation and outcome remains unclear.13,15-17  The interpretation of 
results from these studies is complicated by differences in study design including 
the methods of pathogen detection, the types and copy number of viruses tested, 
the specific patient population being studied and other confounding factors. In 
the study presented in this thesis no association between disease severity and 
detection of more than one viral pathogen was observed. Even more remarkable, 
multiple infections in children older than 3 months had a less severe course 
of disease compared to infections with one viral pathogen. These results were 
confirmed in a new cohort of patients (I. Ahout et al, submitted). 
In agreement with our findings, a less severe course of disease in children with 
bronchiolitis simultaneously infected by more viruses as compared to children 
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infected by one virus has been reported by others.15,18-21 This observation is 
in line with studies documenting that co-infections are not often observed in 
mechanically ventilated children.17, 22 
Disease severity varied with the type of viruses and specific virus pairs involved 
in co-infection. For example, in studies where RSV/Bocavirus and Influenza A/
Coronavirus co-infections were frequently observed, a significantly increased risk 
for hospitalization was reported23, 24, whereas in studies where RSV/Adenovirus 
and RSV/Rhinovirus co-infections were seen, a reduced risk of hospitalization 
was reported.20, 25 Future studies should employ stratified analyses on the effect 
of co-infections on disease outcome to elucidate which combination of viruses 
increase or decrease disease severity.
The detection of viruses by RT-PCR does not prove per se a causal relationship. 
The development of sensitive molecular assays has increased the number of 
viruses detected in respiratory samples compared with conventional methods. 
The detection of viral nucleic acids by RT-PCR can reflect either past infection, 
an asymptomatic or asymptomatic infection, or incipient infection in which 
symptoms have not yet developed. The high viral detection rates in asymptomatic 
children indicate that the presence of viral or bacterial genomes is often not 
associated with disease.26,27 The distinction between co-infection and co-
detection has been ignored in most studies and may be particularly relevant in 
cases with multiple viral infections in which one has to distinguish which virus 
is the cause of disease symptoms.  Epidemiologic studies with both quantitative 
PCR and serologic studies may be of additional value to demonstrate causality 
between viral detection and clinical symptoms for some viruses, especially when 
low copy numbers and multiple viruses are detected. 
Quantitative PCR techniques can, in theory, help identify the agent responsible 
for symptoms based on high acute-phase viral replication. qPCR derived Ct 
values are an indirect measure of viral load, representing the number of PCR 
cycles necessary to pass the detection treshold. Although lower Ct values are 
more likely to suggest a virus as a true cause of acute lower respiratory tract 
infection, Ct values of different viruses are difficult to compare.28, 29 
Virus-virus interactions may influence the host immune response resulting in 
reduced virulence of other respiratory viruses. Greer et al. described a potential 
protective effect of the presence of RV in the nasopharynx on new viral infections 
by the induction of interferon stimulated genes resulting in less severe disease 
or less co-infections.30 Chorazy et al. reported that children with viral co-
infections were less likely to be admitted to the ICU than children with single 
virus infections.21 As this seemingly protective effect of multiple infections was 
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unexpected, they performed secondary analyses to virus-positive, hospitalized 
children with confirmed or suspected acute respiratory infections (ARIs) for whom 
a bacterial test had been ordered during the same hospitalization. Children with 
virus–bacterial co-infection, as compared with children with single virus infection, 
were more likely to be admitted to an ICU.21 This may indicate that undetected 
bacterial co-infections play a role in severe infections caused by a single virus. 
In conclusion, the precise mechanisms of a potentially protective effect of 
multiple viral infections are not yet well understood and more research is needed 
to understand the processes involved in respiratory viral co-infections.
Viral Load
The use of qRT-PCR derived Ct values have allowed an accurate estimation of 
the viral load in clinical samples. Some studies have associated viral load with 
disease severity and failed to establish a causal relationship.31, 32 Other studies, 
however, revealed a significant association between disease severity and viral 
load.18, 33-36
One of the confounding factors on the association between viral load and disease 
severity is that most studies measure Ct values at one time point. Viral load 
is a dynamic process requiring longitudinal measurements to obtain optimal 
interpretation. Studies that measured viral load longitudinally and adjusted for 
disease duration demonstrate that increased viral load and delayed viral clearance 
is associated with increased markers of disease severity in young RSV infected 
children.33, 34, 37, 38 An association between temporal dynamics of viral load and 
clinical symptoms may have important therapeutic implications, supporting a 
potential clinical benefit of RSV antiviral drugs. 
II HOST IMMUNE RESPONSE
An improved understanding of the interactions between virus and host immune 
response is important to better understand factors and mechanisms determining 
disease severity. This may also facilitate the identification of biomarkers that can 
predict clinical outcome.
Virus specific structural components are recognized by pattern recognition 
receptors of the host upon RSV infection of airway epithelial cells. Activation 
of many of these receptors causes up-regulation and expression of several pro-
inflammatory genes in the lung. This leads to recruitment and activation of 
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different leukocytes subsets (monocytes, macrophages, neutrophils, T-cells, NK-
cells), and contributes to the production of inflammatory factors (chemokines 
and cytokines). These in turn suppress viral replication and eliminate the virus 
but simultaneously contribute to tissue damage.
Systemic Immune Response upon RSV Infection
A number of clinical studies have, in line with our results, documented an 
association between RSV disease severity and changes in concentrations of 
inflammatory mediators in blood  including interleukin (IL)-6, IL-8, Granulocyte-
colony stimulating factor (G-CSF) and Chemokine (C-C motif) ligand 5 (CCL-5). 
Several mechanisms may be involved in the systemic inflammatory response 
following local airway inflammation. Inflammatory mediators generated in the 
airways translocate into the circulation, following a natural gradient (due to 
large amounts of inflammatory molecules in the lung) or as a result of increased 
permeability of the capillary bed vascular system which often accompanies 
the lung inflammatory process. In addition, triggers of lung inflammation, 
such as ultrafine particulate matter, LPS and other toxins, translocate from 
the airspaces to the bloodstream, either directly contributing to the systemic 
response or stimulating circulating immune cells such as monocytes to produce 
pro-inflammatory mediators that contribute to the systemic response.  Another 
mechanism is direct infection of circulating cells followed by a systemic 
inflammatory response. Although RSV is assumed to primarily infect epithelial 
cells, RSV RNA has been demonstrated in whole blood, and RSV antigens and 
RNA have been found in circulating blood mononuclear leukocytes blood and 
lung neutrophils.39-43 In addition, in a murine model an association between the 
time course of RSV RNA detected in blood and severity of symptoms has been 
demonstrated.44 Viral particles may be released from infected airway epithelial 
cells and then enter the circulation or circulating cells may take up the virus in 
the airway lumen and then recirculate back into the bloodstream.
Lymphocytopenia in Severe RSV Infection
Severe RSV infections in young children are associated with lower peripheral 
T-cell and NK-cell counts.45-48 The role of lymphocytopenia in disease severity is 
further supported by observations in an experimentally human challenge model 
for RSV infection. Marked differences in subpopulations of white blood cells 
between symptomatic and asymptomatic individuals over time were observed.49 
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RSV-infected subjects developed a relative lymphocytopenia, monocytosis and 
neutrophilia, which closely corresponds with the increase and decrease of clinical 
symptoms.54
The observed lymphocytopenia may be explained in several ways. 
Lymphocytopenia can be the result of accumulation of inflammatory cells, such 
as lymphocytes, at the site of infection. However, although primary RSV infection 
in mice produces a strong lymphocyte infiltration into the lungs, Welliver et al. 
showed a lack of lymphocytes in the lungs of children who died from severe RSV 
bronchiolitis.49 
Lymphocyte apoptosis may be another mechanism for RSV-induced 
lymphocytopenia. Roe et al. demonstrated up-regulated expression of cell 
surface receptors involved in apoptosis (Fas and TRAIL receptor) on CD4+ and 
CD8+ lymphocytes and increased plasma levels of soluble Fas ligand during 
acute illness upon RSV bronchiolitis.46 
A third explanation for lymphocytopenia is a decreased capacity to induce 
T-cell proliferation upon RSV infection. Direct interaction between the virus and 
T-cells, inhibition of T cells by infected antigen presenting cells or a decrease 
in expression of HLA-DR can result in the inhibition of T-cell proliferation. 
Low T-cell proliferative responses and interferon (IFN)-γ production upon RSV 
infection have been described and suggest a role of lymphocyte suppression in 
the pathogenesis of severe RSV infection.50-52 Mejias et al. found suppression of T 
and B-cell related genes in children with RSV bronchiolitis using gene expression 
profiles of whole blood samples.53
Our microarray analyses showed an upregulation of activation markers on PBMCs 
in the severe group and lack of apoptosis. This may suggest that the lymphopenia 
results from recruitment of lymphocytes to the site of infection. More accurate 
measurements at the site of infection are needed to elucidate this. 
Implications for the Future
Mechanisms which contribute to RSV pathogenesis include direct viral 
cytopathology, exaggerated cytotoxic lymhocytes responses, imbalanced 
CD4+ T cell responses, excessive inflammatory responses, and altered immune 
responses due to young age.55, 56 In most cases, however, there is not a single 
causative factor. This may have important consequences for therapy. For 
example, antiviral therapy will not be effective in individuals with an excessive 
immune response and anti-inflammatory therapy may result in further clinical 
deterioration in the individual in which viral induced damage dominates. 
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A comprehensive approach is required to understand the complex biological 
interactions between virus and host in the clinical context, and how this contributes 
to disease severity. The research approach should include multifaceted assays 
that simultaneously (1) examine the virus dynamics, (2) assess innate and 
adaptive immune responses, and (3) interpret the obtained data for integrated 
bioinformatic analyses. 
Oshansky et al. provide a model example how to approach such an investigation 
in children with influenza infection.57 They obtained sequential samples in two 
different compartments (blood and nasal lavages) in a cohort of patients of 
different ages and severity. To identify markers of disease severity, they measured 
a number of virology and immune markers using multifaceted molecular and 
cellular assays. Data were analyzed using state of the art bioinformatic tools. 
This comprehensive strategy revealed an innate profile that correlated with 
disease progression independent of viral dynamics and age.
Using such a “system analysis” approach will capture the complexity of the 
host–virus interaction and accelerate the identification of biomarkers that can 
objectively predict clinical outcome.
III TRANSCRIPTOMICS AND PROTEOMICS
Transcriptomics
With the use of molecular platforms, such as micro-array, it has become possible 
to measure gene-expression profiles of the genome. This enables to link genes 
or clusters of genes (pathways or modules) to disease. Data on blood gene 
expression profiling in children with RSV bronchiolitis are still limited. The studies 
that have been published on this subject indicate that gene expression profiles 
from children with acute RSV bronchiolitis can be discriminated from healthy 
controls and allow to discriminate between viral and bacterial infections.58-60 
Mejias et al. were the first to publish a comprehensive analysis of whole blood 
gene expression profiles in infants with RSV LRTI. They described a significant 
association between gene expression profiles and clinical disease severity of 
acute viral LRTIs.53 In addition a genomic score was developed based on 1,536 
significantly differentially expressed transcripts that correlated with disease 
severity. We used another approach and performed a Prediction Analysis of 
Microarrays (PAM), based on bayesian nonparametric modeling, to identify the 
minimum number of genes that are required to distinguish mild from severe 
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RSV infection. By doing so, we were able to identify olfactomedin-4 (OLFM4) as a 
potential biomarker for disease severity.
To date, most micro-array studies on viral respiratory tract infections are 
performed on whole blood samples. One of the disadvantages of using these 
samples is the uncertainty whether the observed differences in gene expression 
reflect changes in transcriptional activity or an altered cellular composition of 
blood samples. 
The strength of using isolated cell populations for gene-expression studies is 
that it provides a cell-specific RNA source thereby minimizing confounding data 
due to heterogeneous cell populations. Earlier micro-array studies, including 
ours, reveal that blood RNA profiling is certainly more than just an expensive 
blood count: results depend not only on the number and type of cells in the 
blood sample, but also on the activation state and the exposure of the cells to 
stimulatory or inhibitory factors in the blood or in the tissues through which the 
cells have passed.53
These micro-array techniques can also be used to obtain more detailed 
information on the mechanism of disease severity. We performed microarray 
analyses on different PBMC subpopulations (T-cells, B-cells, monocytes and NK-
cells) providing cell-specific information on gene expression. These data are 
currently functionally analysed more in depth. This analysis seeks to compare 
gene expression data from PBMCs, neutrophils and PBMC subpopulations with 
existing gene expression data in order to obtain more insight in pathogenesis of 
viral respiratory tract infections. 
Proteomics 
Proteomic technologies are a tool to study the pathogenesis of infectious diseases 
in both experimental and clinical models. The advantage of this approach is that 
it enables the identification of novel key proteins involved in the pathogenesis 
of severe RSV infection. 
Transcriptome studies have improved our understanding of host cell responses 
to RSV.61-65 However, mRNA expression levels cannot be extrapolated to structure 
and function of proteins. Translational and post-translational modifications 
affect not only the level of a mature protein but also its function. The effects on 
protein structure and biological function of alternative splicing, post-translational 
modifications and virus–host interactions cannot be easily predicted by 
transcriptomics. Another advantage of application of proteome analyses is that 
proteins can be measured in many body fluids while gene expression profiling is 
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dependent on the presence of nucleated cells. 
Viral replication and propagation, but also the host immune response cause 
host cellular proteome variations. One of the most promising applications of 
proteomics is the identification of protein targets for biomarkers, vaccination or 
new treatment strategies. 
In addition, we have shown in chapter 8 of this thesis that proteomic technologies 
can be used to elucidate the molecular mechanism underlying vaccine induced 
RSV specific enhanced disease providing an unbiased overview of these effects 
and to identify protein key players/ biomarkes of enhanced disease. The 
identified protein biomarkers can be used to support the development as well as 
the detailed evaluation of next generation RSV treatment strategies and vaccines.
Most proteome studies investigating RSV infection have been carried out in cell 
lines.66-68 Thus far, the number of clinical studies using proteome analyses in 
children with viral lower respiratory tract infections is limited. Pilot experiments 
show that the protein composition in nasal secretions from children with viral 
LRTIs is different between healthy children and children with viral infections.69, 70 
These findings illustrate that proteomics can be used to identify new markers for 
viral respiratory infection. The identification of a specific proteomic fingerprint 
in adult SARS patients forms an interesting example for the diagnostic and 
prognostic use of proteome analyses.71-73 
Integration of multiple –omics techniques may provide further understanding 
of mechanisms of infection. In our studies, we did not correlate proteomics 
findings with gene expression profiles. Cellular concentrations of protein do 
not strongly correlate with the abundance of their corresponding mRNAs. It has 
been estimated that about 40% of the variation in protein concentration can be 
explained by knowing mRNA abundance.74, 75 Biological explanations such as 
regulatory mechanisms at the levels of transcription, post-transcriptional and 
post-translational modifications and technical issues contribute to the poor 
correlation between transcriptomic and proteomic expression data.
Implications for the Future
Linking gene expression, protein expression and other –omics technologies 
such as metabolomics are important steps to obtain a better understanding of 
the pathogenesis of infectious disease and provide new targets for biomarker 
development, treatment strategies and vaccine development. It is important 
to integrate mRNA and protein expression data into a common framework, to 
scale and merge the data together, and to analyze changes in categories such as 
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functional protein class, subcellular localization, and secondary structure. This 
multisystem approach is depending on the development of new bio-informatics 
tools and close collaboration of clinicians, biologists and bioinformaticians.
The next challenge is to bridge the gap between identification of genes and 
proteins that may serve as biomarker or targets for vaccine development and 
treatment strategies and clinical validation. This is a complicated process 
requiring integration of research findings within worldwide databases. In 
addition, for actual bed-side translation of findings obtained from proteomic 
studies, large clinical multicenter studies for validation have to be performed.76
IV BIOMARKERS
In chapter 1 we reviewed the state of art of biomarkers in pediatric infectious 
diseases. We concluded that gene expression profiles can be used, either directly 
or indirectly, to identify causative pathogens and discriminate between bacterial 
infections, infections caused by other pathogens, such as viruses, and  non-
infectious causes of fever.77 However, this review was published in 2006 and 
since that time much progress has been made. In the following section we 
provide a short update on this topic.
Transcriptomics
Zaas et al. provided a novel approach for diagnosis of acute viral respiratory 
infections based on blood transcriptional profiles from experimentally infected 
and uninfected subjects. They identified an ‘‘acute viral respiratory signature’’ 
of 30 genes, that clearly distinguished symptomatic infected individuals (with 
influenza A, rhinovirus, and RSV) from asymptomatic uninfected individuals.60 
This signature contained genes that were shared by all three viral infections. 
They also identified genes that were more specific for each viral infection 
providing further evidence of the potential value of this approach to define 
diagnostic signatures that are common for a group of pathogens and those that 
are pathogen-specific.
To simplify the complex micro array analyses, Chaussabel et al. developed a 
novel data mining algorithm of blood transcriptional modules based on sets of 
genes that follow similar expression patterns in large numbers of samples. They 
showed that different infectious diseases are characterized by a unique modular 
combination generating a characteristic disease fingerprint.78 Subsequently, 
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clinical markers of disease severity were correlated with changes in host gene 
expression. Transcriptional profiling provides a comprehensive assessment of 
the host response. This allows correlating clinical markers of disease severity 
with changes in host gene expression. To this purpose these investigators 
developed genomic severity score that can help classifying patients according to 
clinical characteristics.78
In a recent study a molecular distance to health (MDTH) score was used in a cohort 
of adult patients with tuberculosis. The MDTH score represents the ‘molecular 
distance’ of a given sample relative to a baseline (for example, healthy controls). 
The number of standard deviations for all qualifying genes is added to yield a 
single value, the global distance of the sample from the baseline.. This score 
allowed to classify patients according to clinical characteristics and to estimate 
disease severity.79, 80 In addition, these scores can be used to monitor treatment, 
since MDTH scores progressively decreased and normalized during treatment.
Another application of genome wide techniques is to identify the disease causing 
micro-organism in clinical samples with multiple micro-organisms. Based on 
host immune responses these techniques can determine whether the microbe is 
causing the disease or if it reflects colonization and/or asymptomatic shedding. 
These assays will be extremely valuable to study dual or triple viral co-infections 
as well as viral-bacterial co-infections. At this moment a golden standard to 
discriminate viral from bacterial respiratory tract infections is lacking, resulting 
in inappropriate use of antibiotics. 
Proteomics
While important steps have been taken in the exploration of clinical applications 
of gene expression profiles, actual bed-side translation of the findings obtained 
from proteomic research has thus far been limited. This may be explained by 
the fact that most proteome techniques are relatively low throughput and too 
time consuming to implement in the clinic. Therefore most proteome studies 
include small numbers of patients and do not have enough statistical power. 
In addition, validated methods to reduce the large numbers of differentially 
expressed proteins to a small number of clinical relevant proteins for further 
validation are not yet available.  
In the future, a systems biology approach to viral LRTIs, which combines different 
“omics” tools such as genomics, transcriptomics, proteomics, metabolomics may 
facilitate further understanding of the mechanisms of infection and contribute to 
find targets for prognostic biomarkers and new treatment strategies. However, 
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better informatics methods are needed to bridge the gap between biomarker 
discovery and validation.76
Implications for the Future
Despite the global health impact of viral respiratory infections, and RSV 
specifically, no accurate virology or immune markers to predict clinical outcome 
are available. Combining several biomarkers into a single classification rule may 
help to improve accuracy and, therefore, clinical usefulness. After validation of 
the potential markers in large clinical sample sets, multiple biomarkers have to 
be tested simultaneously to assess their effectiveness in various combinations 
and improve both sensitivity and specificity. In this thesis we show that a 
combination of heterogeneous markers can distinguish disease severity in young 
RSV-infected children with a higher sensitivity and specificity compared with 
individual markers. Such combinations of multiple biomarkers should be utilized 
in the development of multimarker panels. Markers from different sources can 
be combined and should include clinical parameters, molecular biomarkers and 
biochemical biomarkers. 
At this moment, transcription biomarkers are not available for clinical use since 
processing is too time consuming, expensive and not standardized compared. 
However, novel and affordable PCR-based tools with faster turnaround time 
are currently under development. This will facilitate the application of gene 
expression profiles ‘bed side’ in the future.81
Blood transcriptome analysis has been shown to be useful for the detection of 
new biomarkers for LRTIs. In addition to the blood profiling approach, improved 
genomic approaches that use high-throughput molecular and cellular profiling of 
cells in different clinical subsets will further contribute to biomarker discovery.
Current efforts to discover and develop severity-related biomarkers may 
contribute to a more optimal clinical decision-making. Once new treatment 
strategies will become available, translation of biomarkers into the clinic will 
lead to implementation of personalized therapies that may benefit patients 
with LRTIs. In order to achieve this goal, well-designed large-scale multi-center 
profiling studies should be designed to discover new biomarkers. Extensive 
cellular and molecular profiling of human subjects will generate enormous 
amounts of data. Therefore, efficient data management, advanced bioinformatic 
tools and statistical methods for integrated analyses are essential to provide the 
full potential of high throughput profiling approaches in patients with LRTIs.
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CONCLUSIONS AND FUTURE PERSPECTIVES
In this thesis we identified a number of inflammatory markers to discriminate 
between mild and severe manifestations of viral bronchiolitis in young children. 
Objective assessment of clinical severity of RSV infection in young children may be 
improved by including combinations of immunological parameters. Most of the 
results of the studies in this thesis need to be validated in independent cohorts 
to establish their clinical value. It is tempting to speculate that inflammatory 
markers may precede clinical symptoms and can be used early in the course of 
disease to predict severe outcome. However, the potentially predictive value of 
these markers needs to be further investigated in the future. 
We propose that a combination of inflammatory markers in clinical prediction 
tools can improve patient care and reduce hospitalization rates. We have already 
shown that using linear regression tools new markers can be added to optimize 
prediction rules (Ahout et al. submitted). It would be of great clinical importance 
to select those patients that will not develop a severe course of disease and 
won’t require any supportive interventions. This may reduce unnecessary 
hospitalizations and result in less healthcare costs. For this purpose, prognostic 
biomarkers may have an important clinical value in addition to clinical parameters. 
This is especially relevant in infants below the age of 3 months.
Early identification of patients that will develop a severe course of disease may 
help general practitioners and pediatricians to target individualized monitor or 
treatment strategies. Biomarkers may become a valuable clinical tool once newly 
developed treatment strategies for viral bronchiolitis become available in the 
future. Interestingly, a recent paper reported preliminary data on the antiviral 
activity of a fusion inhibitor, GS-5806, in modulating experimental RSV infection 
in adults.82 Treatment with this fusion inhibitor resulted in reduction of viral 
load and symptom scores. The clinical efficacy of such small molecule antiviral 
agents needs to be assessed in children with natural infections. Until that time, 
biomarkers can also be used for research purposes to stratify patients in clinical 
studies, to study effects of interventions, such as treatment, and as secondary 
end-points in intervention studies. 
Further larger scale studies are required to evaluate the predictive value of co-
infections and viral load dynamics on the clinical course of bronchiolitis. These 
findings are important because they debate the additional value of viral diagnostics 
in clinical prediction models for viral bronchiolitis. At this moment, the clinical 
utility of viral testing in cases of bronchiolitis concerning management decisions 
or clinical outcomes is limited and in the available guidelines viral testing is not 
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recommended for bronchiolitis from a cost-effectiveness perspective.83 
Understanding the complex interactions between the virus and the host, and 
how it defines disease severity, requires a system analysis strategy. This strategy 
should include assays that simultaneously examine viral dynamics and innate 
and adaptive immune responses by employing different ‘omics’ tools such as 
genomics, transcriptomics, proteomics, and metabolomics. This system biology 
approach  has to be combined with sophisticated tools for large data analyses. 
Such an approach will facilitate further understanding of mechanisms of infection 
but will also elucidate new targets for prognostic biomarkers and new treatment 
strategies resulting in better patient treatment. Finally, we expect that ultimately 
an integrative personal omics profile (iPOP) will contribute to personalized 
medicine in both health and disease.84 
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SUMMARY
In this thesis we 1) evaluated the viral-host response in young children with viral 
lower respiratory tract infections (LRTIs), with a focus on respiratory syncytial 
virus (RSV) infections; and 2) identified potential biomarkers to assess disease 
severity in young children with viral LRTIs.
In chapter 2 the use of biomarkers in the field of pediatric infectious diseases 
was reviewed. The development of diagnostic biomarkers may lead a to more 
rapid diagnosis, more reliable discrimination between infectious and non-
infectious diseases, improved management, better outcomes, and a decrease 
in inappropriate use of antibiotics. With the development of transcriptomic 
and proteomic technologies, host immune responses can be unraveled thus 
contributing to better diagnostics and disease monitoring as well as predicting 
the individual’s susceptibility to disease and response to medical therapy. 
Although promising, the clinical application of these technologies is still limited 
at present. 
Children with bronchiolitis show a huge variability in disease severity. Disease 
severity is the result of a dynamic interplay between both host and viral factors. 
In chapter 3 we evaluated the association between the detection of multiple 
viruses by RT-PCR and disease severity in young children with bronchiolitis. 
We showed that the detection of more than one virus is not associated with 
increased disease severity in children with bronchiolitis. Remarkably, in children 
older than 3 months we found an association between more severe disease and 
RSV mono-infections. In addition, we found that viral load in children with single 
RSV infections was not associated with disease severity. We concluded that 
disease severity in children with bronchiolitis is not associated with infection 
by multiple viruses and that other factors, such as age or immune response are 
more important contributors to disease severity.
Subsequently, searching for biomarkers for disease severity, we evaluated 
several inflammatory parameters involved in the host immune response. In 
chapter 4, we investigated the role of MMP-8 and MMP-9 as markers for disease 
severity in children with viral LRTIs. Disease severity of viral LRTIs in children was 
associated with increased gene expression levels, but not with plasma (protein) 
concentrations, of MMP-8 and MMP-9 in both PBMCs and granulocytes. 
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In chapter 5, we showed that severe RSV infection was characterized by young age, 
lymphocytopenia, increased IL-8, granulocyte colony-stimulating factor (G-CSF) 
and IL-6, and decreased chemokine (C-C motif) ligand (CCL-5) concentrations in 
plasma. The combination of IL-8 and CCL-5 plasma levels and CD4+ T-cell counts 
discriminated children with severe from those with mild RSV infection with 82% 
sensitivity and 96% specificity. From these results it can be concluded that the 
use of combinations of inflammatory markers has additional value in assessing 
severity of RSV infection and may guide clinical management in the future.
In chapter 6 we showed that combining genome-wide expression profiling 
of blood cell subsets with clinically well-annotated samples can lead to 
identification of new biomarkers for disease severity of viral RTI. We identified a 
single gene, Olfactomedin-4 (OFLM4) that allowed us to distinguish patients with 
severe disease from those with mild disease. Patients with a high OLFM4 gene 
expression level were more likely to develop severe disease, after correction 
for age at hospitalization and gestational age. These results were validated in a 
new patient cohort and this confirmed OLFM4 in PBMC as a marker for disease 
severity in children with viral lower RTIs.
The results of this study and the ones presented in chapter 4 and 5 support 
the hypothesis that differential expression of genes involved in the immune 
response underlies the severity of RSV infections and that measurement of these 
parameters may improve current tools to predict severity of RSV infection. 
In chapter 7 we used an unbiased approach with proteomic technologies to 
identify targets for the development of biomarkers, future therapeutics or 
prevention strategies against severe RSV infection. We used human airway 
epithelial cells (A549) infected with RSV, human metapneumovirus (hMPV), 
parainfluenzavirus (PIV) type 3 and measles virus (MV) to identify specific and 
common host response markers by 2-D DIGE analyses. Cells infected with RSV 
or hMPV showed more changes in protein expression in comparison with PIV 
and MV-infected cells. The expression of proteins involved in the induction of 
apoptosis upon infection was differentially altered by the four viruses. Some 
of the identified proteins have previously been described for viral induced 
apoptosis by non-respiratory viruses. In addition, we were also able to identify 
novel proteins altered by respiratory viral infection. In conclusion, this study 
shows that proteomic techniques, like the 2-D DIGE analysis, can be used to 
identify proteins that are altered by respiratory viral infections which may serve 
as new targets for future therapeutic modalities.
207
                        
Summary
In chapter 8 we present the results of a study based on the important 
observation from trials with a formalin inactivated experimental vaccine in the 
1960s indicating that severe disease manifestations during RSV infection would, 
at least partially, be caused by a vigorous immune response. The vaccination 
resulted in augmented disease upon subsequent natural RSV infection in 
vaccinated infants as compared to controls. To identify protein markers and 
regulatory mechanisms that are associated with or are underlying these vaccine 
induced aberrant host responses, we used an in vivo mouse model of vaccine 
enhanced disease and applied mass spectrometry assisted protein profiling. 
Using a comparative proteomics approach seven proteins were identified as 
biomarkers of enhanced disease (Epx, Chil3, Itgam, Arg1, Clca3, PurB and Hk3). 
These proteins included proteins specific for the infiltrating eosinophils but also 
proteins that are postulated to play a role in the preceding stages of induction 
and establishment of skewed vaccine induced hypersensitivity responses. 
In chapter 9 we reflect on the results of our studies and clinical implications 
and recommendations for future research are formulated. In the future, a 
system analysis approach using different –omics technologies combined with 
sophisticated tools for large data analyses will facilitate further understanding 
of mechanisms of infection and elucidate new targets for prognostic biomarkers 
and new treatment strategies resulting in better patient treatment.
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Inleiding
De onderzoeken in dit proefschrift richten zich op ernst van ziekte bij kinderen 
met virale onderste luchtweginfecties (OLWI), met een focus op luchtweginfecties 
veroorzaakt door respiratoir syncytieel virus (RSV).
RSV is een veel voorkomende oorzaak van luchtweginfecties en een 
belangrijke reden voor ziekenhuisopnames bij jonge kinderen. Klachten 
van een luchtweginfectie veroorzaakt door RSV variëren van milde bovenste 
luchtwegklachten tot ernstige onderste luchtweginfecties die in sommige 
gevallen leiden tot respiratoir falen waarvoor beademing op een intensive care 
nodig is. De meeste kinderen hebben tenminste één RSV infectie doorgemaakt 
voor de leeftijd van 2 jaar. In Nederland worden jaarlijks ongeveer 1500-2000 
kinderen onder de leeftijd van 1 jaar opgenomen en hiervan worden 100-150 
kinderen beademd op een intensive care afdeling.
Er zijn verschillende risicofactoren (zoals prematuriteit, aangeboren 
hartafwijkingen en chronische longziekten) die kunnen leiden tot een 
ernstiger beloop van RSV infecties. Echter, meer dan de helft van de kinderen 
die opgenomen wordt op een intensive care afdeling was van tevoren goed 
gezond. Het is niet duidelijk waarom juist deze kinderen een ernstiger beloop 
ontwikkelen. Momenteel is het voor artsen moeilijk in te schatten welke kinderen 
ernstiger ziek zullen worden. Bij ongeveer 35% van de kinderen die opgenomen 
wordt vinden geen ondersteunende interventies plaats gedurende de opname. 
Daarnaast wordt 5-7% van de kinderen die beoordeeld worden in het ziekenhuis 
later in het ziektebeloop alsnog opgenomen. Het ontwikkelen van markers in 
bloed of luchtwegmaterialen die ernst van ziekte kunnen voorspellen zouden in 
belangrijke mate artsen kunnen helpen in de beslissing kinderen op te nemen 
danwel naar huis te ontslaan. Hiermee kunnen enerzijds kinderen geselecteerd 
worden die nauw geobserveerd moeten worden gedurende het ziektebeloop en 
anderzijds onnodige opnames voorkomen worden.
De onderzoeken die beschreven zijn in dit proefschrift dienen 2 hoofddoelen:
1. Evalueren van de interacties tussen gastheer en virus in jonge kinderen met 
virale OLWI’s, met een focus op RSV infecties
2. Identificeren van potentiële biomarkers die ernst van ziekte kunnen 
vaststellen in jonge kinderen met virale OLWI’s
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In de afzonderlijke hoofdstukken worden de verschillende onderzoeken 
beschreven.
Hoofdstuk 2 geeft een overzicht van het gebruik van biomarkers in de pediatrische 
infectieziekten. Diagnostische biomarkers kunnen bijdragen aan een snellere 
diagnose, beter onderscheid tussen infectieuze en niet-infectieuze oorzaken, 
betere behandeling en uitkomsten van ziekte, en een afname in het onnodig 
gebruik van antibiotica. De ontwikkeling van transcriptomics en proteomics 
technieken, waarmee de afweerreactie van de gastheer op een microorganisme 
op respectievelijk genexpressie- en eiwitniveau onderzocht kan worden, draagt 
bij aan betere diagnostische mogelijkheden, monitoring, als ook het voorspellen 
van de vatbaarheid van een individu om een bepaalde ziekte te krijgen en het 
voorspellen van de reactie van een individu op een bepaalde behandeling. Ook 
al klinkt dit veelbelovend, de klinische toepassing van dergelijke technieken is 
momenteel nog zeer beperkt.
Kinderen met RSV infecties laten veel variatie zien in ernst van ziekte. Ernst van 
ziekte is het gevolg van de interactie tussen virale factoren en gastheerfactoren. 
Hoofdstuk 3 beschrijft de relatie tussen de detectie van meerdere virale 
pathogenen in neusspoelsel en ernst van ziekte in jonge kinderen met 
bronchiolitis. De detectie van meer dan 1 virus in het neusspoelsel van kinderen 
was niet geassocieerd met toegenomen ernst van ziekte. Kinderen ouder dan 
3 maanden met RSV mono-infecties hadden zelfs een ernstiger ziektebeloop 
dan kinderen bij wie meerdere virussen tegelijkertijd aangetoond waren. Deze 
resultaten suggereren  dat ernst van ziekte in kinderen met bronchiolitis niet 
geassocieerd is met de detectie van meerdere virale pathogenen, maar dat 
andere factoren zoals leeftijd of afweerreactie een belangrijke rol spelen.
In de zoektocht naar biomarkers voor ernst van ziekte werden vervolgens 
verschillende inflammatoire markers, betrokken in de afweerreactie op 
virussen, geëvalueerd. In hoofdstuk 4 onderzochten we de rol van matrix 
metalloproteinases (MMP)-8 en MMP-9 als markers voor ernst van ziekte in 
kinderen met virale OLWI’s. Kinderen met een ernstig beloop van een virale OLWI 
hadden een hogere genexpressie van MMP-8 en MMP-9 in perifere mononucleaire 
bloedcellen (PBMCs) en granulocyten dan kinderen met een milder beloop. 
Plasmaconcentraties van MMP-8 en MMP-9 lieten deze associatie niet zien.
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In hoofdstuk 5 worden verschillende klinische en inflammatoire parameters 
vergeleken in kinderen met een mild, matig of ernstig ziektebeloop. De combinatie 
van IL-8 en CCL-5 plasma concentraties en CD4+ T-celaantallen kon kinderen 
met ernstige ziektesymptomen onderscheiden van die met milde symptomen 
met een sensitiviteit van 82% en een specificiteit van 96%. Op basis van deze 
bevindingen concluderen wij dat het gebruik van combinaties van inflammatoire 
markers van toegevoegde waarde kunnen zijn in het vaststellen van ernst van 
RSV infectie. Dit zou in de toekomst kunnen bijdragen aan klinische beslissingen.
Hoofdstuk 6 laat zien dat het vergelijken van genexpressieprofielen van 
verschillende bloedcelpopulaties van kinderen met verschillende mate van ernst 
van ziekte kan leiden tot de identificatie van nieuwe biomarkers voor ernst van 
ziekte. Eén enkel gen, Olfactomedine-4 (OLFM4), kon het onderscheid maken 
tussen kinderen met ernstige ziekte en die met een milder beloop. Ook na 
correctie voor leeftijd en zwangerschapsduur hadden kinderen met een hoog 
OLFM4 genexpressie niveau vaker een ernstiger ziekte beloop dan kinderen 
met een laag OLFM4. Validatie in een nieuw patiëntencohort heeft bevestigd 
dat OLFM4 een mogelijke marker is voor ernst van ziekte in kinderen met virale 
OLWI’s.
De resultaten van deze laatste studie en die van de studies beschreven in 
hoofdstuk 4 en 5 ondersteunen de hypothese dat verschillen in genexpressie 
en plasmaconcentraties van inflammatoire markers ernst van ziekte kunnen 
reflecteren. Het meten van dergelijke markers kan de huidige beschikbare 
methodes voor het inschatten en eventueel voorspellen van ernst van RSV 
infecties verbeteren. 
Hoofdstuk 7 beschrijft een studie waarin proteomics technieken gebruikt worden 
om eiwitten te identificeren die kunnen dienen als biomarkers, of als kandidaat 
voor toekomstige behandelingsmogelijkheden en preventieve strategieën 
van ernstige RSV infecties. Hiervoor werden humane luchtwegepitheelcellen 
geïnfecteerd met verschillende virussen waaronder RSV met als doel algemene en 
specifieke gastheer respons markers te identificeren met de 2-D DIGE methode. 
Dit is een vorm van gel elektroforese waarbij uit verschillende eiwitsamples 
eiwitten worden gescheiden op basis van grootte en isoelektrisch punt. Omdat 
verschillende samples gelabeld zijn met een verschillende fluorescerende kleur 
kunnen verschillen in aanwezigheid en hoeveelheid van bepaalde eiwitten in 
verschillende samples onderscheiden worden. 
In deze experimenten toonden cellen geïnfecteerd met RSV meer veranderingen 
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in eiwitexpressie vergeleken met cellen geïnfecteerd met een aantal andere 
virussen. De expressie van zowel bekende als nog onbekende eiwitten betrokken 
bij de inductie van geprogrammeerde celdood bleek significant verschillend ten 
opzichte van controles. Dergelijke eiwitten kunnen een mogelijk nieuw target 
zijn voor toekomstige therapeutische of preventieve strategieën.
Eerdere pogingen om een vaccin tegen RSV te ontwikkelen mislukten. In een 
vaccinatie experiment in de 1960s resulteerde vaccinatie bij kinderen in een 
ernstiger beloop van een daaropvolgende natuurlijke RSV infectie vergeleken 
met niet-gevaccineerde kinderen. Meerdere onderzoeken hebben aangetoond 
dat dit ging om een excessieve immuunrespons, echter de precieze aard van deze 
respons is vooralsnog onduidelijk. In hoofdstuk 8 onderzochten wij deze door 
vaccinatie geïnduceerde immuunrespons in een in vivo muizen vaccinatiemodel 
met behulp van op massa spectrometrie gebaseerde proteomics technieken. We 
identificeerden 7 eiwitten die kunnen dienen als marker van de door vaccinatie 
geinduceerde excessieve immuunrespons. 
In hoofdstuk 9 reflecteren we op de resultaten van de afzonderlijke studies. 
Onze belangrijkste bevindingen zijn:
1. Ernst van ziekte in jonge kinderen met een virale OLWI is niet geassocieerd 
met de detectie van meerdere virussen tegelijkertijd of met de virale load
2. Verschillende inflammatoire markers gemeten op genexpressie niveau (MMP-
8 en MMP-9) of in plasma (combinatie van IL-8 en CCL-5 plasmaconcentraties 
en CD4+ T-cel aantallen) kunnen ernstige van milde RSV infecties 
onderscheiden
3. Transcriptoom analyses van patiëntmateriaal heeft geleid tot de identificatie 
van nieuwe biomarkers voor ernst van ziekte (OLFM4)
4. Proteoom analyses van in vitro en in vivo (muizen) modellen hebben meerdere 
gastheer eiwitten aangetoond die betrokken zijn bij de immuunrespons
De geïdentificeerde markers dienen gevalideerd te worden in onafhankelijke 
patiëntcohorten om de klinische waarde te bepalen. Daarnaast zal de 
voorspellende waarde van deze markers onderzocht moeten worden. Toekomstig 
onderzoek moet zich richten op geïntegreerde analyses van virale dynamiek en 
gastheer immuunrespons door middel van het combineren van verschillende –
omics technieken met geavanceerde data analyses. Deze benadering middels 
multisysteem analyse zal de identificatie van nieuwe prognostische biomarkers 
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en aanknopingspunten voor behandelingsmogelijkheden en vaccinatie mogelijk 
maken. 
Indien in de toekomst nieuwe behandelingsstrategieën voor RSV infectie 
beschikbaar komen, worden dergelijke biomarkers een waardevol klinisch 
instrument. Toepassing van dergelijke markers in klinische predictiemodellen 
kan bijdragen aan een verbetering van patiëntenzorg en reductie van 
gezondheidszorgkosten.
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AdV  adenovirus
APC  allophycocyanin
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CCL  chemokine (C-C motif) ligand
CoV  coronavirus
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hMPV  human metapneumovirus
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Mo  months
(m)RNA  (messenger) ribonucleic acid
NK   natural killer
OLFM4  olfactomedin-4
PBMC   peripheral blood mononuclear cells
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PE   phycoerythrin
PerCP   peridinin chlorophyll protein
PeV  parechovirus
226
Addendum
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SELDI-TOF-MS surface-enhanced laser desorption/ionization-time of flight-  
  mass spectrometry 
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